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Polychlorinated dibenzo-p-dioxins and -furans, “dioxins”, are widespread 
environmental pollutants. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is the 
most potent dioxin congener, which in laboratory animals elicits multiple 
responses mainly mediated by the aryl hydrocarbon receptor (AHR). 
Downstream toxic pathways beyond AHR activation are still incompletely 
understood. Here the pathogenesis and mechanism of a novel TCDD-induced 
toxicity syndrome, accumulation of the heme degradation product biliverdin 
in rat liver, was studied. 
All products of heme degradation are biologically active and the respective 
enzymes, heme oxygenase and biliverdin reductase, affect cellular 
defense and signaling in multifaceted ways. This work adds to the current 
understanding of the effect of dioxins on heme metabolism and roles of the 
AHR and an unknown TCDD-resistance gene B in dioxin toxicity. Especially, 
biliverdin reductase might be a candidate of further studies in terms of 
TCDD toxicity. Furthermore, in addition to the classical AHR-mediated 
toxicity of dioxins, there is another mechanism of dioxin toxicity especially 
characteristic for 1,2,3,4,7,8-hexachlorodibenzo-p-dioxin.
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Abstract 
Marjo Niittynen. TCDD-induced accumulation of the heme degradation product 
biliverdin in rat liver. National Institute for Health and Welfare (THL). Research 
133. 203 pages. Helsinki, Finland 2014.  
ISBN 978-952-302-262-1 (printed); ISBN 978-952-302-263-8 (pdf) 
 
Polychlorinated dibenzo-p-dioxins and -furans (PCDD/Fs), “dioxins”, are 
widespread and persistent environmental pollutants. Due to their lipophilicity and 
stability, dioxins accumulate in the food chain finally ending into human diet. In 
Finland, the part of population eating plenty of fish from the Baltic Sea receives 
highest dioxin exposures. Health risk assessment of dioxins is challenging as their 
mechanisms of action are very complicated and not fully understood.  
 
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is the most potent dioxin congener 
and the prototypic compound used in toxicological studies. In laboratory animals, 
TCDD elicits multiple biochemical and toxic responses, which are mainly mediated 
by the aryl hydrocarbon receptor (AHR). AHR- and yet unidentified gene B -
genotypes have major influence on the TCDD-sensitivity of a rat: Han/Wistar (hw)-
type alleles confer increased resistance relative to wild-type (wt) alleles of these 
genes. Here the pathogenesis and mechanism of a novel TCDD-induced toxicity 
syndrome, accumulation of green pigment in rat liver, was studied in order to 
increase understanding of the mechanisms of TCDD toxicity. In liquid 
chromatography-tandem mass spectrometry (HPLC-MS/MS) analysis, the pigment 
was found to consist of the heme degradation product biliverdin and its conjugates. 
 
Heme is the prosthetic group of hemoglobin and several other proteins. At the time 
of degradation of these proteins, the heme part must also be degraded. The rate-
limiting enzyme heme oxygenase (HO-1) first converts heme to biliverdin, which is 
subsequently reduced to bilirubin by biliverdin reductase (BVR-A). Increased serum 
bilirubin is a well-known effect of TCDD in rats. In contrast, TCDD-induced 
biliverdin accumulation has been reported only in specific rat strains of our 
laboratory, foremost in semi-TCDD-resistant line B rats carrying wt alleles of AHR 
but TCDD-resistance alleles (hw) of gene B. Notably, biliverdin accumulation has 
never been detected in TCDD-resistant Han/Wistar (Kuopio) or line A (Kuopio) rats, 
which express only mutated AHR (genotype AHRhw/hw). 
 
It was hypothesised that biliverdin formation is either increased and/or its 
metabolism is decreased due to TCDD-induced changes in HO-1, BVR-A or δ-
aminolevulinic acid synthetase 1 (ALAS-1; the rate-limiting enzyme of heme 
synthesis). In order to probe the hypothesis and further characterize the syndrome, 
following issues were studied: 1) Incidence of the macroscopic biliverdin 
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accumulation syndrome and effect of TCDD on hepatic biliverdin level in 
differentially TCDD-sensitive rat strains, 2) Liver histopathology, 3) Dose-responses 
of TCDD exposure and hepatic biliverdin and bilirubin accumulation, serum 
bilirubin and bile acids, 4) Effect of TCDD on hepatic and splenic expression and/or 
activity of ALAS1, HO-1 and BVR-A, and 5) Effect of TCDD on bilirubin 
excretion. In addition, acute toxicity of TCDD and another dioxin congener, 
1,2,3,4,7,8-hexachlorodibenzo-p-dioxin (HxCDD), were compared in line A, line B 
and H/W rats. Further, the effect of TCDD on the expression of 18 commonly used 
housekeeping genes was investigated in order to find, inter alia, a suitable 
normalization gene for the point 4 above. 
 
At 28 days in line B rats, doses ≥100 µg/kg of TCDD significantly elevated hepatic 
biliverdin, whereas in line A rats hepatic biliverdin remained at the control level 
even after 10,000 µg/kg of TCDD. In TCDD-sensitive Long-Evans rats (Turku/AB; 
genotype AHRwt/wt Bwt/wt), hepatic biliverdin level increased slightly in response to 
TCDD treatment. In correlation analysis between hepatic bile pigments, biliverdin 
conjugates correlated best with biliverdin suggesting it to be their immediate 
precursor. TCDD enhanced bilirubin excretion suggesting that excretory problems 
are not the principal cause for increased serum bilirubin. In general, TCDD had 
moderate inducing effect on hepatic HO-1 and BVR-A, however, curious exceptions 
such as late inhibition of BVR-A in line B rats were detected. TCDD repressed 
hepatic expression of ALAS1 and splenic expression of HO-1. About 50% of the 
studied housekeeping genes were responsive to TCDD; most stable were 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and phosphoglycerate kinase 
1 (Pgk 1). HxCDD did not induce biliverdin accumulation. Instead, it caused severe 
hepatic steatosis, rapid body weight loss, and mortality by an AHR-independent 
mechanism. Both TCDD and HxCDD induced hepatic peliosis. 
 
In conclusion, a fundamental cause behind both TCDD-induced biliverdin 
accumulation and increased serum bilirubin is increased hepatic heme degradation. 
Concurrent incomplete conversion of biliverdin to bilirubin – possibly due to 
complexities in the function of the catalyzing enzyme, BVR-A – is the most likely 
reason for biliverdin accumulation. Biliverdin conjugates are most probably 
secondary products of biliverdin and they form the main part of the accumulating 
pigment. Homozygocity for AHRhw provided complete protection against TCDD-
induced biliverdin accumulation, indicating necessity of the wild-type AHR 
transactivation domain for the syndrome. For Bhw two options remain: Bhw may be 
unrelated to biliverdin metabolism per se but crucial for macroscopic manifestation 
of the syndrome via increasing rat´s TCDD-resistance, or Bhw may be a necessary 
factor for substantial biliverdin accumulation to be possible. Further, it was found 
that in addition to the classical AHR-mediated toxicity of PCDDs, there is another 
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mechanism of PCDD toxicity characteristic for HxCDD but not activated at all or 
only very weakly by TCDD. 
 
Keywords: 2,3,7,8-tetrachlorodibenzo-p-dioxin, 1,2,3,4,7,8-hexachlorodibenzo-p-
dioxin, biliverdin, bilirubin, rat, hepatotoxicity, heme, heme oxygenase, biliverdin 
reductase, sinusoidal distension, hepatic peliosis, housekeeping genes, steatosis 
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Tiivistelmä 
Marjo Niittynen. TCDD:n aiheuttama biliverdiinin kertyminen rotan maksaan. 
Terveyden ja hyvinvoinnin laitos (THL). Tutkimus 133. 203 sivua. Helsinki, Finland 
2014. 
ISBN 978-952-302-262-1 (painettu); ISBN 978-952-302-263-8 (pdf) 
 
Polyklooratut dibentso-p-dioksiinit ja -furaanit (PCDD/F:t), ”dioksiinit”, ovat 
laajalle levinneitä, pysyviä ja ravintoketjussa kertyviä ympäristömyrkkyjä. 
Suomessa runsaasti Itämeren kalaa käyttävä väestönosa altistuu suurimmille 
dioksiinipitoisuuksille. Dioksiinien riskinarviointia vaikeuttaa niiden 
vaikutusmekanismien monimutkaisuus ja puutteellinen tunteminen.  
 
2,3,7,8-Tetraklooridibentso-p-dioksiini (TCDD) on voimakkain dioksiinijohdos ja 
käytetyin malliyhdiste dioksiineja koskevissa toksikologisissa tutkimuksissa. Koe-
eläimissä TCDD aiheuttaa monia biokemiallisia ja toksisia vasteita, jotka välittyvät 
pääasiassa aryylihiilivetyreseptorin (AHR) kautta. AHR:n ja tuntemattoman B-
geenin genotyypit määrittävät rotan TCDD-herkkyyden: Han/Wistar (hw) -tyypin 
alleelit tuottavat suuremman kestävyyden kuin villityypin (wt) alleelit. Tässä työssä 
pyrittiin lisäämään ymmärrystä TCDD:n vaikutusmekanismeista tutkimalla aivan 
uutta TCDD:n aiheuttamaa toksista vaikutusta: vihreän pigmentin kertymistä rotan 
maksaan. Nestekromatografia-massaspektrometria (HPLC-MS/MS) -analyysi osoitti 
pigmentin koostuvan hemin hajoamistuotteesta biliverdiinistä ja sen konjugaateista. 
 
Hemi on hemoglobiinin ja eräiden muiden proteiinien prosteettinen ryhmä. Näiden 
proteiinien hajotessa elimistön on hajotettava myös hemiosa. Tässä tarvitaan kahta 
entsyymiä: hemioksigenaasi (HO-1) katkaisee hemin rengasrakenteen ja muodostaa 
biliverdiiniä, jonka puolestaan biliverdiinireduktaasi (BVR-A) pelkistää bilirubii-
niksi. Kohonnut seerumin bilirubiinipitoisuus on tunnettu TCDD:n vaikutus rotissa. 
Sen sijaan TCDD-altistuksen suurentamia maksan biliverdiinipitoisuuksia on 
kuvattu ainoastaan tietyissä laboratoriossamme kehitetyissä rottalinjoissa, ennen 
kaikkea TCDD:tä keskinkertaisesti kestävissä B-linjan rotissa, joilla on villityypin 
alleelit AHR-geenistä mutta hw-tyypin kestävyyttä lisäävät alleelit B-geenistä. On 
huomionarvoista, että biliverdiinin kertymistä ei ole koskaan havaittu erittäin 
TCDD-kestävissä Han/Wistar (Kuopio) tai A-linjan (Kuopio) rotissa, jotka 
ilmentävät ainoastaan mutatoitunutta AHR-proteiinia (genotyyppi AHRhw/hw).  
 
Työhypoteesin mukaan biliverdiinin kertymisen taustalla olisi joko sen muodostu-
misen lisääntyminen ja/tai metabolian hidastuminen johtuen TCDD-altistuksen 
aiheuttamista muutoksista HO-1:n, BVR-A:n tai hemin synteesitien 1. entsyymin, δ-
aminolevulinaattisyntetaasi 1:n (ALAS-1) ilmenemisessä tai aktiivisuudessa. 
Hypoteesin testaamiseksi ja biliverdiinin kertymisilmiön lisäluonnehtimiseksi 
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tutkittiin seuraavia asioita: 1) silminhavaittavan syndrooman ilmaantuvuus sekä 
TCDD:n vaikutus maksan biliverdiinipitoisuuksiin TCDD-herkkyydeltään erilaisilla 
rottakannoilla, 2) maksan histopatologia, 3) annos-vaste-suhteet TCDD-altistuksen 
ja maksan biliverdiini/bilirubiinipitoisuuden sekä seerumin bilirubiini- ja 
sappihappopitoisuuden välillä, 4) TCDD:n vaikutus ALAS1:n, HO-1:n ja BVR-A:n 
ilmenemiseen ja/tai katalyyttiseen aktiivisuuteen, ja 5) TCDD:n vaikutus bilirubiinin 
erittymiseen. Lisäksi vertailtiin TCDD:n ja 1,2,3,4,7,8-heksaklooridibentso-p-dioksiinin 
(HxCDD) akuuttia toksisuutta A- ja B-linjan sekä H/W-kannan rotissa. Tutkittiin myös 
TCDD:n vaikutusta 18 yleisesti käytetyn normalisointigeenin ilmenemiseen rotan eri 
kudoksissa mm. sopivan vaihtoehdon löytämiseksi kohtaan 4. 
 
Maksan biliverdiinipitoisuus nousi B-rotilla TCDD-annoksella ≥100 µg/kg. A-rotilla 
pitoisuus säilyi kontrollitasolla jopa annoksen 10 000 µg/kg jälkeen. TCDD-herkillä 
Long-Evans (Turku/AB) -rotilla nähtiin lievä vaikutus. Sappipigmenttien välisessä 
korrelaatioanalyysissä biliverdiinikonjugaatit korreloivat parhaiten biliverdiinin 
kanssa, täten viitaten biliverdiinin olevan biliverdiinikonjugaattien välitön edeltäjä. 
TCDD tehosti bilirubiinin eritystä, joten eritysongelmat eivät selitä seerumin 
bilirubiinin nousua. TCDD lisäsi lievästi maksan HO-1:n ja BVR-A:n ilmenemistä 
ja/tai aktiivisuutta, poikkeuksia kuitenkin havaittiin kuten mm. BVR-A:n myöhäinen 
inhibitio B-rotilla. TCDD vähensi ALAS1:n ilmenemistä maksassa ja HO-1:n 
ilmenemistä pernassa. Noin 50 % tutkituista normalisointigeeneistä reagoi TCDD-
altistukseen; stabiileimpia olivat glyseraldehydi-3-fosfaatti dehydrogenaasi 
(GAPDH) ja fosfoglyseraattikinaasi 1 (Pgk 1). HxCDD ei aiheuttanut biliverdiinin 
kertymistä. Sen sijaan se aiheutti vakavaa maksan rasvoittumista, nopeaa 
painonlaskua ja kuolleisuutta AH-reseptorista riippumattomalla mekanismilla. Sekä 
TCDD että HxCDD aiheuttivat maksapelioosia. 
 
Tulokset osoittavat, että yhteinen taustasyy TCDD:n aiheuttamalle biliverdiinin 
kertymiselle sekä seerumin bilirubiinitasojen nousulle on lisääntynyt hemin hajotus. 
Samanaikainen biliverdiinin epätäydellinen pelkistyminen bilirubiiniksi – 
mahdollisesti johtuen BVR-A:n toiminnallisesta monimutkaisuudesta – on 
todennäköisin syy biliverdiinin kertymiselle. Biliverdiinikonjugaatit ovat 
luultavimmin biliverdiinin sekundäärituotteita ja muodostavat pääosan kertyvästä 
pigmentistä. Villityypin AHR-transaktivaatiodomeeni on edellytys TCDD:n 
aiheuttamalle biliverdiinin kertymiselle, sillä homotsygotia AHRhw-alleelin suhteen 
esti kertymisen täysin. Bhw-alleelin osalta on kaksi mahdollisuutta: joko Bhw-alleeli 
ei suoranaisesti osallistu biliverdiinimetaboliaan mutta mahdollistaa syndrooman 
silmämääräisen havaitsemisen kasvattamalla rotan TCDD-kestävyyttä, tai Bhw voi olla 
välttämätön tekijä biliverdiinin huomattavalle kertymiselle. Lisäksi havaittiin, että 
klassisen AHR-välitteisen mekanismin lisäksi on olemassa toinen eräiden  
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PCDD-yhdisteiden toksisuutta välittävä mekanismi, joka on tyypillinen HxCDD:lle, 
mutta jota TCDD aktivoi hyvin vähän tai ei lainkaan. 
 
Avainsanat: 2,3,7,8-tetraklooridibentso-p-dioksiini, 1,2,3,4,7,8-heksaklooridibentso-
p-dioksiini, biliverdiini, bilirubiini, rotta, maksatoksisuus, hemi, hemioksigenaasi, 
biliverdiinireduktaasi, maksapelioosi, normalisointigeenit
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Abbreviations 
 
ABCB6    ATP-binding cassette sub-family B member 6 
AD Alzheimer´s disease  
AH Aryl hydrocarbon 
AHR  Aryl hydrocarbon receptor 
AHR / Ahr The gene encoding AHR 
AHRR Aryl hydrocarbon receptor repressor 
ALAD δ-Aminolevulinic acid dehydratase 
ALAS δ-Aminolevulinic acid synthetase 
AMPK Adenosine monophosphate-activated protein kinase  
AP-1 Activator protein 1 
ARE Antioxidant response element 
ARNT  AH receptor nuclear translocator; the dimerization partner of 
AHR 
ASAT Aspartate aminotransferase  
ATF2 Activating transcription factor 2 
B An unknown gene that affects TCDD sensitivity 
bHLH/PAS   Basic Helix-Loop-Helix/homologous region of Periodic (PER), 
AHR nuclear translocator (ARNT), and Single-minded (SIM) 
proteins 
BR Bilirubin; yellow end product of heme degradation  
BRO Bilirubin oxidase 
BV Biliverdin; green to blue intermediate product of heme 
degradation 
BVR Biliverdin reductase; ubiquitous cytosolic enzyme that converts 
biliverdin to bilirubin 
BVR-A Biliverdin IXα reductase; predominant form of BVR in adult 
mammals. Highly selective for biliverdin IXα isomer. 
BVR-B Biliverdin IXβ reductase; fetal form of BVR. Reduces biliverdin 
isomers IXβ, IXγ and IXδ. Has flavin and ferric reductase 
activities in adult mammals. 
b.w. Body weight 
cAMP Cyclic adenosine monophosphate 
CAR Constitutive androstane receptor 
CO Carbon monoxide 
CoA Coenzyme A 
CPO  Coproporphyrinogen oxidase 
CREB  cAMP response element-binding protein  
CYP1A1 Cytochrome P4501A1, a phase 1 metabolizing enzyme 
CYP1A2 Cytochrome P4501A2, a phase 1 metabolizing enzyme 
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DNA Deoxyribonucleic acid 
DRE Dioxin response element in DNA; called also XRE, xenobiotic 
response element  
EGFR  Epidermal growth factor receptor 
eNOS Endothelial nitric oxide synthase 
ER Estrogen receptor  
ERK1/2 Extracellular signal-regulated kinases 1/2 
EROD Ethoxyresorufin-O-deethylase 
FEC Ferrochelatase 
FR Feed-restricted control group 
FRC Feed-restricted control group  
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
HHV-6 Human herpesvirus 6 
HIV-1 Human immunodeficiency virus 1  
HO Heme oxygenase 
HO-1 Inducible form of HO present in all tissues. Induced during 
cellular stress. 
HO-2 Constitutively expressed form of HO. Expressed mainly in 
vasculature and nervous system. 
HPLC High performance liquid chromatography 
HPLC-MS/MS High performance liquid chromatography-tandem mass 
spectrometry 
H/W Han/Wistar (Kuopio) rat strain. The most TCDD-resistant 
laboratory animal known.  
hw H/W type; the deviant alleles of AHR and B genes from the H/W 
rat; mediates TCDD-resistance 
HxCDD 1,2,3,4,7,8-Hexachlorodibenzo-p-dioxin 
IARC International Agency for Research on Cancer 
IFN-γ Interferon gamma 
IGF-1 Insulin-like growth factor 1 
IL-2 Interleukin 2 
iNOS Inducible nitric oxide synthase  
IR Insulin receptor 
IRK Insulin receptor tyrosine kinase 
IRS-1 Insulin receptor substrate 1 
LD50 Lethal dose 50%; the dose that is estimated to kill 50% of 
animals in an acute toxicity test 
LDL Low-density lipoprotein 
L-E Long-Evans (Turku/AB) rat strain. The most TCDD-sensitive 
rat strain known.  
LOAEL Lowest observed adverse effect level 
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MAPK Mitogen-activated protein kinase 
MCI Mild cognitive impairment 
mRNA Messenger RNA 
MRP2 Multidrug resistance protein 2 
NADH  Nicotinamide adenine dinucleotide 
NADPH Nicotinamide adenine dinucleotide phosphate  
NFAT Nuclear factor of activated T-cells; transcription factor which is 
activated upon T cell stimulation 
NF-κB  Nuclear factor kappa B 
Nrf2  NF-E2-related factor-2; redox-responsive transcription factor 
PBGD  Porphobilinogen deaminase 
PCB Polychlorinated biphenyl 
PCDD Polychlorinated dibenzo-p-dioxin 
PCDF Polychlorinated dibenzofuran 
PCR Polymerase chain reaction 
PEPCK Phosphoenolpyruvate carboxykinase 
Pgk 1  Phosphoglycerate kinase 1 
PKC-βII  Protein kinase CβII 
PKCδ  Protein kinase Cδ 
PPAR Peroxisome proliferator-activated receptor 
PPO  Protoporphyrinogen oxidase 
PXR Pregnane X receptor 
qRT-PCR  Quantitative real-time reverse transcription PCR 
RB Retinoblastoma protein 
ROS Reactive oxygen species 
RT-PCR Reverse transcription PCR 
Ser/Thr/Tyr Serine/Threonine/Tyrosine 
SLC25A11 Mitochondrial 2-oxoglutarate/malate carrier protein 
TCDD 2,3,7,8-Tetrachlorodibenzo-p-dioxin; the most toxic congener of 
dioxins 
TEF  Toxic equivalence factor 
TEQ  Toxic equivalent quantity 
TNF/D-GalN  Tumor necrosis factor/D-galactosamine 
UCoS  Uroporphyrinogen III cosynthase 
UGT1A1  Uridine diphosphate (UDP) glucuronosyltransferase 1A1 
UROD  Uroporphyrinogen decarboxylase 
U.S. EPA United States Environmental Protection Agency 
WHO World Health Organization 
wt Wild type; the typical rat alleles of AHR and B genes 
XRE Xenobiotic response element
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1 Introduction 
Polychlorinated dibenzo-p-dioxins (PCDDs) and polychlorinated dibenzofurans 
(PCDFs), collectively called “dioxins”, are a group of persistent environmental 
contaminants. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is the most potent dioxin 
congener, having also reputation as being the most toxic man-made chemical. 
Dioxins are formed in various combustion and industrial processes as unwanted by-
products. They are widespread in the environment, good news being that the 
concentrations have been declining since 1970’s mainly due to improvements in 
burning processes. Over 90% of human exposure to dioxins occurs via food; in 
Finland a major source is fatty fish from the Baltic Sea followed by meat and dairy 
products. Due to their ubiquitous presence, persistence, potent toxicity and ability to 
accumulate in the food chain, dioxins constitute an environmental hazard for human 
health. Vast amount of research on dioxins has been conducted during past decades, 
and a connection between several human health effects and dioxin exposure has 
been suggested, including cancer, developmental defects, endocrine and 
reproductive disturbances as well as metabolic diseases. The current background 
exposure levels probably do not increase cancer incidence and the more relevant 
concern is indeed comprised by developmental defects. In addition to low 
background levels to which all people are exposed, some severe industrial accidents 
have occurred causing higher human exposures to dioxins. Worth mentioning is also 
dioxins’ presence as impurities in the herbicide Agent Orange during Vietnam war, 
due to which a large number of people are still suffering from serious developmental 
defects and other adverse health effects. 
  
The mediator of dioxin effects in the body is the aryl hydrocarbon receptor (AHR). 
Binding of dioxin to this receptor affects the expression of hundreds or even 
thousands of genes. Therefore, dioxins are able to disturb many physiological 
processes. A characteristic feature of TCDD’s toxicity is large sensitivity differences 
between species and even between the strains of the same species. The largest 
intraspecies difference is the 1000-fold sensitivity difference towards acute lethality 
of TCDD between Han/Wistar (Kuopio) and Long-Evans (Turku/AB) rats. The 
reason for the exceptional resistance of Han/Wistar rats is that they possess mutated 
allelles of AHR. In addition there is another, yet unknown gene B, affecting TCDD 
sensitivity. Despite huge amount of toxicological research on TCDD, the 
biochemical pathways leading to dioxin-induced lethality and other toxic effects are 
still insufficiently understood, which complicates risk assessment.  
 
In this study, the pathogenesis and mechanism of a novel toxic effect of TCDD, 
hepatic biliverdin accumulation, has been addressed. This work started due to quite 
Introduction 
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dramatic observations of green/black livers in so called line B rats after TCDD 
exposure. Line B rats are intermediately TCDD resistant as they possess resistant 
alleles of unknown gene B influencing dioxin sensitivity. It was hypothesised that 
elucidating the biochemical mechanism of biliverdin accumulation would help in 
identifying gene B and thus benefit general understanding of the toxic mechanisms 
of TCDD. Biliverdin is an intermediate product in heme degradation and it has 
distinct green color. Normally biliverdin is rapidly turned to bilirubin, a yellow 
pigment, which is excreted. Cases of biliverdin accumulation are rare but existent in 
humans; in rats no previous cases were found in literature. 
 
In order to clarify the mechanism of biliverdin accumulation, the obvious study 
objects (among others) were the enzymes responsible for heme degradation, heme 
oxygenase (HO-1) and biliverdin reductase (BVR-A). HO-1 is an essential, 
inducible enzyme involved in cellular defence against various stressful insults. It has 
been a subject of growing interest during past decades. Quite interestingly, during 
just a few past years, BVR-A has been recognized to participate in cellular signaling 
and regulation in complex ways. On the other hand, both bilirubin and biliverdin, 
“bile pigments”, are physiologically important, possibly essential molecules due to 
their antioxidant and other biological activities. Therefore, in addition to the 
toxicological dioxin literature, the following literature review includes a look on 
heme metabolism. An overall theory is presented on how TCDD induces biliverdin 
accumulation.  
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? Review of the literature 
2.1 Overview to dioxins and their toxicity 
2.1.1 General properties of dioxins 
Polychlorinated dibenzo-p-dioxins (PCDDs) and polychlorinated dibenzofurans 
(PCDFs) are persistent environmental toxicants collectively called as “dioxins” 
(Figure 1). Coplanar polychlorinated biphenyls (coplanar PCBs) have similar 
biological effects and thus are often classified as dioxins. Sometimes the term 
“dioxin” is used as a synonym of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), the 
most potent congener among the PCDD/Fs (Figure 2). When the biological effects 
of dioxins are investigated, TCDD is the most often used model compound.  
 
The term congener refers to compounds with the same basic structure but different 
number of substituents. Altogether there are 75 possible PCDDs and 135 possible 
PCDFs. Chlorine at lateral positions 2, 3, 7 and 8 results in the characteristic 
“dioxin-like” effects. Hence, those 7 PCDDs and 10 PCDFs that have chlorine at 
positions 2, 3, 7 and 8, are toxicologically the most important. (Lindén et al. 2010; 
Poland and Knutson 1982; Safe 1986). 
 
Dioxins are non-volatile, highly lipophilic molecules and resistant to chemical and 
biological degradation. Due to these properties dioxins are an environmental 
problem, as they bioaccumulate in the food chain ending into tissue fat of higher 
trophic level animals such as fish, birds, and mammals (Loonen et al. 1996). Dioxins 
are able to cross the placenta so the developing embryo or fetus may be exposed 
(Kreuzer et al. 1997). The lipophilicity and stability of dioxins increase with 
increasing number of chlorine substituents in the molecule. The half-lives of 
different PCDDs in adult humans vary from 5 to 13 years, for TCDD the half-life is 
approximately 7.2 years (Milbrath et al. 2009; Tuomisto et al. 2011). In infants, the 
half-life of TCDD is about 5 months (Kreuzer et al. 1997). Half-lives of dioxins are 
species-specific: in rats the half-life of TCDD is about 3 to 4 weeks (Rose et al. 
1976). 
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Figure 1. General structures of polychlorinated dibenzo-p-dioxins (PCDDs) and 
polychlorinated dibenzofurans (PCDFs).   
 
 
 
 
Figure 2. Chemical structure of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).
2.1.2 Comparing the potency of dioxins – TEF concept 
All 2,3,7,8-substituted PCDD and PCDF congeners induce similar biological effects 
through the AHR, although they are observed at vastly different doses. The potency 
differences are due to differences in pharmacokinetics and affinity to AHR (Poland 
and Knutson 1982; Simanainen et al. 2002). Toxic equivalence factor (TEF) is used 
to compare the potency of each congener to that of TCDD (Van den Berg et al. 1998, 
2006). The TEF approach is based on following assumptions: the compounds must 
show a structural relationship to the PCDDs and PCDFs, bind the AHR, elicit AHR-
mediated biochemical and toxic responses, be persistent and accumulate in the food 
chain. Typically, the rank order of potency is TCDD (TEF = 1) > 1,2,3,7,8-
pentachlorodibenzo-p-dioxin (TEF = 1) > hexachlorodibenzo-p-dioxin (3 congeners; 
PCDD 
PCDF 
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TEF = 0.1) > 1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin (TEF = 0.01) > 
octachlorodibenzo-p-dioxin (TEF = 0.0003) (Van den Berg et al. 2006).  
 
By summing the normalized TEF concentrations of each dioxin-like compound in a 
sample, total amount of dioxin-like compounds can be calculated and expressed as 
toxic equivalents (TEQs). Although TEF concept includes assumptions and 
limitations, it has turned out to be a useful approach in risk management of dioxin-
like compounds (Safe 1997; Van den Berg et al. 2000). 
2.1.3 Sources and human exposure 
Dioxins have no industrial or other uses; instead they arise as unwanted by-products 
in various combustion and industrial processes where chlorine and metal catalysts 
are present. Main sources of dioxins include waste incineration in too low 
temperatures, metal smelting and refining, and chlorine bleaching of cellulose pulp. 
They also occur as impurities among PCBs, chlorophenols and some other 
chlorinated chemicals. Chemical accidents may result into formation of dioxins and 
lead to exposure of workers or nearby residents, as happened in Seveso, Italy, 1976, 
in context of explosion of a chemical plant producing trichlorophenol. (Bertazzi et al. 
1998; Lindén et al. 2010).  
 
Dioxins are widespread in the environment. Highest levels can be found in some 
soils, sediments and food of animal origin, whereas concentrations in plants, water 
and air are generally low. Dioxins are also invariably present in humans constituting 
so called “background exposure” (WHO 2010). Dioxin emissions have been 
decreasing since 1980’s due to improved waste incineration and industrial 
techniques (U.S. EPA 2006). It is probable that exposure of general human 
population to dioxins is continuously declining. For example, decrease of dioxin 
concentrations in mother´s milk has been observed during 1988 to 2007 (WHO 
2009). 
 
Food, especially fatty items, is the major source of human exposure to dioxins and 
PCBs contributing more than 90% of the average intake (Liem et al. 2000). Fish is a 
major source of dioxin intake in Finland, comprising about 72−94% of the total 
exposure (Kiviranta et al. 2004). The Baltic Sea is very contaminated with dioxins 
thus contributing to high dioxin levels in e.g. Baltic herring and salmon (Hallikainen 
et al. 2011). In some other European countries, dairy products, meat, fats and oils 
constitute the main exposure route. Average daily intake of dioxins in many 
countries is about 1 pg/kg/d (TEQ per b.w.) or about 50−100 pg/d per person 
(Tuomisto et al. 2011). 
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The WHO recommendation for tolerable daily intake level is 1 to 4 pg/kg/day (in 
TEQ per b.w.) during continuous exposure (WHO 2000). Breast-fed infants are a 
high exposure group of a special concern, as their exposure may be one to two 
orders of magnitude larger (Päpke 1998). Another high-exposure group is comprised 
by those consuming plenty of fish, especially Baltic herring and salmon. However, 
no adverse effects due to dioxin exposure could be found in fishermen having on 
average twofold higher dioxin blood levels as compared to general population; in 
contrast, decreased mortality and risk of cardiovascular diseases were observed 
(Turunen et al. 2008).  
 
Although dioxin concentrations in the environment are declining, there are aspects 
that warrant solid follow-up of their presence in the environment and food items also 
in the future. Since dioxins are present everywhere, virtually all people are exposed 
to low amounts of them throughout life. This is somewhat alarming since margin of 
exposure in regard to some developmental and reproductive effects is very small 
(Miettinen 2006; U.S. EPA 2012; WHO 2000). Another issue is that there have been 
several cases of acute food safety problems due to dioxin-contaminated feed in some 
European countries and US during 1997-2011 (EU 2011; WHO 2010). In addition to 
potential human health risk, these kinds of incidents tend to have substantial 
economical effects (Covaci et al. 2008; Lascano-Alcoser et al. 2011). 
2.1.4 Effects on humans 
A possible link between exposure to dioxins/TCDD and multiple human health 
effects has been suggested, including developmental dental defects, cancer, 
cardiovascular disease, insulin resistance and diabetes, neurological symptoms, and 
endocrine and reproductive effects such as impaired semen quality, decreased 
male/female ratio of births, endometriosis and changes in neonatal thyroid function 
(Akhtar et al. 2004; Alaluusua et al. 1996, 1999, 2004; Baccarelli et al. 2008; 
Bertazzi et al. 1998, 2001; Birnbaum and Cummings 2002; Chang et al. 2010; 
Cranmer et al. 2000; Eskenazi et al. 2002, 2010; Feeley and Brouwer 2000; Lee et al. 
2006; Mayani et al. 1997; Mocarelli et al. 2000, 2011; Pesatori et al. 2003, 2009; 
Rennert et al. 2012; Remillard and Bunce 2002; Steenland et al. 2004; Sweeney and 
Mocarelli 2000; Urban et al. 2007; Warner et al. 2011, 2013). Dioxins are 
prototypical endocrine disrupting compounds, that is, they cause adverse effects via 
affecting endocrine systems (Birnbaum 1995; Birnbaum and Fenton 2003; Mocarelli 
et al. 2008, 2011; WHO/IPCS 2002). After very high exposure to dioxins, as in 
cases of chemical accidents or intentional poisoning, a skin disease called chloracne 
is the characteristic consequence in humans (Geusau et al. 2001; Saurat et al. 2012). 
It is not known that any human being would have died due to acute effects of TCDD 
or other dioxins. 
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The most worrying health effects of dioxins in humans are possibly those on the 
development, as evidence exists that background exposure via mother´s milk can 
cause dental aberrations in children (Alaluusua et al. 1996, 1999). Although dioxin 
concentrations in the environment have declined, the concern of potential effects of 
even low doses during the fetal period or early childhood remains. Another concern 
has been the carcinogenic potential of dioxins. The International Agency for 
Research on Cancer (IARC) has classified TCDD as a class I human carcinogen 
(IARC 1997), however, the current background exposure levels are supposed to 
have minor or even negligible effect on cancer incidence or mortality (Tuomisto and 
Tuomisto 2012). 
2.1.5 Effects on laboratory animals 
TCDD exposure induces numerous toxic and adaptive responses in experimental 
animals. There are wide inter- and even intraspecies differences in the 
manifestations of dioxin toxicity. In terms of acute lethality, the most sensitive 
mammal is guinea pig and the most resistant hamster. In rats and mice, strains with 
widely different sensitivities towards acute lethality of TCDD exist. The 
mechanisms of intraspecies differences vary, but seem to involve aryl hydrocarbon 
receptor (AHR), a transcription factor and main mediator of dioxin toxicities. The 
complex features of dioxin toxicity make the risk assessment very challenging. 
(Lindén et al. 2010; Pohjanvirta and Tuomisto 1994). 
 
The toxic responses to TCDD are dependent on many factors, such as dose, species, 
strain, age and gender of the animal, and the target tissue. Typical 
pathophysiological responses caused by TCDD in rats include thymic atrophy, 
immune dysfunction, wasting syndrome, mortality, hepatic damage and steatosis, 
increase in serum bilirubin, reproductive and endocrine effects, embryonic 
teratogenesis, and tumor promotion. (Birnbaum and Tuomisto 2000; Pohjanvirta and 
Tuomisto 1994; Poland and Knutson 1982; Uno et al. 2004). Some of these effects 
are seen in both sensitive and resistant rat strains, whereas others are seen mostly 
only in sensitive rats. 
 
In mammals, the most sensitive responses to TCDD exposure seem to be increased 
susceptibility towards infections (Lindén et al. 2010; Pohjanvirta and Tuomisto 1994; 
Thigpen et al. 1975), male reproductive effects (Gray et al. 1997; Mably et al. 
1992a,b,c) and effects on tooth development (Kattainen et al. 2001; Miettinen et al. 
2002). In a recent study (Lensu et al. 2011), aversion to novel food items was shown 
to be another extremely sensitive endpoint of TCDD toxicity. 
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2.1.6 AHR, the principal mediator of dioxin toxicity 
The principal mediator of the biological effects of dioxins and related aromatic 
hydrocarbons in the body is the cytosolic protein called aryl hydrocarbon receptor 
(AHR; Poland and Knutson 1982). AHR is a ligand-activated transcription factor 
belonging to Helix-Loop-Helix/Periodic, AHR nuclear translocator, Single-minded 
(bHLH/PAS) protein family. Several genes coding the phase I and phase II drug-
metabolizing enzymes are direct targets of the AHR-driven transcriptional activation 
and have been named the AHR gene battery (Table 1; Nebert et al. 2000). In 
addition, TCDD has been shown to modify (either up- or downregulate) the 
transcription of several hundreds of genes in adult rat or mouse liver, and in human 
hepatoma cells, presumably in an AHR-mediated way (Boverhof et al. 2005, 2006; 
Boutros et al. 2008, 2011; Fletcher et al. 2005; Puga et al. 2000). Basically, 
transcriptional targets of AHR include genes involved in xenobiotic detoxification 
and homeostatic control of endobiotics, as well as genes involved in control of cell 
proliferation, differentiation and inflammation (Bock and Köhle 2009). Findings on 
AHR knockout mice support the role of AHR in normal vascular and hepatic 
development (Nguyen and Bradfield 2008). On the other hand, AHR knockout mice 
have proved to be unresponsive to all major effects of TCDD (Lindén et al. 2010). 
The role of AHR in biology and toxicology is a very wide theme recently covered 
by a book: Pohjanvirta (ed.) 2012. 
Table 1. Typical target genes of AHR-mediated transcriptional activation (the AHR 
gene battery; Nebert et al. 2000) 
Enzyme Acronym 
Cytochrome P4501A1 CYP1A1 
Cytochrome P4501A2 CYP1A2 
NAD(P)H:quinone oxidoreductase NQO1 
Glutathione transferase GSTA1 
UDP glucuronosyltransferase 1A6 UGT1A6 
Cytosolic aldehyde dehydrogenase 3A1 ALDH3A1  
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2.1.6.1 Mechanism of AHR action 
In the absence of ligand, AHR resides in the cytosol as a part of a multiprotein 
complex including heat shock protein 90 dimer, tyrosine kinase c-src, hepatitis virus 
X-associated protein 2, and co-chaperone p23 (Haarmann-Stemmann and Abel 
2012). After ligand binding, AHR dissociates from its cytosolic partners and 
translocates into nucleus, where it forms a dimer with aryl hydrocarbon receptor 
nuclear translocator (ARNT), another member of the bHLH/PAS-family. AHR-
ARNT heterodimer binds to specific sites of genome called dioxin/xenobiotic 
responsive elements (DREs or XREs) situated upstream of target genes (Figure 3). 
Consequently, the expression of target genes is induced or sometimes repressed. A 
prototypical representative of this classical AHR-mediated signaling pathway is 
cytochrome P450 1A1 (CYP1A1) induction as a response to dioxin exposure 
(Lindén et al. 2010; Ma 2012). 
 
 
Figure 3. The classical pathway of AHR-mediated gene expression and negative 
feedback regulation by AHRR.  (Illustration by M. Korkalainen; with 
permission). 
In addition to the interactions with ARNT, AHR functions in protein-protein 
interactions with many other transcription factors. This crosstalk leads to mutual 
modulation of the ability of AHR and the interacting transcription factors to regulate 
the expression of their target genes. The best characterized crosstalk mechanisms 
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include interactions between AHR and aryl hydrocarbon receptor repressor (AHRR), 
estrogen receptor (ER), nuclear factor kappa B (NF-kB), retinoblastoma protein 
(RB)/E2F1 and specificity protein 1 (SP1). Physiologically these interactions may 
have consequences in the areas such as ER signaling, cell cycle progression and 
inflammatory response. (Swanson 2012).  
 
So called non-genomic pathways of AHR signaling are also likely to exist as 
described by Matsumura (2012). One of such pathways results from the release of 
tyrosine kinase c-src upon ligand binding to AHR. The released c-src subsequently 
phosphorylates the epidermal growth factor receptor (EGFR) leading to downstream 
activation of mitogen-activated protein kinases (MAPKs), with further activation of 
the gene expression of proinflammatory enzymes. (Haarmann-Stemmann and Abel 
2012). 
2.1.6.2 AHR ligands 
Various structurally diverse exogenous and endogenous compounds can bind to 
AHR and activate AHR mediated gene expression (Lindén et al. 2010; Nguyen and 
Bradfield 2008). Dioxins and PCBs, environmental contaminants of anthropogenic 
origin, are the most potent class of AHR ligands. Polycyclic aromatic hydrocarbons, 
including e.g. 3-methylcholantrene and benzo(a)pyrene, are another major group of 
contaminants that can bind AHR. However, they produce clearly milder effects than 
dioxins most probably due to their relatively rapid metabolic inactivation (Lindén et 
al. 2010). 
 
Majority of naturally occurring AHR ligands are dietary plant-derived chemicals 
such as flavonoids.  Most of them are relatively weak ligands of AHR (Nguyen and 
Bradfield 2008). An exception is indolo(3,2-b)carbazole present in some cruciferous 
vegetables, as it binds AHR strongly. However, it does not cause toxicity most 
probably due to its rapid metabolism (Pohjanvirta et al. 2002; Lindén et al. 2010). 
Mammalian endogenous compounds that can bind and activate AHR include e.g. 
tryptophan and its metabolites, indigo, indirubin, bilirubin, biliverdin, arachidonic 
acid metabolites such as lipoxin A4, several prostaglandins and retinoids (Gambone 
et al. 2002; Lindén et al. 2010; Seidel et al. 2001). On the other hand, an endogenous 
compound 7-ketocholesterol has antagonist effects on AHR-mediated gene 
expression (Savouret et al. 2001). The existence of a wide variety of compounds 
capable to bind and activate/inhibit AHR supports the view that AHR has multiple 
roles in normal physiology, embryonic development and adaptive response to 
xenobiotics, although no high-affinity endogenous ligand has yet been found. In 
some cases, AHR may be activated ligand-independently, e.g. via cyclic adenosine 
monophosphate (cAMP) or low density lipoprotein (LDL; Nguyen and Bradfield 
2008). 
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2.2 Rat models 
2.2.1 H/W and L-E rats 
Han/Wistar (Kuopio; H/W; LD50 > 10,000 µg/kg) and Long-Evans (Turku/AB; L-E; 
LD50 10-20 µg/kg TCDD) rats are the most TCDD-resistant and the most TCDD-
sensitive rat strains, respectively. They display the largest known intraspecies 
difference, about 1000-fold, in TCDD-induced acute lethality. This makes H/W rats 
the most TCDD-resistant mammals known, whereas L-E rats are slightly more 
sensitive than e.g. Sprague-Dawley rats (LD50 25-60 µg/kg, Beatty et al. 1978). The 
exceptional TCDD resistance of H/W rats is related to a mutated AHR allele (AHRhw) 
and to another, unknown gene B allele (Bhw) (Pohjanvirta 1990, 1998; Tuomisto et al. 
1999b). The AHRhw allele possesses a point mutation that results in an abnormal 
splicing variant and C-terminus transactivation domain and a smaller AHR protein 
in H/W rats compared with the wild-type receptor present in TCDD-sensitive strains 
such as Sprague-Dawley and L-E (~98 kDa versus 106 kDa, respectively) (Elferink 
and Whitlock 1994; Pohjanvirta et al. 1998; Pohjanvirta et al. 1999). The identity of 
gene B has not yet been determined, but it may encode a protein participating in the 
AHR signaling pathway.  
 
In H/W rats, the binding of TCDD to the AHR and the subsequent binding of the 
receptor complex to the DNA occur normally (Lindén et al. 2010). However, due to 
alternative splicing in the transactivation domain of the receptor protein, the 
initiation of the transcription of some, but not all, genes is ineffective. As a 
consequence, some responses, called Type I endpoints, of H/W rats to TCDD are 
same as in sensitive rat strains, whereas other responses are clearly attenuated and 
called Type II endpoints (Table 2; Lindén et al. 2010; Simanainen et al. 2002, 2003). 
Very little is known about the particular protein-protein interactions that are 
disturbed/destroyed due to abnormal transactivation domain of AHRhw, subsequently 
leading to ineffective transcription of some normally TCDD-inducible genes. Gene 
B affects Type II endpoints but not Type I endpoints. It is noteworthy that an 
attenuated Type II effect (if measurable) occurs at similar doses in H/W rats as the 
respective normal effect occurs in L-E rats. (Simanainen et al. 2002; Tuomisto et al. 
1999b). 
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Table 2. Classification of TCDD-induced biochemical and toxic responses into 
Type I and Type II endpoints. The latter (Type II) endpoints are sensitive 
to alterations in the transactivation domain of AHR whereas the former 
(Type I) endpoints are not. 
 
2.2.2 Rat lines A, B and C 
The two H/W-type TCDD resistance genes, AHRhw and Bhw, have been segregated 
into separate rat lines by crossbreeding H/W and L-E rats (Tuomisto et al. 1999b). 
The resultant three new rat lines are called A, B and C (Figure 4) and they differ 
vastly in their TCDD-resistance: Line A has the mutated AHRhw allele and the wild-
type B allele (genotype AHRhw/hw Bwt/wt) and appears to be as TCDD-resistant as 
H/W. Line C has the wild-type alleles of both genes (genotype AHRwt/wt Bwt/wt) and 
is almost as TCDD-sensitive as L-E. Line B expresses wild-type AHR but is 
intermediately TCDD-resistant due to H/W-type resistance alleles of gene B 
(genotype AHRwt/wt Bhw/hw). Since lines A and B have only one of the H/W type 
resistance genes (either AHRhw or Bhw), it has been possible to study the effects of 
each resistance gene independently from the other. This has provided a novel 
approach for resolving mechanisms of dioxin toxicity.  
 
Lines A, B and C are similar in respect to the ethoxyresorufin-O-deethylase (EROD) 
activity (marker for CYP1A1 induction), dental defects and thymic atrophy, which 
are typical Type I effects. Instead, Type II effects such as mortality, body weight 
Type Effect Reference 
I CYP1A1 induction Unkila et al. 1993 
I Thymic atrophy Pohjanvirta et al. 1989 
I Fetotoxicity Huuskonen et al. 1994 
I Dental defects (incisor tooth defect, 3rd molar 
depletion) 
Alaluusua et al. 1993; Kattainen et 
al. 2001; Simanainen et al. 2002 
II Acute lethality Pohjanvirta et al. 1993 
II Hepatotoxicity Pohjanvirta et al. 1989 
II Wasting syndrome Pohjanvirta et al. 1989; Simanainen 
et al. 2002 
II Liver tumor promotion Viluksela et al. 2000 
II Hyperbilirubinemia Simanainen et al. 2002, 2003; 
Tuomisto et al. 1999b; Unkila et al. 
1994 
II Increased serum tryptophan level, free fatty acids 
level, aspartate aminotransferase (ASAT) activity 
Pohjanvirta et al. 1989; Simanainen 
et al. 2002, 2003; Unkila et al. 1994 
II Lipid peroxidation Pohjanvirta et al. 1990 
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loss and increased serum bilirubin show strain-dependence, line C being the most 
sensitive, line B intermediately sensitive and line A the most resistant to these effects. 
This is in concordance with the observations in H/W and L-E rats and confirms the 
conception that TCDD-induced short-term toxicity involves at least two different 
AHR-mediated signaling pathways leading to Type I and Type II endpoints, the 
wild-type transactivation domain being critical only for the latter effects. 
(Simanainen et al. 2002, 2003; Tuomisto et al. 1999b). 
 
 
 
Figure 4. Crossbreeding of H/W and L-E rats, and the resultant novel rat lines A, B 
and C (Tuomisto et al. 1999b). AHR and gene B genotypes as well as 
 are shown for each strain/line. 
Line B and line C rats both express wild-type AHR. However, TCDD-induced Type 
II responses (e.g. mortality, wasting and hyperbilirubinemia) are weaker in line B 
than in line C rats. This implies that gene B, in addition to AHR, is somehow 
involved in the mechanistic pathways of these responses. Especially, Bhw allele 
seems to influence TCDD efficacy (magnitude of effect) for serum aspartate 
aminotransferase (ASAT) and bilirubin levels (Simanainen et al. 2003) but the 
reason for this is unknown.  
 
Results from rats heterozygous in respect of both resistance alleles (genotype 
AHRhw/wt Bhw/wt) suggest that products of AHRhw and Bhw interact in a way that 
increases resistance more than either heterozygous gene alone (Tuomisto et al. 
1999b). Therefore, the product of Bhw could be a specific protein participating AHR 
signaling pathway. However, according to studies of Korkalainen et al. (2003, 2004) 
gene B is not the AHR dimerization partner ARNT, neither the negative regulator 
AHRR. Other possible candidates include, for example, the various coactivators 
interacting with the transactivation domain of AHR. 
 
Line A (AHRhw/hw Bwt/wt) 
LD50 > 10,000 µg/kg 
 
Line C (AHRwt/wt Bwt/wt) 
LD50 20-40 µg/kg 
Han/Wistar (AHRhw/hw Bhw/hw) 
LD50 > 10,000 µg/kg 
x 
Long-Evans (AHRwt/wt Bwt/wt) 
LD50 10-20 µg/kg 
Line B (AHRwt/wt Bhw/hw) 
LD50 400-800 µg/kg 
> 6 generations of crossbreeding 
FIG. 4 
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Some further information of the characteristics of gene B comes from the study 
where the temporal development of the resistance in line A and line B rats was 
studied. Both types of resistance were shown to develop postnatally (Simanainen et 
al. 2004). However, the time course of resistance development associated with 
AHRhw and Bhw alleles is different. Line A rats are fairly resistant to TCDD already 2 
days after birth and full resistance to acute lethality develops during the first week. 
In line B rats, complete resistance was gained at the age of 28 days in females and 
42 days in males. Resistance associated with the Bhw allele starts to develop between 
days 14 and 28. Therefore, Bhw allele might be related to some physiological 
function that matures between the postnatal days 14 and 28 (Simanainen et al. 
2004). 
2.3 Selected features of (acute) dioxin toxicity 
Acute dioxin toxicity in rats and other experimental animals includes numerous 
pathophysiological changes, most importantly, delayed mortality, wasting syndrome, 
hepatotoxicity and changes in clinical chemistry parameters. A short look is taken 
on some of these consequences, as well as on the TCDD-induced oxidative stress 
and the specific properties of HxCDD-induced acute toxicity, as these issues are 
essential background for Results and Discussion. 
2.3.1 Acute lethality and wasting syndrome 
Lethal dose of TCDD varies widely among animal species and strains, in addition, 
gender has a minor effect. Acute lethality caused by TCDD is typically delayed in 
nature, with the time to death from exposure being 2–5 weeks in rats (Pohjanvirta 
and Tuomisto 1994). Prior to death, animals reduce their feeding dramatically (a 
behaviour called hypophagia) and as a result, their body weight declines 
substantially, even by over 50%. Body fat stores and to some extent muscle mass are 
depleted. This phenomenon is known as the wasting syndrome. It is a rather 
uncommon manifestation of chemical toxicity. In addition to rats, TCDD-induced 
hypophagia and body weight loss have been reported in other animals such as mice, 
hamsters and guinea-pigs (Kelling et al. 1985; Lindén et al. 2010; Pohjanvirta and 
Tuomisto 1994).The biochemical basis of wasting syndrome is unclear; however, 
TCDD apparently leads to lowered body weight set point. Based on experiments 
including pair-fed rats, depletion of energy stores as a consequence of hypophagia is 
a major cause of acute mortality in dioxin-exposed rats. Yet other mechanisms must 
also exist since force-fed rats do not loose weight but still die at approximately same 
time after TCDD administration. (Lindén et al. 2010; Pohjanvirta and Tuomisto 
1994). 
 
From a biochemical point of view, wasting syndrome is associated with changes in 
energy metabolism including effects on gluconeogenesis, de novo fatty acid 
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synthesis, serum free fatty acids and triglycerides, as well as glycogen and fat 
storage in liver and adipose tissue, respectively (Croutch et al. 2005; Gorski et al. 
1988, 1990; Muzi et al. 1989; Tuomisto et al. 1999a; Viluksela et al. 1999; Weber et 
al. 1991a,b). Reduced gluconeogenesis is probably due to inhibition of key enzymes 
of gluconeogenesis: phosphoenolpyruvate carboxykinase (PEPCK), pyruvate 
carboxylase and glucose 6-phosphatase (Weber et al. 1991a,b). Reduced 
gluconeogenesis leads to a lowering of blood glucose, reduction in plasma insulin 
and free insulin like growth factor (IGF-1) levels and activation of adenosine 
monophosphate-activated protein kinase (AMPK; Croutch et al. 2005).  
 
At doses high enough to cause body weight loss, TCDD reduces circulating insulin 
levels in rats. Insulin, among other factors, is involved in the regulation of long-term 
energy balance but its possible role in wasting, if any, is undefined (Lindén et al. 
2010). In addition to reduced gluconeogenesis, a possible cause for reduced insulin 
levels after TCDD exposure is impairment of the glucose-stimulated insulin 
secretion, an effect seen in isolated pancreatic islets from TCDD-treated rats 
(Novelli et al. 2005). On the other hand, the function of insulin may be enhanced by 
TCDD, as insulin sensitivity at the whole organism level has been shown to improve 
after TCDD administration in rats and mice (Lindén et al. 2010). This is in contrast 
with the observations in humans, where higher levels of dioxins and other endocrine 
disrupting compounds have been associated with insulin resistance (Alonso-
Magdalena et al. 2011). 
2.3.2 Hepatotoxicity of dioxins 
A major target organ for TCDD toxicity in laboratory animals is liver (Boverhof et 
al. 2005, 2006; Chang et al. 2005; Goodman and Sauer 1992; Mann 1997; 
Pohjanvirta and Tuomisto 1994). Hepatic hyperplasia, fatty infiltration, and necrosis 
have been reported in several species (Birnbaum and Tuomisto 2000). In rats, the 
major features of TCDD´s hepatotoxicity are hepatocellular hypertrophy, 
multinucleate hepatocytes, steatosis and inflammatory cell infiltration. 
Abnormalities in hepatic plasma membrane and proliferation of both smooth and 
rough endoplasmic reticula have been reported (Pohjanvirta and Tuomisto 1994). 
Hepatotoxicity is also reflected by the altered serum transaminases, dehydrogenases 
and bilirubin (Birnbaum and Tuomisto 2000). Notable species and strain differences 
in TCDD´s hepatotoxicity exist: TCDD induces extensive hepatic necrosis in rabbit, 
whereas in rats and mice the effect is milder consisting of scattered, mainly 
centrilobularly located necrotic foci (Pohjanvirta and Tuomisto 1994). Further, H/W 
rats exhibit much milder liver lesion than L-E rats, hence, hepatotoxicity belongs to 
Type II dioxin effects (Pohjanvirta et al. 1989).  TCDD decreases bile flow dose-
dependently (Yang et al. 1977, 1983) and some dioxins other than TCDD have been 
shown to increase serum bile acid concentrations (Brewster et al. 1988; Couture et al. 
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1988). Bile acids are well-known hepatotoxicants and potent suppressors of PEPCK 
expression, therefore, altered bile acid synthesis and transport might contribute to 
TCDD-induced hepatotoxicity (Fletcher et al. 2005). 
 
The wide range of hepatic effects may have its basis in the extensive changes in 
hepatic gene expression after TCDD exposure. For example, in adult rat or mouse 
liver, hundreds or even thousands of genes are affected. Both induction and 
repression of gene expression are consequences of TCDD exposure (Lindén et al. 
2010). TCDD causes hepatic accumulation of porphyrins, especially uroporphyrin, 
in rats and mice (Goldstein et al. 1973, 1982). However, in rats, porphyria may 
occur predominantly during subchronic or chronic exposures and is not a major 
response during acute exposure. See the Section 2.7.2 for this effect.  
 
In rats and other rodents, long-term TCDD treatment leads to the development of 
tumors of many sites, including liver. Female rats seem to be more prone to tumor-
promoting activity of TCDD and this effect has been used as a basis for quantitative 
cancer risk assessment for TCDD. However, TCDD does not behave like a complete 
carcinogen (Knerr and Schrenk 2006; Viluksela et al. 2000). L-E rats are about 100-
fold more sensitive than H/W rats to the tumor promoting effect of TCDD 
(Viluksela et al. 2000). Altered metabolism of endogenous molecules such as 
estradiol can lead to the formation of quinones and redox cycling. This has been 
hypothesized to play a role in the enhanced sensitivity of female rats to dioxin-
induced liver tumors (Birnbaum and Tuomisto 2000).  
2.3.2.1 Fatty liver 
TCDD is known to cause fatty degeneration (steatosis) of the liver in rats and other 
species (Birnbaum and Tuomisto 2000; Poland and Knutson 1982). Fat is depleted 
from the white adipose tissue and concurrently accumulated in the liver (Pohjanvirta 
et al. 1990). However, it is unlikely that the mobilization of the peripheral adipose 
stores would alone cause fatty liver, since in a study on L-E rats, the TCDD-treated 
rats accumulated fat in the liver whereas the pair-fed controls did not (Pohjanvirta et 
al. 1990). Instead, the probable principal reason for fatty liver is the altered function 
of hepatocytes due to TCDD administration. This is supported by the reports of 
Kawano et al. (2010) and Lee et al. (2010) suggesting that hepatic steatosis induced 
by AHR activation is accompanied by upregulated CD36/fatty acid translocase and 
peroxisome proliferator-activated receptor (PPAR) expression, resulting in the 
upregulation of fatty acid uptake and accumulation of lipids in the liver. In addition, 
AHR activation was shown to result in inhibition of hepatic export of triglycerides 
and suppression of fatty acid oxidation, thus further favouring the development of 
steatosis (Lee et al. 2010). 
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2.3.3 TCDD-induced oxidative stress 
Oxidative stress refers to an imbalance between the production and manifestation of 
reactive oxygen species (ROS), and the ability of a biological system to readily 
detoxify them or to repair the resulting damage. Oxidative stress is a well known 
consequence of TCDD exposure in rodents (Reichard et al. 2005; Senft et al. 2002, 
Shertzer et al. 1998; Stohs 1990; Stohs et al. 1990). A variety of mechanisms are 
suggested to be responsible for the TCDD-induced oxidative stress, as TCDD both 
reduces the expression levels of protective antioxidant enzyme systems, and induces 
the production of excessive amounts of ROS. Microsomes, mitochondria and 
leukocytes are typical sources of ROS following TCDD exposure 
(Latchoumycandane et al. 2003; Reichard et al. 2005; Stohs 1990; Wong and Cheng 
2011). Types of ROS produced in response to TCDD exposure include superoxide 
anion, hydrogen peroxide, and possibly hydroxyl radical (Hassoun et al. 2003; 
Senft et al. 2002; Shertzer et al. 1998; Stohs et al. 1990). 
 
The oxidative stress generated by TCDD seems to be dependent on the AHR 
genotype (Alsharif et al. 1994; Mohammadpour et al. 1988). L-E vs. H/W rat model 
supports this, as hepatic lipid peroxidation, an indicator of oxidative stress, was 
induced by TCDD dose-dependently in L-E but not in H/W rats (Pohjanvirta et al. 
1990). In concordance with this, subtle induction of HO-1, an enzyme easily 
induced by oxidative stress (Alam and Cook 2003), was seen in L-E rats but not in 
H/W rats after TCDD exposure (Boutros et al. 2011). HO-1 has also been shown to 
be increased in hepatic macrophages of Sprague-Dawley rats dosed with 2 or 4 
µg/kg TCDD (Nishimura et al. 2001). Most probably, oxidative stress can be 
classified as Type II dioxin effect, as it seems to be alleviated in rats resistant to 
acute toxicity of TCDD due to altered AHR. 
 
Other indicators of oxidative stress include e.g. increased hepatic and macrophage 
deoxyribonucleic acid (DNA) damage, increased urinary excretion of 
malondialdehyde, decreased hepatic membrane fluidity, and decreased glutathione, 
nonprotein sulfhydryl and nicotinamide adenine dinucleotide phosphate (NADPH) 
contents of liver (Stohs 1990). For example, Stohs et al. (1990) showed that TCDD 
exposure first increased but later at 12 days decreased cytosolic NADPH content by 
34% in female Sprague-Dawley rats, total decrease being even 50−70%. 
Antioxidants may alleviate, but not totally eliminate, the toxicity of TCDD. (Ciftci 
and Ozdemir 2011; Hassan et al. 1985; Pohjanvirta et al. 1990).  
 
The precise role of the oxidative stress in the expression of the toxic manifestations 
of TCDD has not been clearly determined to date, but it may be relevant e.g. for the 
carcinogenic potential of dioxins (Lindén et al. 2010; Shertzer et al. 1998). 
According to a recent review by Wong and Cheng (2011), oxidative stress induced 
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by dioxin and some other environmental toxicants may be an important factor 
behind male reproductive dysfunction. The increase in oxidative stress disrupts the 
cell junctions between testicular cells leading to deleterious effects on male 
reproductive capability (Wong and Cheng 2011). TCDD has been shown to induce 
oxidative stress in epididymis of adult rats (Latchoumycandane et al. 2003). In 
addition, decreased epididymal sperm levels in F1 male rats is one of the most 
sensitive adverse effects of TCDD following a maternal dose of 0.064-1.0 µg/kg 
(Bell et al. 2010; Mably et al. 1992a,b,c). 
2.3.4 Specific properties of HxCDD-induced toxicity 
The potency of 1,2,3,4,7,8-hexachlorodibenzo-p-dioxin (HxCDD) is about 10% of 
that of TCDD for typical AHR-mediated effects (TEF = 0.1; Van den Berg et al. 
2006). Among some other hexa-substituted dioxins and furans, it belongs to the 
most toxic dioxin congeners after TCDD and 1,2,3,7,8-pentachlorodibenzo-p-dioxin 
(for both, TEF = 1). For all mammals, as well as for avian and fish species studied 
so far, TEFs seem to be valid also for lethality (Van den Berg et al. 1998, 2000). 
Surprisingly, H/W rats have been shown to be more sensitive to HxCDD than to 
TCDD in terms of acute lethality (Table 3; Pohjanvirta et al. 1993), LD50 value of 
HxCDD being 2530 µg/kg for female H/W rats. For some characteristic short-term 
effects, the normal rank order of sensitivity holds even in H/W rats with TCDD 
being the most potent congener (Pohjanvirta et al. 1995; Simanainen et al. 2002). 
For L-E rats, the typical rank order between TCDD and HxCDD holds also for acute 
lethality, LD50 value of HxCDD being 132 µg/kg for female L-E rats (Table 3; 
Pohjanvirta et al. 1995). 
Table 3. LD50 values of HxCDD and TCDD for female rats (Pohjanvirta et al.  
1993, 1995). Highlighted value indicates the most potent congener in 
each case. 
Rat strain LD50 (µg/kg TCDD) LD50 (µg/kg HxCDD) 
H/W >9600 2530 
L-E 10 132 
 
 
It has been hypothesised that the mechanism of acute lethality caused by large doses 
of HxCDD is different from the prime, canonical AHR-mediated action mechanism 
of dioxin-like compounds (Pohjanvirta et al. 1995). This second mechanism can 
only be detected using animals highly resistant to the prime mechanism, such as 
H/W rats. Other highly chlorinated dioxins with a relatively low affinity to AHR 
such as 1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin may share this alternative toxic 
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pathway with HxCDD, but it appears to be especially characteristic to HxCDD 
(Pohjanvirta et al. 1995). 
 
Interestingly, in a study where the levels of 121 endocrine disrupting compounds 
were studied in breast milk samples from Denmark and Finland, HxCDD, as one of 
six chemicals out of 121, and the only PCDD/F, was found to have significantly 
higher levels in Danish than in Finnish samples. In less stringent statistical analysis 
also TCDD and many other endocrine disrupting compounds exhibited higher levels 
in Denmark than in Finland. It remains to be clarified, whether these findings are 
somehow linked to much higher incidence of male reproductive disorders in 
Denmark than in Finland (Krysiak-Baltyn et al. 2010). 
2.4 Heme and its synthesis 
Heme is a complex of protoporphyrin IX and ferrous iron (Figure 5). It is a 
functionally essential prosthetic group of various proteins. These so called 
hemoproteins have diverse biological functions including transportation and storage 
of diatomic gases (as exemplified by hemoglobin and myoglobin), chemical 
catalysis (cytochrome P450 superfamily, catalase, peroxidases, etc.), diatomic gas 
detection (neuronal PAS2, soluble guanylyl cyclase), and electron transfer (e.g. 
cytochromes C, B5 and B558). In addition, heme acts as a cellular messenger via 
heme-regulated proteins such as Bach1 and δ-aminolevulinic acid synthetase 
(ALAS1). (Furuyama et al. 2007; Gozzellino et al. 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Chemical structure of heme. 
Heme is a necessary molecule for all aerobic organisms. The two largest pools of 
hemoproteins in the body are hemoglobin in red blood cells and myoglobin in 
muscles. According to some estimates about 80-85% of total heme of the body is in 
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hemoglobin, 12-17% in myoglobin and 3% in other hemoproteins. (Gozzellino et al. 
2010; Ponka 2003; Shibahara et al. 2002). Heme is synthesized virtually in all 
tissues, but the principal sites are erythroid cells (about 85%) and hepatocytes 
(nearly all the rest; Ponka 1997). 
 
In mammals, eight enzymes are involved in heme biosynthesis (Figure 6). δ-
Aminolevulinic acid synthetase (ALAS) is the first and the rate-limiting enzyme of 
this pathway and it exists as two isozymes. ALAS1 (hepatic or non-specific ALAS) 
is expressed in all tissues, whereas the expression of ALAS2 is restricted to 
erythroid cells. Both ALAS isozymes catalyze the formation of δ-aminolevulinic 
acid from glycine and succinyl coenzyme A (succinyl CoA) in mitochondria. δ-
Aminolevulinic acid is transported to cytosol, where the subsequent four enzymatic 
steps take place. The resultant coproporphyrinogen III is transported back into 
mitochondria by the transport protein ATP-binding cassette sub-family B member 6 
(ABCB6) or mitochondrial 2-oxoglutarate/malate carrier protein (SLC25A11), and 
the last three steps of heme biosynthesis occur in mitochondria. Finally, heme 
molecule is transported to cytosol by an unknown heme transporter. (Furuyama et al. 
2007). 
 
Free heme is a potent pro-oxidant due to its reactive iron atom that can catalyze the 
formation of hydroxyl radical from hydrogen peroxide. Since free heme 
concentration exceeding 1 µM is toxic, intra- and extracellular free heme levels must 
be precisely maintained. Intracellular control is achieved through the regulation of 
the synthesis and catabolism of heme. Extracellular, systemic free heme levels are 
maintained at non-toxic area by help of specific plasma proteins such as haptoglobin 
and hemopexin, which bind cell-free hemoglobin and free heme, respectively. 
Hemoglobin-haptoglobin and heme-hemopexin complexes are recognized and taken 
up via endocytosis by e.g. macrophages and liver parenchymal cells. (Eskew et al. 
1999; Furuyama et al. 2007; Gozzellino et al. 2010; Sassa 2004). 
 
Heme itself has the capability of determining the rate of its synthesis and 
degradation. Heme regulates ALAS1 expression in a negative feedback manner 
(Furuyama 2007). On the other hand, free heme induces the heme-degradative 
enzyme HO-1 (see the next section) and thus enhances its own degradation. A 
number of mechanisms are suggested to be involved in the negative feedback 
regulation of ALAS1 expression by heme. These include reduction of transcription 
(Yamamoto et al. 1982, 1988) and translation (Sassa and Granick 1970; Yamamoto 
et al. 1983), destabilisation of mRNA (Hamilton et al. 1991) and inhibition of 
mitochondrial transport of precursor protein (Yamauchi et al. 1980). ALAS2 
expression is not suppressed by heme as large amounts of heme are needed for the 
efficient production of hemoglobin during erythroid differentiation. 
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Figure 6. Heme synthesis pathway. Rate-limiting enzymes are in bold.
Abbreviations: ALAD, !-aminolevulinic acid dehydratase; ALAS, !-
aminolevulinic acid synthetase; CPO, coproporphyrinogen oxidase; FEC, 
ferrochelatase; PBGD, porphobilinogen deaminase; PPO, 
protoporphyrinogen oxidase; UCoS, uroporphyrinogen III cosynthase; 
UROD, uroporphyrinogen decarboxylase. 
2.5 Heme degradation 
Heme degradation is a two-step process, where heme oxygenase (HO) first cleaves 
the porphyrin ring of heme to a linear tetrapyrrole biliverdin. Subsequently, 
biliverdin is rapidly reduced to bilirubin by biliverdin reductase (BVR; Figure 7). 
These compounds have characteristic colors: heme is red, biliverdin blue to green 
and bilirubin yellow. Biliverdin is water-soluble whereas bilirubin is lipophilic. 
(McDonagh et al. 2001). 
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Figure 7. Degradation of heme. BVR, biliverdin reductase; HO, heme oxygenase. 
(Modified from Wikimedia Commons). 
A majority, about 80% of plasma bilirubin originates from hemoglobin heme, the 
rest coming from myoglobin and other hemoproteins (Shibahara et al. 2002). Spleen 
is the major site of destruction of senescent erythrocytes, followed by liver and bone 
marrow. HO and BVR are ubiquitous enzymes, and apparently most, if not all, 
aerobic cells degrade at least small amounts of heme. The newly formed bilirubin is 
bound to plasma albumin and transferred to liver. As a lipophilic compound, it may 
enter hepatocytes by diffusion but other mechanisms may exist as well (Kamisako et 
al. 2000). In the hepatocyte, uridine diphosphate glucuronosyltransferase 1A1 
(UGT1A1) adds two equivalents of glucuronic acid to bilirubin to produce the more 
water soluble bilirubin diglucuronide, which is subsequently excreted into bile. Due 
to their characteristic colors and presence in bile, bilirubin, biliverdin and their 
derivatives are often referred to as bile pigments. In medicine, heme synthesis and 
degradation processes are important due to various associated disorders such as 
porphyrias and neonatal as well as other hyperbilirubinemias. 
 
Notably, bile pigments are not simply by-products of heme catabolism, but 
physiologically important, possibly essential molecules. This is due to a wide range 
of biological activities assigned to them during the last years and decades. Most 
importantly, bilirubin (and to some extent also biliverdin) is an efficient antioxidant, 
but bile pigments possess also anti-inflammatory, anti-viral, anti-apoptotic and anti-
mutagenic properties (Bulmer et al. 2008; Stocker et al. 1987; Stocker 2004). 
2.5.1 Heme oxygenase (HO) 
Heme is oxidatively cleaved to biliverdin by the rate-limiting enzyme heme 
oxygenase which was first described by Tenhunen et al. (1968). Due to high 
regiospecificity of the reaction, biliverdin IXα is the predominant biliverdin isomer 
formed in vertebrates. Heme oxygenases are an evolutionarily conserved family of 
Heme Biliverdin Bilirubin 
HO BVR 
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enzymes found in bacteria, algae, plants and animals. Two catalytically active, 
structurally related forms exist, the inducible HO-1 and the constitutively expressed 
HO-2. In addition, HO-3 isoform with negligible catalytic activity has been 
identified. HO-1 and HO-2 have different expression profiles: while HO-2 is a 
constitutive enzyme expressed mainly in vasculature and nervous system, HO-1 
responses to stress in all tissues. Induction of HO-1 is essential for cellular 
protection against various stressful situations, as evidenced by the severity of the 
few animal and human cases where HO-1 is lacking (Foresti et al. 2004; Gozzellino 
et al. 2010; McDonagh 2001; Poss and Tonegawa 1997; Radhakrishnan et al. 2011; 
Shibahara et al. 2002; Tenhunen et al. 1968; Yachie et al. 1999). 
 
In addition to biliverdin, equimolar amounts of carbon monoxide (CO) and ferrous 
iron are released in the reaction catalyzed by HO (Shibahara et al. 2002). Biliverdin 
is then rapidly converted to bilirubin by biliverdin reductase. All products of heme 
degradation are biologically active. CO is a vasoactive molecule and a potential 
neural messenger; in addition it may possess anti-inflammatory, anti-apoptotic and 
anti-proliferative effects (Foresti et al. 2004). Free ferrous iron (Fe2+) leads to rapid 
upregulation of iron-sequestering protein ferritin, but iron has also many other 
regulatory functions, including activation of specific genes (Foresti et al. 2004; 
Öllinger and Pratscke 2010). Importantly, free iron, like free heme, is a potent pro-
oxidant, and for this reason its amount in cells must be strictly regulated. Iron is 
either stored in ferric state within ferritin or it is transported to bone marrow to be 
recycled for heme synthesis in erythroid cells (Gozzellino et al. 2010; Shibahara et 
al. 2002). Biological activities of biliverdin and bilirubin are covered in the next 
sections (2.5.2–2.5.4). 
 
The expression level of HO-1 is normally low in cells other than macrophages, but 
various initiators of stress markedly activate HO-1 in virtually all cell types 
(Abraham and Kappas 2008; Foresti et al. 2004; Poss and Tonegawa 1997). These 
include e.g. hyperthermia, heme, heavy metals, oxidized lipoproteins, ultraviolet 
irradiation, hydrogen peroxide, inflammatory cytokines, and hypoxia (Alam and 
Cook 2003; Choi and Alam 1996; Ewing and Maines 1991; Murphy et al. 1991; 
Poss and Tonegawa 1997; Siow et al. 1995). TCDD exposure has been shown to 
induce HO-1 in the liver of L-E rats and hepatic macrophages of Sprague-Dawley 
rats (Boutros et al. 2011; Nishimura et al. 2001). The ability of HO-1 to respond to 
many stress signals is probably associated with the various stress-activated 
regulation elements within the HO-1 promoter, including activator protein 1 (AP-1) 
sites, CCAAT/enhancer-binding protein sites, phorbol ester response elements, 
heme response elements, and antioxidant response elements (Alam and Cook 2003; 
Inamdar et al. 1996). Further, several xenobiotic response elements (XREs) are 
present in the regulatory region of HO-1 but they have not been functionally 
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characterized (Bock and Köhle 2010). Characteristic features in the regulation of 
HO-1 expression are remarkable interspecies and inter-individual differences. In 
some specific situations, repression of HO-1 activity may be protective; especially, 
this may be a defense strategy developed in humans (Shibahara et al. 2003). 
 
Altogether, heme catabolism by HO-1 is an important cellular protection mechanism 
against oxidative and other stressful insults. Active HO-1 diminishes the amount of 
the pro-oxidant heme, and, on the other hand, the reaction products are strongly 
antioxidant, inhibit cell death, apoptosis, and aberrant proliferation (Gozzellino et al. 
2010; Idriss et al. 2008). Direct evidence for the protective role of HO-1 comes from 
the study of Poss and Tonegawa (1997), which showed that oxidation of 
macromolecules and tissue injury arise spontaneously in genetically modified mice 
deficient of HO-1. Further, the two known humans with verified HO-1 deficiency 
suffered from severe symptoms such as endothelial injury and general inflammation 
and eventually died at the age of 6 and 15 years (Radhakrishnan et al. 2011; Yachie 
et al. 1999).  
 
In recent years, HO-1 has received attention as a potential therapeutic target. HO-1 
was found to be up-regulated in disease models such as endotoxemia and ischemia 
in rodents (Rizzardini et al. 1994; Takeda et al. 1994) and in pathological states such 
as atherosclerosis, acquired immunodeficiency syndrome, diabetes mellitus and 
Parkinson´s and Alzheimer´s disease in humans (Alam and Cook 2003; Abraham 
and Kappas 2008). It has been suggested that heme degradation pathway, especially 
the ratio of HO-1 and BVR-A, might be a promising serum biomarker source for the 
early detection of Alzheimer´s disease (Mueller et al. 2010). HO-1 has complex 
effects on apoptosis and cell cycle in carcinogenesis, therefore, HO-1 is a possible 
target for anti-cancer treatment (Fang et al. 2004). In humans, expression of the HO-
1 gene is modulated by two functional polymorphisms in the promoter. A short 
dinucleotide repeat (<25 GT) in the HO-1 gene promotor is associated with 
enhanced transcriptional activity whereas the longer dinucleotide repeat has been 
associated with increased susceptibility to atherosclerosis and some lung diseases, 
however, contradictory results exist (Abraham and Kappas 2008; Kikuchi et al. 2005; 
Yamada et al. 2000; Yasuda et al. 2006). Induction of HO-1 has been shown to be 
protective in transplantation in many experimental models but it is yet unclear 
whether this property can be utilized clinically (Öllinger and Pratscke 2010). 
2.5.2 Biliverdin 
In vertebrates, biliverdin is continuously produced from catabolism of senescent or 
damaged erythrocytes and of the heme released during turnover of cytochrome P450 
enzymes and other heme containing proteins (Shibahara et al. 2002). Some 
vertebrates – birds, amphibians and reptiles – excrete biliverdin from the liver 
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directly into bile, but most mammals reduce most or all of it regiospecifically to 
bilirubin IXα. Biliverdin has a wide occurrence in the animal kingdom. It occurs e.g. 
in the plasma of many marine fish, in the blood of tobacco hornworm, the wings of 
moth and butterfly, the shell of bird eggs, the serum and egg of frog, the placenta of 
dog (Fang and Bada 1990), the milk of buffalo and sheep (Jandal 1995; Kumar et al. 
1983), and in human amniotic fluid (Krasner et al. 1969, 1971). In addition, 
biliverdin is found in plants, cyanobacteria and algae as a biosynthetic precursor for 
essential photoresponsive bilin pigments. Biliverdin is also used for camouflage or 
possibly photoprotection in insects and other lower organisms (McDonagh 2001). In 
normal human plasma, biliverdin was long unrecognized, but according to a recent 
report where sensitive analysis methods were used, its plasma level in control 
women was assessed to be 0.12 µM (Nytofte et al. 2011). Higher plasma values  
????– 6.5 µ M) were reported for normal healthy individuals by Gåfvels et al. (2009). 
Conjugated biliverdin has been found in post mortem bile of humans, and it is a 
major pigment in rabbit bile (Garay et al. 1965; Muñoz et al. 1986). However, it is 
unclear whether conjugated biliverdin is a product of the enzymatic conjugation of 
free biliverdin or a result of the oxidation of bilirubin conjugates (Garay et al. 1965; 
Noir et al. 1965). According to Garay et al. (1965), in many animal species 
conjugation of both biliverdin and bilirubin may occur simultaneously. Conjugated 
biliverdin was recently found also in normal human serum, and its level was 
increased in patients suffering from hepatocellular carcinoma or cirrhosis (An et al. 
2010). 
 
In human blood, bilirubin is bound with serum albumin, which prevents its toxic 
effects (Ahlfors 1981; Blauer and Wagniere 1975). Also biliverdin binds to albumin 
to the same binding site, yet somewhat less tightly than bilirubin (Ahlfors 1981). 
Concordantly, in serum of fish and frogs as well as in eggs of frogs, biliverdin is 
tightly bound to a carrier protein, although the nature of this binding is different 
from that in humans (Fang and Bada 1990). Tight binding to proteins explains why 
biliverdin is retained in serum of certain marine fish. The concentration of biliverdin 
in some fish species has been reported to be 1.1−6 mg/100 ml (= 19−103 µM; 
Fang and Bada 1990). These are extraordinary high concentrations in comparison 
with other vertebrates. 
 
All natural biliverdins seem to be formed by ring cleavage of the heme molecule, 
instead of being synthesized from smaller units (McDonagh 2001). Depending on at 
which carbon bridge the cleavage occurs, four structural isomers are possible; IXα, 
IXβ, IXγ and IXδ. In vertebrates biliverdin IXα is the predominant type of biliverdin, 
however, very small amounts of the IXβ isomer and even smaller amounts of the 
IXγ and IXδ isomers are produced in humans and other mammals. Due to 
conformational flexibility and depending on the environment, the color of 
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biliverdins can vary from blue to green. Biliverdin is easily excreted (McDonagh 
2001). For this reason, it has been wondered why biliverdin is reduced in an energy 
consuming reaction to lipophilic, not excretable bilirubin in mammals. At least two 
possible explanations exist. One is related to the development of placental animals, 
since McDonagh et al. (1981) showed that only bilirubin, not biliverdin, can readily 
pass through the placenta between fetus and the mother. This is supported by the 
fact that many non-mammalian vertebrates such as several birds, reptiles and 
amphibians, predominantly excrete unconjugated biliverdin (Himes and Cornelius, 
1975; Lin et al. 1974; McDonagh et al. 1981). Another benefit resulting from the 
reduction of biliverdin to bilirubin is the potent antioxidative capacity of bilirubin 
(Doré et al. 1999; Stocker et al. 1987; Stocker 2004). 
2.5.2.1 Biological effects of biliverdin 
In normal mammalian metabolism, biliverdin is rapidly and quantitatively reduced 
to bilirubin as the responsible enzyme, biliverdin reductase, is ubiquitously present 
in tissues (McDonagh 2001). Because of this rapid conversion of biliverdin to 
bilirubin it is difficult to identify a function that is exclusive to biliverdin. 
Nevertheless, various biological effects have been assigned on biliverdin (Table 4). 
Like bilirubin, also biliverdin is a potent antioxidant via its peroxyl radical 
scavencing activity. Often the action of biliverdin is inhibitory in nature. For 
example, it is an inhibitor of protein kinase Cδ (PKCδ), a suppressor of alloimmune 
responses, and it interferes with virus replication (Table 4). Biliverdin has been 
shown to function as a ligand of the AH receptor (see Section 2.6.1).  
 
Biliverdin may also have a critical function in embryogenesis. It is necessary for the 
proper dorsal axis development in Xenopus laevis embryos (Falchuk et al. 2002), 
suggesting that biliverdin is a gene regulator. It is present in the cytoplasm of the 
oocyte, eggs and stage 1 embryos affecting mRNA synthesis (Falchuk et al. 2002). 
However, in addition to the reports of Falchuk et al. (2002) and Montorzi et al. 
(2002), no further studies were found that would confirm the effects of biliverdin on 
embryogenesis. Biliverdin is also present in human amniotic fluid peaking at about 
16 weeks (Krasner et al. 1969, 1971). This probably reflects the gradual 
development of fetal heme catabolism. 
 
2.5.2.2 Green jaundice and biliverdinaemia in humans 
The yellowish skin/tissue color characteristic to jaundice is caused by bilirubin. A 
form of jaundice exists where the color of skin is green instead of yellow. This is 
usually a sign of biliverdinaemia, that is, elevated levels of biliverdin in serum. 
(Gåfvels et al. 2009; Huffmann et al. 2009; Larson et al. 1947; Tickner and 
Gutteridge 1978). 
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Table 4. Biological effects of biliverdin. 
Effect of biliverdin Species where studied Reference 
Antioxidant (peroxyl radical scavenger) In vitro Stocker 2004 
Anti-mutagen Salmonella mutagenicity 
test; cultured 
mammalian cells 
Bulmer et al. 2007 
Confers resistance against 
chemoterapeutics 
Human pancreatic 
cancer cells 
Nuhn et al. 2009 
Determinant factor of dorsal axis 
development 
 
Xenopus laevis Falchuk et al. 2002; 
Montorzi et al. 2002 
Inhibitor of protein kinase Cδ (PKCδ) 
 
In vitro Gibbs et al. 2012 
Inhibits Toll-like receptor-4  expression In vitro (mouse 
macrophages) 
Wegiel et al. 2011 
Protects against acute liver damage in 
mouse TNF/D-GalN model (BVR and 
eNOS required) 
Mouse Wegiel et al. 2011 
Endogenous ligand and activator of AH 
receptor  
 
Human, rat and guinea 
pig cell lines  
 
 
Phelan et al. 1998 
Inhibitor of virus replication (hepatitis C, 
HIV-1, HHV-6) 
 
In vitro (various cell 
lines) 
 
Lehmann et al. 2010; Mori 
et al. 1991; Nakagami et 
al. 1992; Zhu et al. 2010 
 
Suppressor of alloimmune responses 
(Prolongs cardiac allograft survival. 
Synergistic effect with CO.) 
Mouse Yamashita et al. 2004 
Suppressor of IL-2 and IFN-γ production 
through inhibition of NFAT and NF-κB 
activation (i.e., nuclear translocation). 
 
In vitro (mouse 
splenocytes) 
Gibbs and Maines 2007; 
Yamashita et al. 2004 
 
Suppressor of T-cell proliferation 
 
In vitro (mouse 
splenocytes) 
Yamashita et al. 2004 
Elevates hepatic DNA synthesis and 
mitotic index in hepatotectomized rats 
 
Rat i.p. Okazaki et al. 1978  
Activator of ornithine decarboxylase in liver 
 
Rat Matsui et al. 1979 
Tumor promoter: promotes neoplastic cell 
formation in liver epithelial cells after they 
In vitro (liver epithelial 
cells)  
Lafarge-Frayssinet et al. 
1983  
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are pre-incubated with aflatoxin B1 
(This effect is possibly related to the up-
regulation of ornithine decarboxylase 
activity by biliverdin.) 
 
Abbreviations: AH, aryl hydrocarbon; BVR, biliverdin reductase; CO, carbon monoxide; eNOS, 
endothelial nitric oxide synthase; HIV-1, human immunodeficiency virus-1; HHV-6, human 
herpesvirus 6; IL-2, interleukin 2; IFN-γ, interferon gamma; i.p., intraperitoneally;  NFAT, nuclear 
factor of activated T-cells; NF-κB, nuclear factor kappa B; TNF/D-GalN, tumor necrosis factor/D-
galactosamine. 
 
 
Whereas jaundice is a common clinical finding, green jaundice is a rare condition 
(Huffmann et al. 2009). Green jaundice and biliverdinaemia have been described 
only in humans. Although some fish species may have extremely high serum levels 
of biliverdin, it belongs to their physiology (Fang and Bada 1990). The only 
reported animal cases found in literature which might be interpreted as abnormally 
high levels of biliverdin are the situations where the bile color of cod and salmon 
changed from yellow to green under starvation. It is also known that fish such as 
Anguilla japonica (freshwater eel) deactivate the enzymes BVR and uridine 
diphosphate glucuronosyltransferase (UGT) during starvation and excrete 
unconjugated biliverdin directly into bile (Fang and Bada 1990). This skipping of 
the reduction of biliverdin is suggested to be a way of preserving energy under 
conditions of malnutrition. 
 
In 1947, Larson et al. studied a large number of jaundice patients for the presence of 
biliverdin. On the basis of this study and other reports on green jaundice or 
biliverdinaemia from the past 70 years, it seems that most often green jaundice is 
seen in the context of obstructive jaundice, especially that of carcinomatous origin 
(An et al. 2010; Larson et al. 1947; Tickner and Gutteridge 1978; Wardle and 
Williams 1981). Biliverdinaemia has been reported also in context of hepatitis, 
hepatic necrosis due to paracetamol intoxication, malnutrition, (alcoholic) cirrhosis, 
multisystem POEMS syndrome and biliary atresia (Fenech et al. 1967; Greenberg et 
al. 1971; Gåfvels et al. 2009; Huffman et al. 2009; Prichard 1972; Wardle and 
Williams 1981; Yasuda et al. 1994). In the above-mentioned studies, the highest 
plasma biliverdin concentration, 98 µM, was reported in case of obstructive jaundice 
(Wardle and Williams 1981). However, since biliverdinaemia is such a rare 
symptom, it most probably does not always accompany these diseases. In some rare 
cases, biliverdinaemia has been seen without increases in serum bilirubin values 
(Gåfvels et al. 2009; Yasuda et al. 1994). Interestingly, biliverdinaemia is usually 
not detected in the jaundice of the indirect type, i.e., in hemolytic cases (Larson et al. 
1947; McDonagh 2001). This is in accordance with the view that biliverdin 
reductase is not the limiting factor of heme catabolism, instead it is present in tissues 
in surplus amounts relative to basal need (McDonagh 2001). 
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The pathogenesis, or the immediate molecular cause, of biliverdinaemia is in most 
cases unclear. Suggested reasons include failure of change in biliverdin to bilirubin 
in liver and/or other tissues (Fenech et al. 1967; Greenberg et al. 1971; Larson et al. 
1947). This might be due to cellular damage such as, for example, necrosis in 
context of paracetamol intoxication, or inhibition of BVR e.g. by bile acids during 
obstructive jaundice. In the paracetamol-induced necrosis decreased activity of BVR 
was indeed detected (Wardle and Williams 1981). Two case reports exist where 
mutation in the gene coding for BVR-A (the main type of BVR in adults; see 
Section 2.5.3) explains biliverdinaemia. In one case, where the patient suffered from 
alcoholic cirrhosis without jaundice, a heterozygous nonsense mutation in BVR-A 
was shown to underlie biliverdinaemia (Gåfvels et al. 2009). Mutation in BVR-A 
might lead to decreased capacity of BVR-A, although biliverdinaemia manifests 
only after compromised liver function. Similarly, Nytofte et al. (2011) reported two 
unrelated cases where biliverdinaemia was observed during obstructive cholestasis 
due to gallstones. In both patients, investigations revealed the same homozygous 
mutation in BVR-A. In cases of malnutrition, deficiency of NADH or NADPH might 
result in decreased rate of biliverdin to bilirubin conversion (Greenberg et al. 1971). 
Oxidation of bilirubin back to biliverdin has been mentioned as a possibility but 
seems not to be the most likely reason (Larson et al. 1947). 
2.5.3 Biliverdin reductase (BVR) 
In mammals, biliverdin is rapidly and quantitatively reduced to bilirubin by the 
ubiquitous cytosolic enzyme biliverdin reductase (BVR), which was first described 
by Singleton and Laster (1965). Bilirubin is subsequently transferred to liver for 
conjugation and excretion. Biliverdin reductase (BVR) exists in two forms, 
biliverdin IXα reductase (BVR-A) and biliverdin IXβ reductase (BVR-B). However, 
BVR-A is the predominant form while BVR-B is postulated to have major metabolic 
significance only during fetal growth. BVR-A is highly selective for biliverdin IXα 
isomer, whereas BVR-B reduces the other biliverdin isomers (IXβ, IXγ and IXδ). In 
addition, BVR-B has flavin and ferric reductase activities in adult mammals. BVR-
A and BVR-B are encoded by different genes and have distinct molecular weights 
and sequences. (McDonagh 2001; Pereira et al. 2001).  
 
BVR-A catalyzes the regiospecific addition of hydrogen to the –HC(10)=C-N group 
of biliverdin IXα. The reaction mechanism of both BVR-A and BVR-B is 
compulsory ordered kinetic mechanism, in which NADPH must bind first followed 
by the substrate. After the reduction of biliverdin molecule, there is sequential 
release of the product and oxidized cofactor. Both biliverdin and bilirubin at 
sufficient high concentrations can inhibit BVR-A. (Kutty and Maines 1981; 
McDonagh 2001; Rigney et al. 1989; Rigney and Mantle 1988). 
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For a long time the catalysis of the reduction of biliverdin IXα to bilirubin was the 
only known function of BVR. However, currently BVR-A is thought to have 
multiple functions in cellular signaling due to its function as a transcription factor 
and serine/threonine/tyrosine (Ser/Thr/Tyr) kinase, intracellular transporter of 
regulators such as heme, and as a scaffold/adaptor protein. (Ahmad et al. 2002; 
Florczyk et al. 2008; Gibbs et al. 2012; Maines 2005; Tudor et al. 2008) 
 
BVR-A is evolutionarily highly conserved in its primary structure and molecular 
properties (Maines 2005). However, it undergoes post-translational modifications 
resulting to variants with different molecular weights (Huang et al. 1989a, 1989b). 
BVR-A is the only known dual pH and dual cofactor dependent enzyme: with 
NADH as cofactor it exhibits a peak of activity at pH 6.7, whereas with NADPH as 
cofactor the peak of activity resides in the basic range (pH 8.7) (Franklin et al. 2007; 
Maines 2005). Franklin et al. (2007) have shown that the apparent peak of activity 
observed at neutral pH with NADH as cofactor is an anion-dependent activation, 
where inorganic phosphate mimics the role of 2´-phosphate of NADPH thereby 
stabilizing the interaction between NADH and the BVR-A enzyme. Still another rare 
feature is that BVR-A needs to be autophosphorylated for its activity (Maines 2005; 
Salim et al. 2001). On the other hand, BVR-A phosphorylates serine and threonine 
moieties in proteins such as insulin receptor substrate 1 (IRS-1), protein kinase CβII 
(PKC-βII) and HO-2, and activates oxidative stress-responsive transcription factors 
c-Jun, c-Fos, activating transcription factor 2 (ATF2), cAMP response element-
binding protein (CREB) and NF-kB of the mitogen activated protein kinase (MAPK) 
pathway (Tudor et al. 2008). Phosphorylated BVR-A interacts with members of 
MAPK family, in particular with the extracellular signal-regulated kinases 1/2 
(ERK1/2), and regulates the expression of inducible nitric oxide synthase (iNOS; 
Barone et al. 2012). Due to its wide spectrum of functions, BVR-A is postulated to 
participate in central cellular processes of growth, apoptosis, oxidative response and 
gene expression (Florczyk et al. 2008). The reductase function of BVR-A is 
considered cytoprotective. 
 
BVR-A was long considered to be solely a cytosolic protein; today it is known to 
exist in other cellular parts as well. In response to specific stimulus such as 
bromobenzene or bacterial lipopolysaccharide (LPS), BVR-A has been shown to 
undergo nuclear translocation. In nucleus, BVR-A forms dimers and binds to 
regulatory sites such as AP-1 of genes such as HO-1 and ATF-2, thus regulating 
cellular stress-response (Ahmad et al. 2002; Kravets et al. 2004; Maines 2005). On 
the other hand, BVR-A has been shown to exist in external plasma membrane of 
macrophages, where it quickly converts biliverdin to bilirubin. This starts a 
signaling cascade through tyrosine phosphorylation at the cytoplasmic part of BVR-
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A, and is one way for biliverdin to modulate inflammatory response (Wegiel et al. 
2009). Concomitantly with HO-1, BVR-A has been found in caveolae of rat 
pulmonary artery endothelial cells, and it is suggested that by facilitating caveolae 
mediated signaling cascades heme degradation pathway may confer cellular 
protection (Kim et al. 2004). Similarly, BVR-A has been found to colocalize with 
HO-1 in mitochondria (Converso et al. 2006). 
 
Via its kinase activities, BVR-A may have a significant role in glucose metabolism. 
BVR-A itself is a substrate for insulin receptor tyrosine kinase (IRK) activity, 
whereas BVR-A directly phosphorylates IRS-1 peptides at sites known to negatively 
affect glucose uptake. Insulin-mediated glucose uptake was increased in cultured 
cells when BVR-A expression was knocked down using small interfering RNA. 
Thus, BVR-A seems to have potential antagonistic role in the insulin signaling 
pathway. (Lerner-Marmarosh et al. 2005). 
 
Currently many agents or situations are known to modulate the expression, 
localization and/or catalytic activity of BVR-A (Table 5). The promoter region of rat 
BVR contains recognition sites for several regulatory proteins connected with 
oxidative stress and development, including e.g. activator protein 1 (AP-1; 
McCoubrey et al. 1995). Interestingly, TCDD is a known transcriptional activator of 
AP-1-regulated genes. BVR-A promoter organisations differ between humans and 
rats, but mouse and human genes share the same structural features and in the 
promoter, the sequences of consensus regulatory elements are more similar (Gibbs et 
al. 2010).   
 
The product of BVR-A, bilirubin, is cytoprotective due to its potent antioxidant 
capacity. Barañano et al. (2002) have suggested that BVR-A functions in 
bilirubin−biliverdin antioxidant cytoprotectant cycle, which would have a major role 
in intracellular antioxidant defense. However, this view has been strongly 
questioned by other researchers. For example, Maghzal et al. (2009) showed that 
many experimental models of bilirubin oxidation did not yield biliverdin at all or 
only in low amounts. Debate is still ongoing (Jansen and Daiber 2012; Maghzal et al. 
2009; McDonagh 2010a, 2010b; 2010c; Sedlak and Snyder 2009; Stocker and 
Maghzal 2009). 
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Table 5. Inductive, dual and inhibitory effects of different agents on BVR-A. 
Agent or situation Effect on BVR-A Species Organ Reference 
Inductive effect 
Lipopolysaccharide Translocation into 
nucleus ↑ 
Rat  
 
Kidney Maines et al. 
2001 
 
Lipopolysaccharide Increase in surface 
expression on 
macrophages  
Mouse  Macrophages Wegiel et al. 
2009 
Smokers with primary 
spontaneous 
pneumothorax  
(mechanism: oxidative 
stress 
via HIF-1α) 
Induction of mRNA 
and protein levels 
(concomitant with HO-
1 and H-ferritin)  
Human  Lung 
macrophage 
Goven et al. 
2010 
 
 
 
 
 
Bromobenzene Translocation into 
nucleus ↑ 
Rat  Kidney Maines et al. 
2001 
Heat shock (6 hours 
post-hyperthermia) 
Elevation of mRNA 
levels 
Rat  Kidney McCoubrey et 
al. 1995 
Renal carcinoma Elevation of mRNA, 
protein and reductase 
activity levels 
Human  Kidney Maines et al. 
1999 
Hypoxia  
 
Activation of hBVR 
promoter 
Human  Gibbs et al. 
2010 
Acute myeloid leukemia mRNA upregulated Rat  Spleen Papiez et al. 
2009 
H2O2, insulin, sodium 
arsenite, cobalt 
protoporphyrin  
Stimulation of kinase 
activity of BVR-A  
In vitro Kidney cells Lerner-
Marmarosh et al. 
2005; Miralem et 
al. 2005 
Dual effect 
Alzheimer´s disease/ 
mild cognitive 
impairment 
Protein levels 
increased BUT activity 
decreased 
Human  Hippocampus Barone et al. 
2011a 
Inhibitory/repressive effect 
Biliverdin Inhibition of hBVR 
promoter 
Human  Gibbs et al. 
2010 
Mercuric chloride Inhibition of activity Rat Kidney Kutty and 
Maines 1983 
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Biliverdin (> 5 µM) Substrate inhibition Rat / In 
vitro  
 
Enzyme 
purified from rat 
liver 
Kutty and 
Maines 1981 Bilirubin (> 0.5-1.0 µM) Competitive inhibition 
Hematin Inhibition 
Zinc protoporphyrin Inhibition 
Sulfhydryl reagents Inhibition 
TNFα-activated NF-κ B Suppression of hBVR 
promoter 
Human  Gibbs et al. 
2010 
Bromobenzene Selective suppression 
of enzyme variants in 
liver and kidney but 
not in spleen 
Rat  Liver and 
kidney 
Huang et al. 
1989c; Huang 
and Maines 
1990 
 
Abbreviations: hBVR, human biliverdin reductase; HIF-1-α, hypoxia-inducible factor 1-α, NF-κB, 
nuclear factor kappa B; TNFα, tumor necrosis factor α 
 
It is notable that BVR-A is upregulated in certain cancers, and that in experimental 
models, BVR-A overexpression protects mouse fibroblasts against the effect of 
tested chemotherapeutics (Florczyk et al. 2011). Heme degradation pathway has 
been proposed for a promising serum biomarker source for the early detection of 
Alzheimer´s disease (Mueller et al. 2010). Intriguing recent results are that although 
total BVR-A protein levels were increased in the hippocampus of patients with 
Alzheimer´s disease (AD) or mild cognitive impairment (MCI), the activity of BVR-
A was reduced (Barone et al. 2011a). This discrepancy is apparently due to 
differences in the phosphorylation status of BVR-A, and underlines the importance 
of phosphorylation for BVR-A activity. Post-translational modifications such as 
phosphorylation of critical Ser/Thr/Tyr residues seem to play a major role in the 
regulation of the neuroprotective and metabolic activities of BVR-A. The reduced 
phosphorylation of Ser/Thr/Tyr residues of BVR-A in hippocampus of patients with 
AD or MCI might contribute to the impaired glucose metabolism seen in both 
disorders (Barone et al. 2011a). 
2.5.4 Bilirubin 
Bilirubin is a yellow, lipophilic end product of heme degradation and the main 
pigment of bile. 250−400 mg of bilirubin is formed every day in adult humans 
primarily from hemoglobin degradation in spleen. Bound to serum albumin, 
bilirubin is transported to liver, where it is transferred from blood into hepatocytes 
both actively and passively. At the luminal side of the hepatocyte endoplasmic 
reticulum, bilirubin is conjugated with glucuronic acid in a reaction catalyzed by 
UGT1A1, resulting in water-soluble bilirubin mono- and diglucuronides. Depending 
on species, glucose and xylose derivatives are also found (Stocker 2004). 
Conjugated bilirubin is excreted into bile via multidrug resistance protein 2 (MRP2) 
export transporter proteins. UGT1A1 is regulated by various transcription factors 
Review of the literature 
 
THL — Research 133 • 2014 52 
TCDD-Induced Accumulation 
of the Heme Degradation 
Product Biliverdin in Rat Liver 
 
including AHR. (Bock 2011a, 2011b; Bock and Köhle 2010; Jansen and Bittar 
2004). 
 
Bilirubin was long considered solely as a waste product of the body, whose high 
levels were known to be potentially toxic. Nowadays bilirubin is recognized as a 
powerful antioxidant, i.e., scavenger of free radicals, and it has been shown to 
possess immunomodulatory, anti-inflammatory and antiapoptotic activity thus 
having beneficial effects in the body. Despite being cytoprotective at low 
concentrations, bilirubin at high concentrations is cytotoxic and induces apoptosis. 
(Bock and Köhle 2010; Kapitulnik 2004; Oakes and Bend 2005; Ryter 2012; 
Stocker et al. 1987; Stocker 2004). 
 
Jaundice is a common clinical finding caused by increased bilirubin levels. It may 
originate from hepatic failure/primary hepatocellular damage, blockage of biliary 
outflow or increased degradation of hemoglobin (hemolysis; Guyton 1986; Gåfvels 
et al. 2009). Depending on which form of bilirubin, conjugated or unconjugated, is 
elevated, the underlying cause of elevation may be evaluated. Under physiological 
conditions, plasma bilirubin concentration in humans ranges from 4 to 20 µM, most 
of which is unconjugated pigment bound to albumin. When bilirubin concentration 
exceeds 43 µM (2.5 mg/decilitre), jaundice will occur (Jansen and Bittar 2004). In 
newborns, plasma unconjugated bilirubin is normally elevated due to hemolysis and 
immaturity of UGT1A1. If neonatal hyperbilirubinemia worsens up to total serum 
concentration of 428 to 514 µM or more, the risk increases that unconjugated 
bilirubin accumulates in focal brain regions leading to neuronal damage and cell 
death (Bock and Köhle 2010). Phototherapy and exchange transfusion are effective 
ways to treat hyperbilirubinemia (Bock and Köhle 2010). A healthy human liver is 
capable of handling three times the normal daily load of bilirubin without abnormal 
elevations in its concentration in the blood (Okazaki et al. 1978).  In rats plasma 
total bilirubin is about 4 µM, of which about 30% is unconjugated (Unkila et al. 
1994). 
 
Both the free unconjugated, albumin-bound, and conjugated forms of bilirubin have 
been shown to exhibit antioxidant activity, which is based on a pair of reactive 
hydrogen atoms. Via hydrogen donation, bilirubin can scavenge radicals such as 
lipid peroxyl radical followingly: LOO• + bilirubin → LOOH + bilirubin•. Bile 
pigments have been shown to scavenge both 1e and 2e oxidants, for example, singlet 
oxygen, quinones, peroxyl radicals, α-tocopheroxyl radical, hypochlorous acid, 
nitric oxide, peroxynitrite and nitroxyl radical, but they do not act on superoxide 
anion radical or hydrogen peroxide. (Stocker 2004). 
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After the water-soluble antioxidants ascorbate and ubiquinol-10, albumin-bound 
bilirubin is proposed to represent a second-line antioxidant defence against lipid 
peroxidation in extracellular space. Bilirubin has also been shown to protect plasma 
proteins from oxidative damage. In cell membranes, bilirubin (and biliverdin) inhibit 
membrane lipid peroxidation in synergy with α-tocopherol, the most important lipid-
soluble antioxidant in humans. Although much of the evidence for the importance of 
bilirubin as an antioxidant in vivo is indirect, like induction of HO-1 as a response to 
oxidative stress, there is also more direct evidence. For example, it has been shown 
that hyperbilirubinemia results in reduced oxidative injury in rats, and that serum 
samples from patients with Gilbert´s syndrome display higher total antioxidant 
capacity than serum from individuals with normal bilirubin levels. (Bulmer et al. 
2008; Dennery et al. 1995; Ryter 2012; Stocker et al. 1987; Stocker 2004). 
 
It has been suggested that bilirubin would be an important intracellular antioxidant 
via BVR-A-catalyzed cycling of bilirubin-biliverdin (Barañano et al. 2002; Sedlak 
and Snyder 2009). However, as bilirubin concentration in cells has been estimated to 
be very low, around 50 nM, and biliverdin seems to be only a minor product of 
bilirubin oxidation (except when bilirubin is albumin-bound), the existence and 
importance of this antioxidant cycle has been questioned. Established cellular 
antioxidants such as glutathione and ascorbate exist in much higher concentrations 
in cells. On the other hand, it should be noted that in pathological conditions such as 
in pancreatic cancer cells, induction of HO-1 has been observed, leading to clearly 
elevated levels of biliverdin/bilirubin and thus making cancer cells resistant to 
oxidative stress generated by chemoterapeutics. (Jansen and Bittar 2004; Maghzal et 
al. 2009; Nuhn et al. 2009; Stocker 2004). 
 
Both bilirubin and biliverdin have been shown to have protective effects in animal 
models of tissue injury and organ transplantation. Beneficial effects of bilirubin have 
also been observed in several epidemiological studies. According to them, natural 
elevations of bilirubin or elevations due to Gilbert´s syndrome are associated with 
protection against cardiovascular diseases, cancer, diabetes and lung disease. (Ryter 
2012; Zelenka et al. 2012).  
2.6 Interactions between heme metabolism and AHR 
2.6.1 Biliverdin and bilirubin as AHR ligands 
Bilirubin is one of several potential endogenous ligands of  mammalian AHR 
(Nguyen and Bradfield 2008). The possibility that bilirubin might be an AHR ligand 
was first suggested by Kapitulnik and Gonzalez (1993), who found that microsomal 
CYP1A1/1A2 mRNA and protein levels were constitutively elevated in the livers of 
Gunn rats, a strain of rats that are congenitally jaundiced, thus suggesting that 
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bilirubin is an endogenous inducer of the CYPs. Later Sinal and Bend (1997) 
reported that a substantial dose-dependent increase in CYP1A1 mRNA and EROD 
activity occurred after treatment of Hepa 1c1c7 cells with either hemin, biliverdin or 
bilirubin, bilirubin being the most potent of the three compounds. This effect was 
absent in the AHR- or ARNT-deficient mutant cells, indicating that the effect 
required functional AHR. Phelan et al. (1998) showed that bilirubin and biliverdin 
competitively inhibited [3H]TCDD specific binding to the cytosolic AHR, thus 
revealing that these compounds truly are AHR ligands. They also showed that 
physiological concentrations (1−10 µM) of bilirubin and biliverdin induced DRE-
driven luciferase gene expression in stably transfected mouse, guinea pig, rat, and 
human cells. Phelan et al. (1998) suggest that bile pigments, among other 
endogenous, weak ligands of AHR, may have significance in inducing transient 
changes in gene expression in order to achieve appropriate cellular response in 
specific physiological and biochemical situations. 
2.6.2 AHR-mediated induction of HO-1 and UGT1A1 
AHR, which is embedded in complex signaling networks (Puga et al. 2009), seems 
to participate in regulation of HO-1 and UGT1A1 in crosstalk with other 
transcription factors including for example NF-E2-related factor-2 (Nrf2), 
constitutive androstane receptor (CAR) and pregnane X receptor (PXR; Bock and 
Köhle 2010). 
 
Typical inducers of HO-1 include its substrate heme and various factors causing 
oxidative stress. The latter type of induction is mediated e.g. by the ubiquitous 
transcription factor Nrf2, which binds to antioxidant response elements (AREs) 
present in the regulatory region of HO-1. In addition, several xenobiotic response 
elements (XREs) are present in regulatory region of HO-1 although they have not 
been functionally characterized (Alam et al. 1999; Alam and Cook 2003; Bock and   
Köhle 2010). Crosstalk has been shown to take place between AHR and Nrf2 in 
regulation of several genes belonging to classical AHR battery (Yeager et al. 2009). 
Although HO-1 does not belong to that set of genes, it appears to be induced 
efficiently by mixed agonists of AHR and Nrf2 (Bock and Köhle 2010; Köhle and 
Bock 2006). In vivo, TCDD has been shown to induce HO-1 in a couple of studies 
(Boutros et al. 2011; Nishimura et al. 2001), however, no induction was seen in rats 
expressing only mutated AHR, supporting the participation of AHR in the regulation 
of HO-1. 
 
Via its glucuronidation activity, hepatic UGT1A1 controls serum bilirubin level 
(Bock and Köhle 2010). UGT1A1 is inducible e.g. by nuclear receptors PXR and 
CAR, in addition, human UGT1A1 has a core XRE-element in its enhancer region, 
and AHR is one of the transcription factors mediating the induction of human 
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UGT1A1 (Yueh et al. 2003) but not that of rats (Bock 2011b). It has also been 
shown that bilirubin induces human UGT1A1 through AHR dependent pathway 
(Togawa et al. 2008). Via induction of HO-1 and UGT1A1, AHR may contribute 
both to local and systemic bilirubin homeostasis, respectively, and have impacts on 
e.g. atheroprotection. This might be one of the physiologic functions of AHR. (Bock 
and Köhle 2010). 
2.7 Effect of TCDD on heme metabolism 
The main known effects of TCDD on heme metabolism include 1) changes in 
ALAS1 expression and activity, 2) induction of porphyria and 3) increased serum 
bilirubin levels. 
2.7.1 Expression and catalytic activity of ALAS1 
About 40 years ago, TCDD was shown to be a potent inducer of hepatic δ-
aminolevulinic acid synthetase (ALAS1) activity in chick embryo liver (Poland and 
Glover 1973). In mice, ALAS1 activity was found to increase in response to 
repeated exposure to 4 weekly doses of 25 µg/kg TCDD, but not with lower doses. 
A single dose of 150 µg/kg also induced the effect in 21 days (Goldstein et al. 1973). 
However, in rats a single dose of TCDD did not result in induction of ALAS1 either 
acutely or 16 weeks later (Goldstein et al. 1982; Tofilon and Piper 1982; Woods 
1973), but after repeated exposure of Sprague-Dawley rats to a low dose (1 
µg/kg/week) of TCDD for 16 weeks induction of ALAS1 was reported (Goldstein et 
al. 1982). Much later, Fletcher et al. (2005) showed that exposure of Sprague-
Dawley rats to a single, high dose of TCDD (40 µg/kg) resulted in a marked 
reduction of hepatic ALAS1 mRNA expression at 7 days. In conclusion, species 
differences in TCDD´s effects on ALAS1 expression and activity seem obvious; 
otherwise, the mechanisms of these effects are quite unclear. One possible link 
between TCDD and ALAS1 is the transcription factor AP-1: Guberman et al. (2003) 
suggested that AP-1 complex has an inhibitory effect on ALAS-1 expression, and 
TCDD has been shown to induce AP-1 (Puga et al. 2000).  
2.7.2 Porphyria 
Porphyrias are a group of diseases caused by decreased activity (<50%) of one or 
more enzymes of the heme synthesis pathway (Figure 6). Typical consequences 
include urinary excretion and tissue deposition of porphyrins, the intermediate 
products of heme synthesis, leading to various clinical symptoms. Porphyrias are 
mostly genetic diseases, but acquired elements such as drugs, chemicals, heavy 
metals or hormones may be critical for the disease manifestation. Indeed, porphyrias 
are an example of disorders involving complex interactions between genes and 
chemicals. (Downey 1999; Smith and Elder 2010).  
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TCDD belongs to the most potent porphyrogenic agents known (Downey 1999; 
Goldstein et al. 1973). The porphyrogenic effect of TCDD has been detected both in 
humans and in laboratory animals such as mice and rats (Downey 1999; Goldstein et 
al. 1973; Kociba et al. 1978; Pelclova et al. 2006; Smith and Elder 2010). The effect 
seems to be more pronounced in mice than in rats: in susceptible mice already a 
single dose of TCDD induces porphyria, whereas chronic exposure seems to be 
required for TCDD-induced porphyria in rats (Cantoni et al. 1981; Goldstein et al. 
1982; Smith and Elder 2010). Relatively high doses of TCDD are required for the 
manifestation of porphyria even in mice (Davies et al. 2008; Goldstein et al. 1973). 
 
The porphyrogenic effect of TCDD results into accumulation of uroporphyrin in the 
liver, a condition termed “hepatic uroporphyria” (Goldstein et al. 1973) due to 
suppressed activity of the uroporphyrinogen decarboxylase (UROD). Inhibition of 
UROD is most likely caused by oxidative mechanism, and an inhibitor of UROD, 
uroporphomethene, which is an oxidation product of uroporphyrinogen, has been 
isolated from porphyric liver. In concordance with oxidative background, porphyrin 
accumulation is strongly potentiated by iron. Further, studies using transgenic 
knockout mice have demonstrated that CYP1A2 is required for TCDD-induced 
uroporphyria (Smith et al. 2001). AHR genotype has a major influence on the 
severity of porphyria as studied in mice (Davies et al. 2008; Smith and Elder 2010). 
In rats, ALAS1 induction and porphyria seem to be associated and occur related to 
chronic exposures, but not after a single, even high dose of TCDD. 
2.7.3 Increased serum bilirubin 
TCDD has profound effects on serum bilirubin in rats and some other rodents. In 
rats, total and/or conjugated forms have been shown to increase in response to acute, 
subacute or subchronic exposure to TCDD (Buu-Hoi et al. 1972; Kociba et al. 1976; 
Pohjanvirta and Tuomisto 1994; Simanainen et al. 2003; Tuomisto et al. 1999b; 
Unkila et al. 1994; Zinkl et al. 1973). Acute toxicity studies in L-E rats have shown 
that both total and conjugated bilirubin are progressively elevated with time, and the 
departure from control values is significant already 1 day after the exposure (Unkila 
et al. 1994). In L-E rats, serum bilirubin may rise to a level of approximately 100 
times the concentration in control rats (Pohjanvirta et al. 1995). In contrast, in H/W 
rats expressing only mutated AHR, even extremely high dose of TCDD (9600 µg/kg) 
induced only modest, about 3-fold, increase in serum bilirubin, and interestingly, 
only unconjugated bilirubin was increased with no change in conjugated bilirubin 
(Unkila et al. 1994). In rat lines A, B and C, sensitivity to increased bilirubin levels 
after short-term TCDD exposure was in concordance with the order of the LD50 
values of these rat lines (Simanainen et al. 2003; Tuomisto et al. 1999b). Increased 
serum bilirubin belongs to Type II dioxin endpoints.  
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The mechanism by which TCDD elevates serum bilirubin is not definitely proven. 
Bilirubin clearance from blood to liver and its conjugation seem to function properly 
(Pohjanvirta et al. 1995). Indications of hampered hepatobiliary excretory function 
due to TCDD treatment exist in the literature (Hwang 1973; Yang et al. 1977, 1983) 
but stagnant bile flow has not been generally found (Pohjanvirta et al. 1995; 
Tuomisto et al. 1999b). The ratio of unconjugated and conjugated forms seems to 
persist in most cases, suggesting increased formation of bilirubin (Simanainen 2004). 
Hepatic induction of HO-1 detected in a couple of studies is in concordance with 
this view (Boutros et al. 2011; Nishimura et al. 2001). Possibly the mechanism is 
somewhat different depending on the type of exposure (acute, subacute or 
subchronic). Wasting syndrome might contribute to the increased serum bilirubin as 
substantial body weight loss probably involves some loss of muscle mass and blood 
volume, which might lead to increased destruction of hemoglobin and myoglobin 
and consequently to increased formation of bilirubin. However, wasting syndrome 
does not fully explain bilirubinemia in TCDD treated rats, as pair-fed rats, which 
also loose their weight similarly due to restricted feeding, did not show significantly 
increased bilirubin levels (Unkila et al. 1994). Among the most toxic PCDDs 
(TCDD, 1,2,3,7,8-pentachlorodibenzo-p-dioxin, HxCDD and 1,2,3,4,6,7,8-
heptachlorodibenzo-p-dioxin), TCDD is clearly most potent in inducing increases 
in serum/plasma bilirubin (Pohjanvirta et al. 1995; Simanainen et al. 2002). In some 
specific cases such as in congenitally jaundiced Gunn rats, TCDD may reduce serum 
bilirubin by inducing its hepatic catabolism (Cohen et al. 1986). 
 
 
 
 
THL — Research 133 • 2014 59 
TCDD-Induced Accumulation 
of the Heme Degradation 
Product Biliverdin in Rat Liver 
 
3 Aims of the study 
The aim of this study was to (1) solve the chemical composition of the green 
pigment accumulating in line B rats´ livers after TCDD exposure and (2) 
characterize the mechanism leading to the accumulation of that pigment. The 
hypothesis for point 1 was that the pigment constitutes of biliverdin, an intermediate 
product of heme degradation. As this hypothesis was proved true, the following 
more detailed questions were set in order to answer the point 2. 
 
- How does TCDD affect the expression and activity of the enzymes 
responsible for the formation and elimination of biliverdin? 
- What is the dose-response for the TCDD exposure and hepatic 
accumulation of biliverdin and bilirubin? 
- Is the basic reason for elevated serum bilirubin, a well-known effect of 
TCDD, its induced formation or decreased elimination? 
- Does HxCDD induce biliverdin accumulation? 
- Are biliverdin levels elevated in line A or L-E rats after high/lethal doses of 
TCDD? 
 
Answers to these questions would elucidate the mechanism of biliverdin 
accumulation and the roles of AHR and gene B in it. 
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4 Materials and Methods 
4.1 Animals and animal husbandry 
The rat strains/lines used in this thesis are shown in Table 6. All rats were obtained 
from the SPF (specific pathogen free)-barrier unit of the National Public Health 
Institute, Kuopio, Finland. Regular health surveillances consisting of bacteriological 
and serological screening as proposed by FELASA (FELASA 1996; FELASA 2002) 
indicated that the animals were free of typical rodent pathogens. Rats were housed in 
stainless-steel wire-mesh cages with pelleted (I-V) or powdered (II) R3 or R36 feed 
(Ewos, Södertälje, Sweden; Lactamin, Stockholm, Sweden) and tap water available 
ad libitum except for the feed-restricted groups of L-E rats (II). Rats were mainly 
kept in groups of 2−4 animals, but in some cases singly (I, II, IV). The temperature 
in the animal room was 21±1 °C, relative humidity 50±10%, and lighting cycle 
12/12 hr light/dark. All study plans were approved by the Animal Experiment 
Committee of the University of Kuopio and the Kuopio Provincial Government. The 
age of rats in the beginning of the experiments was usually 8−12 weeks; exceptions 
are mentioned. Body weights of the rats were recorded regularly throughout the 
experiments.  
Table 6. Rat strains used in the study. 
Rat 
strain/line 
AHR 
genotype 
B  
genotype 
LD50 of TCDD 
(µg/kg); males 
LD50 of TCDD 
(µg/kg); females 
Reference 
Long-Evans 
(L-E) 
AHRwt/wt Bwt/wt 18 10 Pohjanvirta et 
al. 1993 
Han-Wistar 
(H/W) 
AHRhw/hw  Bhw/hw >9600 >9600 Unkila et al. 
1994 
Line A AHRhw/hw  Bwt/wt >10,000 >2000 Tuomisto et al. 
1999b 
Line B AHRwt/wt Bhw/hw 830 410 Tuomisto et al. 
1999b 
Line C AHRwt/wt Bwt/wt 40 19 Tuomisto et al. 
1999b 
 
4.2  Chemicals 
TCDD and HxCDD were purchased from UFA Oil Institute (Ufa, Russia) and were 
over 98% pure as analyzed by gas chromatography-mass spectrometry. They were 
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dissolved in corn oil.  Biliverdin IXα (80% purity) was purchased from Sigma (St. 
Louis, MO; I) and from Chromatrin, Dublin, Ireland  (IV, V); in Study III it was a 
gift from Dr. T. Mantle (Trinity College, Dublin, Ireland). Bilirubin was purchased 
from Sigma and was a mix of three bilirubin isomers, XIIIα, IXα, and IIIα in a 
proportion of 11%, 77% and 12%, respectively. Other chemicals used are given in 
the original publications. 
4.3 Extraction of the hepatic pigment (I, III, V) 
Before pigment extraction, the livers were usually perfused with buffer or saline in 
order to diminish the amount of blood in liver samples. Perfusion was made under 
ether anaesthesia (I) or in most cases (IV, V) right after decapitation of the rat. In 
Study III the pigment was extracted from non-perfused livers. 
 
For mass spectrometric analysis (I) the extraction procedure of dark green/black 
liver pigment was as follows [modified from Bonkovsky et al. (1986)]. Liver 
homogenates (10%, w/v) were prepared in 0.25 M sucrose/20 mM Tris-Cl (pH 7.4). 
Proteins were precipitated by adding 0.8 ml 15% trichloroacetic acid to 0.5 ml of 
homogenate. After centrifugation, uncolored supernatant was discarded and the 
precipitate was suspended in 0.8 ml of ice-cold acetone/concentrated HCl (97.5:2.5, 
v/v), and centrifuged. Supernatants of ten parallel samples were combined and 
concentrated under nitrogen to a final volume of about 500 µl. At this stage, the 
mixture appeared in two phases. The lower one (volume 50-80 µl) contained the 
pigment and it was next applied to thin layer chromatography (TLC) plates for 
preliminary separation. 
 
In later studies (III, V), the pigment extraction procedure was further developed for 
the purpose of quantitative high performance liquid chromatography (HPLC) 
analysis. The final version of the procedure differs from the above in that pigment 
was extracted from the protein precipitate with 0.8 ml of methanol. Resulting 
methanol extracts were filtered with Minisart SRP 15 filters having the pore size of 
0.20 µm (Sartorius, Göttingen, Germany), and analyzed immediately with HPLC. 
4.4 Preparative thin-layer chromatography (I) 
Concentrated pigment was separated to its components by applying it on silica gel 
plates (SIL G-25, Macherey-Nagel, Düren, Germany). Development was done with 
chloroform:methanol:water (65:25:3). Bands were scraped off the plates and 
suspended in methanol (300 µl). Silica was removed by centrifugation. Methanol 
extracts were filtered using 0.45 µm Spartan 30/B filters (Schleicher&Schuell, 
Dassel, Germany) and stored at -20 °C for mass spectrometric analysis. 
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4.5 Liquid chromatography–mass spectrometry (HPLC-MS/MS) 
(I) 
In liquid chromatographic separations before mass spectrometric detection the 
Rheos 4000 HPLC (Flux Instruments, Danderyd, Sweden) equipped with LaChrom 
autosampler L-7200 Merck Hitachi (Hitachi, Tokyo, Japan) and Spectroflow 757 
UV-detector was used. Symmetry C18 column (5 µm; 4.6x150 mm) with a guard 
column (Waters) was used. Mass spectrometric analysis was performed using a 
Finnigan LCQ ion trap mass spectrometer fitted with an electrospray ionisation 
source (San Jose, CA, USA). 
 
The liquid chromatography conditions were as follows. Methanol containing 0.2% 
formic acid and water with 0.2% formic acid were used as eluents. A 20 min 
gradient was employed to increase methanol from 50 to 100%. Methanol was 
maintained at 100% for 5 min, after which the column was restored to initial 
conditions in 2 min. An automatic injection volume of 20 µl with a flow-rate of 1 
ml/min was used. The eluate from HPLC column was divided in a 1:9 ratio. The 
smaller part was directed to the mass spectrometer and the larger to the UV-detector. 
UV-detection was carried out at 377 nm. Electrospray mass spectrometry was 
performed using positive ion mode. The capillary temperature was 225 °C, source 
voltage 4 kV, sheath gas flow 100 (arbitrary units, scale 0–100 units), capillary 
voltage 20 V and tube lens offset 10 V. Maximum ion time was 200 ms. 
4.6 Quantitative HPLC (III, V) 
Quantification of biliverdin, bilirubin and their conjugates in hepatic extracts was 
done by reverse phase HPLC (Waters, Milford, MA) equipped with Waters 
autosampler 717 and Waters diode array detector 996. Symmetry C18 column (5 µM; 
4.6 x 150 mm, Waters) with a guard column was used. Eluent A was a mixture of 
0.1 M ammonium dihydrogen phophate and methanol in 56:44 ratio, respectively 
(pH 3.4). Eluent B was methanol. A 27 min gradient was applied: the composition in 
the start was 70% eluent A, 30% eluent B; during 0−15 min eluent B was linearly 
increased to 100% and maintained for 10 min, after which the column was restored 
to initial conditions in 2 min. In Study V the 100% methanol was maintained 59 min 
instead of 10 min due to an unknown compound eluting at 53–56 min. An automatic 
injection volume of 25 µl with a flow-rate of 1 ml/min was used. 
 
Biliverdin and bilirubin standards were prepared in methanol and dimethyl sulfoxide 
(DMSO), respectively. DMSO had to be used due to bilirubin´s low solubility in 
methanol. Biliverdin standard curves were constructed using 5 to 9 dilutions of 
biliverdin IXα corresponding to concentrations 0.02–4 µM. For standard curves of 
bilirubin isomers, 5 dilutions were prepared corresponding to 0.02–0.44 µM of 
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bilirubin XIIIα, 0.15–3.1 µM of bilirubin IXα, and 0.02–0.48 µM of bilirubin IIIα. 
The r values for all standard curves were >0.997. 
 
Detection wavelengths were 377 nm for biliverdin and 460 nm for bilirubin. 
Identification of biliverdin and bilirubin in samples was based on the same retention 
time and similarity of the UV-VIS spectrum recorded at λ 250–750 nm with the 
respective standard compound. The peaks that had similar UV-VIS spectrum but 
different retention time compared with the standard biliverdin or bilirubin were 
considered conjugates of biliverdin or bilirubin, respectively. The peak areas were 
converted to concentrations in extracts using the formula: 
concentration = (peak area – intercept)/slope. 
 
The amounts of biliverdin and bilirubin conjugates were calculated using the 
standard curves of biliverdin IXα and bilirubin IXα, respectively, thus assuming that 
the molar absorption coefficients of the conjugates are the same as that of 
unconjugated biliverdin or bilirubin. This approach has been used previously e.g. by 
Lengyel et al. (2005) and it is justified as differences in the UV-VIS spectra of the 
parent bile pigment and its glucuronide conjugates are marginal (Brower et al. 2001; 
Lengyel et al. 2005; Noir et al. 1965; Wu 1983). Since there are no commercial 
standard preparations for bilirubin conjugates or biliverdin conjugates available, 
using bilirubin and biliverdin as calibrators for the respective conjugates was 
considered the best way to approximate their concentrations. 
4.7 Histopathology (I, III) 
In the histological examination of Study I, ten-week-old male rats of line B were 
used. The rats were dosed with 300 µg/kg of TCDD intragastrically and decapitated 
2, 7, 14, 28, or 35 days later. In Study III, 2−4 animals from selected treatment 
groups (see the original publication) were used for histological examination.  
 
Liver samples were preserved in 10% neutral buffered formalin, dehydrated, 
embedded in paraffin wax and cut to the thickness of 5 µm. The tissue slices were 
mounted on glass slides and stained with Mayer’s hematoxylin and eosin for general 
morphology or with Masson’s trichrome stain for the verification of fibrosis. Two 
pathologists examined the slides using light microscope. Stainings were performed 
in accordance with standard protocols. 
4.8 Concentration of HO-1 protein and catalytic activity of 
BVR-A (IV, V) 
Hepatic and splenic concentrations of HO-1 protein were determined using the Rat 
Heme Oxygenase-1 solid-phase EIA Kit (Precoated; Takara Bio Inc., Otsu Shiga, 
Japan) based on a sandwich method utilizing two mouse monoclonal anti-rat HO-1 
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antibodies to detect rat HO-1 by a two-step procedure (IV, V). Analysis was carried 
out on a precoated 96-well plate according to the manufacturer’s instructions. HO-1 
concentrations were normalized to total protein concentrations of the supernatants 
determined by the Bradford method (1976). 
 
BVR-A activity was determined in liver cytosols of line A and line B rats (IV, V) using 
Shimadzu UV-1601 spectrophotometer (Fennolab, Fenno Medical Oy, Kyoto, Japan) 
and Starna Brand 1 cm cuvets (Optiglass Ltd, Hainault, Essex, UK).  BVR-A 
activity was identified as a spontaneous increase in absorbance at wavelength 460 
nm, reflecting the formation of bilirubin in the solution. The initial composition of 
the reaction (volume = 3.08 ml) was 100 mM Tris (pH 8), 10 µM biliverdin, and 150 
µl of cytosol. Immediately after mixing these components, the change in absorbance 
was followed for 10 x 1 min to record the blank rate. Thereafter, β-NADPH was 
added to the reaction at final concentration of 100 µM (final volume of the reaction 
was 3.1 ml), and the change of absorbance was followed again for 10 x 1 min to 
record the BVR-A activity. The amount of bilirubin formed in a min was calculated 
using the molar absorption coefficient of 52,500 M-1cm-1 (Rigney et al. 1989) and 
divided by the total protein concentration of the cytosol (determined by the Bradford 
method, 1976) to get the BVR-A activity expressed as the amount of bilirubin 
formed in nmol/min/mg total protein. 
4.9 Clinical chemistry (V) 
Total bilirubin was determined in serum, liver homogenate and bile samples by a 
modified diazo method using p-nitrobenzenediazonium salt (ThermoFisher 
Scientific, Vantaa, Finland) to give a corresponding azobilirubin. Direct bilirubin 
was determined in serum samples using diazotized sulfanilic acid (ThermoFisher 
Scientific). Total bile acids were determined in serum and liver homogenate 
supernatant samples using enzyme cycling amplification method (Total Bile Acids 
Assay Kit, Alere Ltd, Stockport, UK). Bilirubin and total bile acid analyses were 
performed with a clinical chemistry analyzer (Konelab 30i, ThermoFisher Scientific).  
4.10 Analysis of hepatic crude fat (III) 
A piece (about 4 g) of deep-frozen liver was weighed, minced with scissors and 
frozen in a pre-weighed bowl overnight at -20 °C. Subsequently, the tissue was dried 
in a Savant Modulyo freeze-dryer (Savant, Holbrook, NY) overnight and the weight 
of the dried tissue recorded. The dried tissue was powdered and extracted in a 
Soxhlet-apparatus with 300 ml toluene for 20 hr, after which the toluene was 
evaporated in a rotavapor. The sample was transferred to a pre-weighed decanter by 
rinsing with hexane, which was then allowed to evaporate. The decanter was kept at 
+40 °C overnight, allowed to cool in a desiccator, weighed, and the amount of fat 
was calculated.   
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4.11 mRNA expression levels (II, IV) 
mRNA expression levels of ALAS1, HO-1, BVR-A, CYP1A1, CYP1A2 as well as 
of housekeeping genes β-actin, β-2 microglobulin, glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), hypoxanthine guanine phosphoribosyl transferase, 
phosphoglycerate kinase 1 (Pgk 1), ribosomal protein L13A, succinate 
dehydrogenase complex A and TATA box binding protein were analyzed in line B 
liver and spleen samples using quantitative real-time reverse transcription-
polymerase chain reaction (qRT-PCR)1. Analysis included following steps: 
 
RNA-isolation and RT-PCR 
Total RNA was isolated from homogenized liver and spleen samples using GenElute 
Mammalian Total RNA Miniprep Kit (Sigma-Aldrich, St. Louis, MO). Isolated total 
RNAs were subjected to DNAse1 –treatment with the DNA-free kit (Ambion, 
Austin, TX). 1.2 µg (or 0.6 µg) of this RNA was then used for reverse transcription 
in a 20 µl (or 10 µl) reaction that was performed with Omniscript reverse 
transcriptase (Qiagen, Hilden, Germany) using random hexanucleotides (Roche, 
Mannheim, Germany) as primers. The reaction mixture was incubated at 37 ºC for 
1.5 h. Resulting cDNAs were diluted in a 1:6 ratio with water and used in 
subsequent analysis. 
 
Cloning of ALAS1, HO-1 and BVR-A gene fragments  
169 to 284-nt-long fragments of ALAS1, HO-1 and BVR-A double-stranded cDNAs 
were cloned using line A rat cDNA as a template. PCR was performed with 
HotStarTaq DNA polymerase (Qiagen) on TGradient-thermocycler (Biometra, 
Göttingen, Germany). The “touchdown” method was applied: the annealing 
temperature was set at 63 °C for the first cycle and then decreased by 1 °C / cycle 
down to 57 °C. A total of 40 cycles were run. The primers were ordered from 
Sigma-Genosys Ltd., Cambridgeshire, UK, and are shown in the original publication 
(IV).   
 
PCR products were purified from the agarose gel using Sigma GenElute Gel 
Extraction Kit (Sigma). They were cloned by blunt-end ligation into pCR-Script 
SK(+) Amp plasmids (Stratagene, La Jolla, CA). XLB-1 supercompetent cells 
(Stratagene) were used in transformations. The plasmids were purified by Wizard 
Plus SV Minipreps DNA Purification System (Promega, Madison, WI). The inserts 
were sequenced with an A.L.F.express DNA sequencer (Amersham-Pharmacia 
Biotech, Uppsala, Sweden) using Thermo Sequenase CY5 Dye Terminator Kit 
(Amersham-Pharmacia Biotech). Previously prepared CYP1A1, CYP1A2 and β-
1 In Study II the effect of TCDD on the expression level of 18 commonly used housekeeping genes was 
analysed. Here the methods used by the author of this thesis are described; the rest of the methods used in 
Study II are given in the original publication.  
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actin plasmids (Korkalainen et al. 2004; Korkalainen et al. 2005) as well as purified 
PCR products of the above named housekeeping genes [produced by R. Pohjanvirta 
as explained in the original publication (II)] were also used for production of 
external standard curves in mRNA quantitation. 
 
Quantitative real-time RT-PCR (qRT-PCR) 
The mRNA expression levels were analyzed using QuantiTect SYBR Green PCR 
Kit (Qiagen) and Rotor-Gene 2000 Real-Time Amplification System (Corbett 
Research, Mortlake, NSW, Australia). The 20 µl reaction mixture contained cDNA 
derived from 15 ng of total RNA, 0.5 µM each primer and 10 µl QuantiTect. The 
PCR was initiated with an incubation step of 15 min at 95 °C to activate HotStarTaq 
DNA polymerase. The “touchdown” method was applied: the annealing temperature 
was set at 63 °C for the first cycle and then decreased by 1 °C / cycle down to 57 °C. 
The cycling procedure was denaturation at 95 °C for 20 s, annealing at 57 °C for 20 
s, and extension at 72 °C for 20 s with fluorescence acquired. A total of 45 cycles 
were run. A melting curve was run at 55–99 ° C to verify the specificity of PCR 
products. Standard curve PCRs were carried out using 1−4 replicates of each 
dilution of plasmid/purified PCR product. The used dilutions varied between 10-
4−10-11 (relative to original plasmid at a concentration of 200 ng/µl). The Rotor-Gene 
2000 version 4.6 software was employed to obtain the threshold cycle (Ct) for best 
fit (least squares method) of the standard curve. The Ct values were then converted 
to concentrations by the formula:  
 
Calculated concentration = 10(slope x Ct +intercept)  
 
The instrument analysis software was always allowed to carry out dynamic tube 
corrections. Reaction efficiencies were between 85 and 99%. All R values 
were >0.996. A negative control containing all the components of the reaction 
mixture but water replacing the template was included in each run.  
4.12 Statistics 
In general, for variables with homogenous variances (p > 0.05 in Levene´s test) 
groups of each strain/line were compared using one-way analysis of variance 
(ANOVA). If this test showed a significant difference, the least significant 
difference test or Duncan´s multiple range test (Study II) was used as a post-hoc test 
for detecting the deviating group(s). In case of non-homogenous variances 
(according to Levene´s test, p < 0.05), the non-parametric Kruskal-Wallis ANOVA 
was used and followed by the Mann-Whitney U test. P-values less than 0.05 were 
considered statistically significant. Student’s t-test, or in case of non-homogenous 
variances, Mann-Whitney U test, were used to detect significant differences in 
comparisons involving no more than two groups. For line B rats of Study V, Pearson 
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correlations (r) were calculated for different combinations of hepatic biliverdin, 
bilirubin and their conjugates in dosing groups of 100–300 µg/kg of TCDD. In 
addition, Pearson correlations between hepatic bile pigments were calculated for 
different treatment groups of L-E rats.  
4.13 Experimental designs 
The used rat strains, dioxin treatments, analyzed tissues and follow-up times are 
outlined in Table 7.   
 
Study I: Incidence of the “black liver” syndrome and identification of the pigment 
components 
 
Incidence of the syndrome 
The original observations of a new kind of toxicity, hepatic accumulation of dark 
green or black pigment, were made among a large number of rats (>300), which 
were tested with TCDD during the production, selection, and characterization of the 
new lines A, B, and C (for details, see Tuomisto et al. 1999b). These rats included 
the three new lines A, B and C, their hybrid offspring with L-E rats, and H/W x L-E 
F2 generation rats. They represented both genders and various age groups (4−57 
weeks at the time of exposure) and were treated intragastrically with a wide range of 
single TCDD doses (10−2000 µg/kg). The results of these observations, that is, the 
incidence of the syndrome, are presented in the Study I. 
 
Histopathology 
The liver histopathology was studied in line B male rats using the appropriate dose 
(300 µg/kg) and duration of exposure (2, 7, 14, 28 and 35 days) in regard to pigment 
accumulation based on necropsy observations among over three hundred rats as 
explained above. The aim was to explore the possible histological alterations 
associated with pigment accumulation. 
 
Identification of pigment components 
The aim was to identify the components of the green liver pigment. Due to its 
distinctive green color it was hypothesized that the pigment consists of biliverdin, an 
intermediate product of heme catabolism. For pigment collection, line B female rats 
were dosed intragastrically with 300 µg/kg of TCDD at the age of 9−11 weeks. 
After 3 to 5 weeks, all rats were ether-anesthetized, livers were perfused and 
collected. Pigment was extracted as explained above (Section 4.3). It was pre-
separated into its components using TLC (4.4). TLC bands were extracted from the 
plate and analysed using HPLC-MS/MS (4.5). 
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Study II:  Applicable housekeeping genes for normalization of mRNA expression 
in TCDD-treated rats 
In Study II, expression of a wide range of commonly-employed housekeeping genes 
was first determined with microarrays followed by verification of a selected subset 
by qRT-PCR. The used rat strains, TCDD doses, analyzed tissues and follow-up 
times are shown in Table 7. In L-E rats, TCDD treatment at lethal doses leads to a 
pronounced loss of body weight, which may indirectly influence hepatic gene 
expression. Therefore, a feed-restricted control group (FRC) of L-E rats was 
included into the study. Rats of the FRC group were put on a restricted feeding 
regimen intended to mimic TCDD-induced wasting; for detailed information see the 
original publication.  
 
Study III: Differences in acute toxicity syndromes of TCDD and HxCDD 
Study III consisted of two experiments. Experiment I involved male H/W, line A, 
and line B rats, and its purpose was to compare acute toxicity of TCDD and HxCDD 
in rat strains differing in their AHR- or gene B -genotype. H/W and line A rats were 
dosed with 2000 or 10,000 µg/kg of either TCDD or HxCDD. Line B rats received 
200, 600 or 2000 µg/kg of TCDD or HxCDD or corn oil vehicle. Body weight 
change and mortality were monitored for 46 days. In Experiment II, which was 
carried out in order to supplement the data received from Experiment I, line B male 
rats were dosed with 1000 or 10,000 µg/kg of either TCDD or HxCDD. Randomly 
selected animals (n = 4) were euthanized on day 7 post-exposure for histology, and 
the remaining rats per group were monitored for 46 days. TCDD or HxCDD were 
administered to rats as a single dose, except when the dose was 2000 µg/kg or more. 
In that case, the substances were given as 1000 µg/kg boluses twice a day over 1 or 
5 days.  
 
The rats were weighed twice a week for the duration of the experiments. Animals 
were considered nonsurvivors and euthanized if their general condition was severely 
debilitated. Nonsurvivors, and on day 46 post-exposure all surviving rats were 
euthanized by decapitation. All animals were subjected to macroscopic examination 
at necropsy. General color of the liver and presence of green/dark spots was 
determined. Stomach and intestine were visually inspected for hemorrhage. From 
animals euthanized by decapitation, liver samples were collected for analysis of 
crude fat and biliverdin (stored at –80 °C), and for histology.  
 
Study IV: Effect of TCDD on key enzymes of heme synthesis and degradation 
The aim of Study IV was to examine whether the increased hepatic biliverdin 
concentrations in line B rats were associated with either augmented synthesis of 
heme or biliverdin (elevated ALAS1 or HO-1 expression, respectively) or with 
decreased metabolism of biliverdin (reduced BVR-A expression and/or catalytic 
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activity). The studied tissues were liver and spleen. Line A and line B rats were 
dosed with 300 µg/kg of TCDD and killed 2, 7, 14, 32 or 35 days later by 
decapitation. Controls received corn oil and were decapitated 2 or 35 days later. The 
dose 300 µg/kg TCDD was chosen because it is large enough to cause the syndrome 
of hepatic biliverdin accumulation at a fairly high incidence in line B rats during 
follow-up time of 3-5 weeks (I). mRNA expression levels of ALAS1, HO-1 and 
BVR-A were also analyzed in L-E rats used in Study II. Groups of L-E rats were 
control, TCDD-treated (100 µg/kg, 10 days), and feed-restricted control (FRC, 10 
days). 
 
Spleen and a piece of liver were rapidly removed after decapitation of the rats, flash-
frozen in liquid nitrogen and stored at –80 °C for subsequent analysis. The 
remaining part of the line A and line B rats’ livers was used for immediate cytosol 
preparation. When there were prematurely died rats, they were inspected at 
necropsy, but no samples were collected. 
 
Study V: Dose-response of TCDD-induced effects on parameters of heme 
degradation; Effect of TCDD on excretion of bilirubin 
The aim of Study V was to define the dose-response relationships between TCDD 
exposure and several parameters of heme degradation, as this might help in 
elucidating the biochemical mechanism of biliverdin accumulation. One of the key 
questions was the origin of conjugated biliverdin, i.e., is it formed via conjugation of 
free biliverdin or as a result of bilirubin oxidation. 
Separate experiments were carried out: 
− Line B female rats were used for defining the dose-responses of TCDD 
exposure and hepatic biliverdin, bilirubin, HO-1 protein and BVR-A 
activity levels, as well as serum bilirubin and bile acids. 
− Hepatic accumulation of biliverdin is most probably related to increased 
serum bilirubin, a well-known effect of TCDD in rats. Does TCDD elevate 
serum bilirubin via increasing heme degradation or decreasing biliary 
excretion of bilirubin? Effect of TCDD on biliary bilirubin excretion was 
studied in line C rats. 
− If studied using sensitive methodology (HPLC), is it possible to detect 
TCDD-induced changes in hepatic biliverdin in L-E rats, although no 
macroscopic syndrome has ever been observed? This was studied using the 
liver samples from the L-E rats of Studies II and IV. 
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5 Results 
5.1 Incidence of TCDD-induced “black liver syndrome” in rats 
(I, III-V) 
A novel TCDD-induced syndrome, accumulation of green/dark pigment in rat liver 
(“black liver syndrome”) was first detected during the development of new rat lines 
A, B and C (Tuomisto et al. 1999b). At that time, a large number of rats were tested 
with a wide range of TCDD doses and inspected at necropsy: the results of necropsy 
observations of more than 300 rats including the three new lines, their hybrid 
offspring with L-E rats, and H/W x L-E F2 generation rats are presented in Table 8.  
 
The syndrome was never detected in rats expressing only mutated AHR, i.e., in line 
A or H/W x L-E F2 generation rats with verified AHRhw/hw genotype (Table 8). In 
addition, macroscopic syndrome has never been detected in H/W rats (I, III) or in L-
E rats (I, IV, V). The majority of “black liver” cases were recorded in line B, line B 
x L-E or line A x L-E rats, that is, in rats with at least one resistance allele (AHRhw 
or Bhw; I). In subsequent studies (III, IV), the incidence of the macroscopic 
syndrome in line B rats varied from 57 to 100% with TCDD doses of 200–2000 
µg/kg, whereas no cases were recorded in line A rats even after 10,000 µg/kg of 
TCDD (III, IV).  
 
Black liver syndrome was detected in rats exposed at widely different ages (4 to 57 
weeks), therefore, the age of rat at exposure was not a critical factor in the 
development of the syndrome. Usually it took 3−5 weeks for macroscopic syndrome 
to develop, but as expected, in HPLC analysis of subsequent studies, hepatic 
biliverdin levels were found to be raised already before macroscopic signs (V; see 
Section 5.3). Depending on the TCDD dose and duration of exposure, mild and 
severe syndromes were seen. In mild/medium cases livers had few to numerous 
black spots. In severe cases, the overall color of liver was black and liver was 
swollen containing black or dark green fluid. Perfusion changed the color of affected 
livers from red with black spots to pale with green spots indicating that the pigment 
of interest was indeed green. Sometimes livers had yellowish color in addition to 
black spots, suggesting increased bilirubin levels. 
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 Table 8. Number of rats with dark green or black pigment in their livers (I). 
Rat strain/line Genotype Gender Dose (µg/kg) n Green/dark spots in liver 
 # (%) 
H/W x L-E F2 AHRhw/hw, B unknown male 1000 6 0 (0%) 
H/W x L-E F2 AHRhw/hw, B unknown female 1000 9 0 (0%) 
A AHRhw/hw, Bwt/wt male 700−2000 14 0 (0%) 
A AHRhw/hw, Bwt/wt female 700−2000 22 0 (0%) 
A AHRhw/hw, Bwt/wt male 12,000−30,000 3 0 (0%) 
B AHRwt/wt, Bhw/hw male 10−100 27 4 (15 %) 
B AHRwt/wt, Bhw/hw female 10−100 22 2 (9%) 
B AHRwt/wt, Bhw/hw male 300−2000 20 9 (45%) 
B AHRwt/wt, Bhw/hw female 300−2000 48 25 (52%) 
C AHRwt/wt, Bwt/wt male 10−100 40 2 (5%) 
C AHRwt/wt, Bwt/wt female 10−100 35 0 (0%) 
A x L-E AHRhw/wt, Bwt/wt male 10−100 5 0 (0%) 
A x L-E AHRhw/wt, Bwt/wt female 10−100 13 1 (8%) 
A x L-E AHRhw/wt, Bwt/wt male 300−2000 6 3 (50%) 
A x L-E AHRhw/wt, Bwt/wt female 300−2000 9 4 (44%) 
B x L-E AHRwt/wt, Bhw/wt male 50−2000 9 5 (56%) 
B x L-E AHRwt/wt, Bhw/wt female 50−2000 6 2 (33%) 
C x L-E AHRwt/wt, Bwt/wt male 10−100 9 5 (56%) 
C x L-E AHRwt/wt, Bwt/wt female 10−100 4 0 (0%) 
Note: Age of rats at exposure was 4−57 weeks and time point of observation six weeks 
post-exposure or one day before the expected death. 
 
5.2 Chemical composition of the green liver pigment (I)  
The chemical composition of the green pigment accumulating in line B rats’ livers 
after TCDD exposure is presented in Table 9. As indicated, pigment was found to 
consist mainly of biliverdin and its monoglucuronide; in addition, small amounts of 
other biliverdin conjugates were found. 
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 Table 9. The compounds found in the green liver pigment extracted from the livers 
of line B female rats 35 days after a single intragastric TCDD dose (300 
µg/kg; I) 
Note: Analysis was made with HPLC-MS/MS. Biliverdin was identified using authentic 
standard. The molecular masses and daughter ion patterns implied that the other peaks 
absorbing light at the absorption maximum of biliverdin (377 nm) represent biliverdin 
conjugates named in the table. No commercial preparations of biliverdin conjugates exist.
Compound Rough estimate of the 
contribution to the total 
amount of green pigment 
Comments 
Biliverdin Major   
Biliverdin 
monoglucuronide 
Major   
Unidentified biliverdin 
conjugate  
(= “Compound I” in I) 
Minor Molecular mass equals to biliverdin 
monoglucuronide – hydroxyl group 
Biliverdin methyl 
ester 
Minor Not known, whether methylation has 
occurred in vivo or spontaneously in 
extractant (methanol) 
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5.3 Effect of TCDD on parameters of heme degradation: dose-
response (V) 
Effect of TCDD (3−300 µg/kg, 28 days) on hepatic biliverdin and bilirubin, HO-1 
protein concentration and catalytic activity of BVR-A as well as serum bilirubin and 
bile acids in line B rats is summarized in Table 10. Part of the endpoints were 
assessed also in L-E rats (Table 10). Main results include: 
 
Macroscopic observations 
A few line B rats in the high dose groups had yellowish liver (3/6 in each of the 
dosing groups of 200 and 300 µg/kg TCDD) and some rats had black spots in liver 
(1/6, 2/6 and 2/6 in dosing groups 100, 200 and 300 µg/kg TCDD, respectively). All 
black liver cases were mild, that is, only few dark spots were detected in the liver 
tissue. No black spots or yellowish color were detected in the livers of L-E rats. 
 
Body weights 
In groups of line B rats treated with 30−300 µg/kg TCDD, body weight development 
differed significantly from control indicating wasting syndrome. In L-E rats, TCDD-
treatment (100 µg/kg, 10 days) or restricted feeding resulted in weight losses of 32 ± 
2% and 19 ± 3% relative to the day 0, respectively, whereas at the same time 
controls increased their weight 4 ± 3%. 
  
Hepatic concentrations of biliverdin and bilirubin  
In control line B rats, the mean hepatic biliverdin and its conjugate concentrations 
were 0.9 and 0.7 nmol/g, respectively; bilirubin and its conjugates were under the 
detection limit2. At doses of 100 µg/kg TCDD or more, hepatic concentrations of 
biliverdin, bilirubin and their conjugates were significantly elevated (Table 10). The 
maximal concentrations of biliverdin and its conjugates, 4.8 and 49.5 nmol/g (group 
means) were reached with the dose 200 µg/kg TCDD, whereas the highest 
concentrations of bilirubin and its conjugates were 22 and 28 nmol/g, respectively 
(group means; dose 300 µg/kg TCDD). Dose 100 µg/kg of TCDD increased hepatic 
biliverdin, biliverdin conjugate and total bilirubin concentrations significantly also 
in L-E rats, although the effect on the two latter analytes was clearly milder than in 
line B rats (Table 10). Further in L-E rats, feed-restriction induced similar increase 
in hepatic bilirubin level as TCDD exposure but had no influence on hepatic 
biliverdin (Table 10).  
 
 
 
 
2The detection limit of the employed HPLC method for the three bilirubin isomers was not deliberately 
studied but the lowest detectable concentration of each isomer is presumably around 0.01 µM in the 
methanol extracts.  
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Serum bilirubin 
In line B rats, the two lowest doses (3 and 10 µg/kg) had a slight diminishing effect 
on serum conjugated bilirubin, whereas the latter dose (10 µg/kg) elevated serum 
unconjugated bilirubin. All higher doses (30−300 µg/kg) dose-dependently 
increased the serum levels of both forms of bilirubin (Table 10). 
 
Hepatic concentration of HO-1 and catalytic activity of BVR-A 
Hepatic HO-1 protein expression was significantly increased at doses 100−300 
µg/kg TCDD, whereas the catalytic activity of BVR-A was increased only with the 
dose 100 µg/kg (Table 10). Hepatic expression of HO-1 protein correlated strongly 
with serum total bilirubin level (r = 0.918, p < 0.001) whereas hepatic BVR-A 
activity did not, supporting the well-established view that HO-1 is the rate-limiting 
factor in heme degradation. 
 
Bile acids 
Compared with the control, the highest dose of TCDD (300 µg/kg) increased the 
level of serum bile acids about 2.6-fold in line B rats. Other doses did not have 
significant effects. In L-E rats, TCDD slightly decreased, whereas feed-restriction 
increased, the hepatic level of bile acids (Table 10). 
 
Correlations between bile pigments 
In line B rats dosed with 100−300 µg/kg of TCDD, correlation between hepatic 
bilirubin and its conjugates was strong (r = 0.91), whereas it was weak between 
biliverdin and bilirubin (r = 0.01), as well as between biliverdin conjugates and 
bilirubin conjugates (r = -0.04; Figure 8). Biliverdin conjugates correlated best with 
biliverdin (r = 0.50; Figure 8). In L-E rats, positive correlation between biliverdin 
and its conjugates was high in both control (r = 0.78) and TCDD-treated groups (r = 
0.78). In addition, there was a good correlation between biliverdin and total bilirubin 
in control group (r = 0.55), but a negative correlation in the TCDD-treated group (r 
= -0.43). Thus it seems that the high positive correlation between biliverdin and its 
conjugates persists even after TCDD treatment, whereas TCDD treatment turns the 
positive correlation between biliverdin and total bilirubin into negative. 
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Figure 8. Pearson correlations between hepatic content of bile pigments in line B 
rats 28 days after 100−300 µg/kg TCDD. Solid arrows denote for known 
enzymatic steps (A and B), dashed arrows denote for hypothetical 
conversions (C and D). Asterisks (**) denote for statistical significance at 
the level of p < 0.01. Based on correlation coefficients, it seems that 
biliverdin conjugates are more likely formed enzymatically from biliverdin 
(step C) than oxidatively from bilirubin conjugates (step D). On the other 
hand, there might be problems in conversion of biliverdin to bilirubin, as 
their amounts do not correlate (step A), whereas there is a strong 
correlation between the substrate and product of another known 
enzymatic step, conjugation of bilirubin (step B). For original data, see 
Study V. 
5.4 Effect of TCDD on HO-1, BVR-A and ALAS1; time-response 
(IV) 
Effect of TCDD (100 or 300 µg/kg; time points 2, 7, 10, 14 and 32/35 days) on 
mRNA expression of HO-1, BVR-A and ALAS1, protein expression of HO-1, and 
catalytic activity of BVR-A in line A, line B and L-E rats is summarized in Table 11. 
Main points include: 
 
Hepatic expression of ALAS1 mRNA  
TCDD significantly decreased hepatic expression of ALAS1 mRNA in all studied 
rat strains (Table 11). 
 
Hepatic expression of HO-1 mRNA and protein  
In liver, HO-1 mRNA and protein displayed initial repression due to TCDD on 
postexposure day 2. At later time points, induction of HO-1 protein but not HO-1 
mRNA was seen (Table 11). 
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Hepatic BVR-A activity 
In both line A and line B rats, TCDD significantly increased hepatic BVR-A activity 
and mRNA expression on post-exposure day 14 (Table 11). However, at 5 weeks 
BVR-A activity was still induced in line A rats but reduced to 51% of control in line 
B rats (Table 11). At this time point, 5 out of 6 line A rats had yellowish liver, 
whereas in 4 out of 7 line B rats hepatic accumulation of dark green pigment (“black 
liver”) was observed.  
 
Splenic expression of HO-1 mRNA and protein  
In spleen, TCDD strongly repressed the expression of HO-1 mRNA in line A and 
line B rats at all measured time points. Amount of HO-1 protein was also decreased 
(Table 11). 
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5.5 Effect of TCDD on bilirubin excretion (V) 
In line C rats, exposure to 10 µg/kg of TCDD significantly increased both serum and 
bile total bilirubin levels on post-exposure day 7, but decreased the amount of bile 
secreted per h per g body weight. Calculation of bilirubin clearance showed that 
despite the reduction in bile volume, the amount of excreted bilirubin per h per g 
body weight was 40% larger in TCDD-treated rats relative to control.  
5.6 Differences in acute toxicities of TCDD and HxCDD (III) 
The potency of HxCDD is about 10% of that of TCDD for typical AHR-mediated 
effects. The acute toxicity of TCDD and HxCDD was compared using H/W, line A 
and line B rats. A very high dose of HxCDD (10,000 µg/kg) reduced body weight 
more effectively than an identical dose of TCDD in all studied rat strains. In H/W 
and line A rats, the estimated LD50 values were >10,000 µg/kg and 2000−10,000 
µg/kg for TCDD and HxCDD, respectively; for line B rats they were 480 µg/kg and 
1000−2000 µg/kg, respectively. Thus, HxCDD was more potent than TCDD in 
inducing acute mortality in H/W and line A rats, contrary to what is predicted by 
TEFs. In line B rats, the expected rank order of potencies prevailed. 
 
HxCDD (10,000 µg/kg) caused gastrointestinal hemorrhage and pale (fatty) livers in 
line A and H/W rats whereas TCDD did not. In line B rats, HxCDD (≥600 µg/kg) 
caused pronounced hepatic fatty degeneration, whereas TCDD (200−10,000 µg/kg) 
induced hepatic accumulation of biliverdin, detected both as black livers in 
necropsies and in quantitative biliverdin analysis of selected livers using HPLC. 
Mean hepatic biliverdin content was 6 nmol/g in controls, and 20 and 34 nmol/g in 
line B rats that received 200 µg/kg and 600 µg/kg of TCDD, respectively. The 
corresponding values for biliverdin conjugates were 0, 24 and 49 nmol/g.  
 
No macroscopic accumulation of biliverdin was detected in H/W or line A rats even 
after 10,000 µg/kg of TCDD or in any rat dosed with HxCDD (200−10,000 µg/kg). 
For line A rats dosed with TCDD (10,000 µg/kg) and some line B rats dosed with 
HxCDD (200−600 µg/kg), absence of biliverdin accumulation was verified using 
HPLC. Both congeners caused peliosis-like sinusoidal distension in liver; most 
severe cases were detected in line B rats exposed to HxCDD (2000 µg/kg). 
5.7 Applicable housekeeping genes for dioxin studies (II) 
In Study II, 18 commonly used housekeeping genes were analysed in order to find a 
widely applicable housekeeping gene for acute toxicity studies of TCDD. About 
50% of the studied housekeeping genes were responsive to TCDD in rat liver with 
the magnitudes of change up to nearly 10-fold (Table 12). Phosphoglycerate kinase 
1 (Pgk 1) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) retained their 
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basal expression levels in all experimental settings (Table 12). Hepatic expression of 
β-actin, a commonly used housekeeping gene, increased in response to TCDD in L-
E and line B rats if the exposure lasted 7 days or more. However, TCDD did not 
influence the expression of β-actin in spleen. Due to these findings, the 
housekeeping genes for the Study IV were selected as follows: β-actin mRNA was 
used for normalization of the gene expression data derived from spleen, whereas 
GAPDH mRNA was used for normalization of the gene expression data derived 
from liver.  
5.8 Hepatic peliosis, a novel response to dioxin exposure (I, III) 
In the histopathological examination of TCDD-treated (200 or 300 µg/kg) line B rats, 
a characteristic TCDD-induced liver response was seen (Studies I and III). This 
consisted of swollen hepatocytes with hydropic degeneration, formation of giant 
hepatocytes with multiple nuclei, necrosis of single cells or of small foci, fibrosis, 
vacuolization and infiltration of inflammatory cells in sinusoids. Additionally from 
day 28 on, hepatic sinusoids displayed a clear tendency towards distension reaching 
hepatic peliosis-like stage with membrane bound cysts by day 35. Some of these 
cysts contained erythrocytes or leukocytes. Mild cases of sinusoidal distension were 
recorded in line A and H/W rats after TCDD or HxCDD (2000 µg/kg) exposure; 
worst cases were recorded in HxCDD (2000 µg/kg, 23 days) -exposed line B rats 
(III). Peliotic process seems to start centrilobularly (III). 
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6 Discussion 
6.1 Overall conception of TCDD´s effects on heme degradation 
in rats 
6.1.1 Occurence of TCDD-induced biliverdin accumulation 
This thesis shows that TCDD is able to cause extensive hepatic accumulation of the 
heme degradation product biliverdin in both genders of line B, as well as in some 
other rat strains expressing wild-type AHR. This is a novel observation in terms of 
TCDD toxicity. Biliverdinaemia, i.e., increased serum biliverdin, has been described 
in humans associated to a variety of disease states, however, it is a rare phenomenon 
(Huffmann et al. 2009). A noteworthy property of TCDD-induced biliverdin 
accumulation in rats is its dependence on the genetic factors, AHR and unknown 
gene B, which makes the syndrome intriguing from the mechanistic point of view. 
Further, TCDD-induced biliverdin accumulation is associated with increased serum 
bilirubin, a well-known effect of TCDD. Biliverdin accumulation belongs to Type II 
effects of TCDD, as it is sensitive to alterations in the transactivation domain of 
AHR. At least one AHRwt allele is required for TCDD-induced biliverdin 
accumulation, whereas AHRhw allele in homozygous form seems to provide 
complete protection against this response. 
 
Biliverdin accumulation was found to be an invariable response in line B rats as 
hepatic biliverdin (and also bilirubin) levels were elevated in all line B rats treated 
with the dose 100 µg/kg of TCDD or more (V). Apparently, the TCDD dose able to 
cause significant accumulation of biliverdin conjugates is between 30 and 100 µg/kg 
when exposure time is 28 days (V). Therefore, in line B rats, biliverdin 
accumulation is slightly less sensitive response to TCDD than wasting, a typical 
Type II response, which was significant with the dose 30 µg/kg of TCDD (V). The 
expression and/or activity of the enzymes responsible for heme degradation, HO-1 
and BVR-A, was also increased with the dose 100 µg/kg of TCDD (V), hence 
coinciding biliverdin accumulation, whereas serum unconjugated bilirubin was 
slightly increased already with lower doses (10 and 30 µg/kg of TCDD). Possibly 
the dose 100 µg/kg of TCDD strongly increases heme degradation, whereas some 
enhancement of the process occurs even with lower doses.  
 
In L-E rats, macroscopic cases of biliverdin accumulation have never been observed, 
although L-E rats are known to exhibit vast increases in serum bilirubin after TCDD 
exposure (Pohjanvirta et al. 1995; Unkila et al. 1994). However, when studied using 
sensitive analytical methods such as HPLC, acutely lethal dose of TCDD (100 µg/kg) 
Discussion 
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was found to increase hepatic biliverdin and bilirubin levels in L-E rats (V). In 
contrast to bilirubin, hepatic biliverdin was not increased in feed-restricted control 
L-E rats. This suggests that increased hepatic (and serum) bilirubin level after 
TCDD exposure may be partly secondary to weight loss, whereas increase in 
biliverdin seems to be a specific consequence of TCDD toxicity occuring e.g. in line 
B and L-E rats, and possibly other rats with wild-type AHR. Instead, rat strains 
expressing only mutated AHR, i.e., H/W and line A rats, were completely protected 
from the syndrome (I, III, IV). Therefore, the normal transactivation domain of 
AHR (Lindén et al. 2010; Pohjanvirta et al. 2012) is required for TCDD-induced 
biliverdin accumulation. As for many other effects of TCDD, the critical molecular 
events involving the transactivation domain and finally leading to specific toxicities 
(in this case, biliverdin accumulation) remain still unknown. 
   
HxCDD (200–10,000 µg/kg) did not induce macroscopic biliverdin accumulation or 
elevations in hepatic biliverdin level as measured with HPLC in any of the studied 
rat strains (line A, line B, and H/W rats; III). According to the TEF concept, about 
300–1000 µg/kg of HxCDD should induce an increase in hepatic biliverdin level in 
line B rats. As only part of the animals were studied using HPLC, it is not possible 
to say that HxCDD´s inability to induce biliverdin accumulation would have been 
definitely shown. Especially, the possibility remains that the effect is masked by the 
early death of HxCDD-treated animals due to other reasons; however, results of 
single animals do not support this. For example, two line B rats dosed with 600 
µg/kg of HxCDD exhibited slightly reduced hepatic biliverdin level on postexposure 
day 46 (however, the difference to the control level was not statistically significant), 
and the only line B rat that survived 46 days after exposure to 2000 µg/kg of 
HxCDD did not show any macroscopic signs of biliverdin accumulation. Thus it 
seems that biliverdin accumulation is specific to TCDD, whereas HxCDD causes 
extensive hepatic steatosis with similar or slightly lower equivalent doses (absolute 
HxCDD dose 600 µg/kg = 60 µg/kg in TEQs), as studied in line B rats (III). As 
HxCDD has been shown to induce modest increases in serum bilirubin in rats 
(Pohjanvirta et al. 1995; Simanainen et al. 2002), the effect of TCDD and HxCDD 
on heme degradation is partly similar (both increase serum bilirubin, TEFs apply) 
and partly different (only TCDD induces biliverdin accumulation, TEFs do not 
apply).  
6.1.2 TCDD elevates serum bilirubin by enhancing heme degradation 
Increase in serum bilirubin is a well-known effect of TCDD in rats and some other 
rodents, but the underlying mechanism has been unclear (Pohjanvirta and Tuomisto 
1994). In general, depending on which type of bilirubin is increased − unconjugated, 
conjugated or both − it is possible to evaluate the cause and pathology of jaundice 
(Guyton 1986). In this thesis, it is shown that in line B rats, TCDD induces dose-
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dependent increases of both unconjugated and conjugated bilirubin in liver and 
serum finally reaching about 50 to 70-fold levels relative to control. Increase of both 
types of bilirubin suggests hemolytic type of jaundice, i.e., increased bilirubin 
formation (Guyton 1986). This is supported by the findings that TCDD increased 
bilirubin excretion into bile and did not markedly increase serum bile acid level, 
suggesting that cholestasis or other major unspecific decline in biliary excretory 
function is not a probable reason for increased serum bilirubin (V). Therefore, the 
principal reason for increased serum bilirubin levels detected in rats after TCDD 
exposure is most probably increased degradation of heme. This conclusion is further 
supported by the inducing effect of TCDD on the expression and/or activity of the 
enzymes responsible for bilirubin formation, HO-1 and BVR-A (IV, V). TCDD-
induced hepatic peliosis (I, III) as well as repression of ALAS1 mRNA expression 
in liver (IV) are also in concordance with increased hepatic heme content and 
degradation: hepatic peliosis particularly stands for presence of blood-filled cysts in 
liver, whereas free heme is a potent repressor of ALAS1 expression (Tzirogiannis et 
al. 2004; Yamamoto et al. 1988). All these matters strongly suggest that for some 
unknown reason, TCDD increases hepatic content of heme, which leads to increased 
hepatic heme degradation and bilirubin formation. This is suggested to be the 
principal reason for increased levels of bilirubin in serum and liver after TCDD 
exposure in rats. However, this conclusion does not exclude the possibility that 
TCDD might also decrease bilirubin excretion in some situations, depending e.g. on 
the dose of TCDD or exposure time. 
 
A peculiar finding detected both in line A and line B rats is the TCDD-induced 
repression of HO-1 mRNA and protein expression in spleen (IV). It has been 
suggested that HO-1 is normally induced in spleen due to large amounts of heme 
present (Braggins et al. 1986). Based on this, the simplest explanation for the 
repression of HO-1 in spleen would be that splenic content of heme is diminished 
due to TCDD exposure, which would lead to attenuation of the inducing effect of 
heme on the expression of splenic HO-1. Decreased splenic amount of heme might 
be associated with or even a consequence of the pooling of blood in liver, which 
occurs in hepatic peliosis, or related to the development of that condition. On the 
other hand, hypoxia has been shown to repress HO-1 expression in cultured human 
cells (Shibahara 2003), however, no literature was found on whether TCDD would 
induce splenic hypoxia. Altogether, the essential finding is that the consequences of 
TCDD exposure on HO-1 expression, and therefore on heme degradation, seem to 
be largely different in liver and spleen.  
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6.1.3 Origin of biliverdin monoglucuronide 
The green liver pigment was found to consist mainly of biliverdin and biliverdin 
monoglucuronide, small amounts of other biliverdin conjugates were also found (I). 
In line B rats in Study V, the relative and absolute accumulation of biliverdin 
conjugates was remarkably stronger than that of unconjugated biliverdin. Therefore, 
the question is not only why biliverdin accumulates but also why and how its 
conjugates, mainly monoglucuronide, accumulate. Two theoretically possible 
sources of biliverdin conjugates exist: (1) enzymatic conjugation of biliverdin, and 
(2) oxidation of bilirubin conjugates. In Study V, it is shown that biliverdin 
conjugates are most likely formed via conjugation of biliverdin, not by oxidation of 
the respective bilirubin conjugates. The principal evidence is based on the 
correlations of hepatic bile pigments in line B rats treated with high doses (100−300 
µg/kg) of TCDD. In these rats, a high correlation was detected between bilirubin and 
its conjugates, i.e., between the substrate and the products of an enzymatic reaction 
(Figure 8; V). In contrast, the correlation between biliverdin and bilirubin was 
surprisingly poor, suggesting that reduction of biliverdin does not obey 1st order 
kinetics in current conditions, and other products than bilirubin might be formed 
from biliverdin. Further, biliverdin conjugates correlated best with free biliverdin, 
resembling the situation between bilirubin and its conjugates (Figure 8). Additional 
support comes from the results on L-E rats, as TCDD disrupted the positive 
correlation between biliverdin and total bilirubin, but had no effect on the positive 
correlation between biliverdin and its conjugates (V).  
 
Study I of this thesis is most probably the first to report the presence of conjugated 
biliverdin in rats. However, there are other studies showing the presence of 
conjugated biliverdin in mammals: it is the dominant green pigment in rabbit bile 
(Garay et al. 1965) and has recently been detected in human serum (An et al. 2010). 
Garay et al. (1965) suggested almost 50 years ago that in many animal species 
conjugation of both biliverdin and bilirubin may occur simultaneously. The issue of 
biliverdin conjugation has apparently not been thoroughly studied, but the results of 
this thesis support the above view of Garay et al. (1965). Although it has not been 
shown that biliverdin would be a substrate for UGT1A1, it might be possible as 
UGT1A1 has broad substrate specificity (Basu et al. 2004).  
 
The other theoretical possibility, oxidation of bilirubin conjugates to biliverdin 
conjugates, seems less probable due to the observed poor correlation of their hepatic 
concentrations. Further support comes from the literature, as many studies suggest 
that in most conditions, bilirubin is not efficiently oxidized to biliverdin (Jansen and 
Daiber 2012; Maghzal et al. 2009; McDonagh 2010a, 2010c; Shishido et al. 2003).  
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6.1.4 Current hypothesis on TCDD-induced biliverdin accumulation 
Current hypothesis on TCDD-induced biliverdin (and bilirubin) accumulation is 
formulated as follows. (1) The principal cause of increased serum and hepatic 
bilirubin levels after acutely toxic doses of TCDD is most probably increased 
bilirubin formation, i.e., increased degradation of heme, not decreased biliary 
excretion (IV, V). (2) In mammals, conversion of biliverdin to bilirubin is normally 
quantitative and rapid as BVR-A is present in excess (McDonagh 2001). Here it is 
postulated that in addition to enhancement of heme degradation, TCDD hampers the 
quantitative hepatic conversion of biliverdin to bilirubin to various degrees in line B 
and some other rat strains with AHRwt allele but does not abolish it totally, leading to 
hepatic accumulation of biliverdin, bilirubin and their conjugates (Figure 9). In line 
A and H/W rats, which  express only mutated AHR, conversion of biliverdin to 
bilirubin seems not to be hampered even after huge doses of TCDD (I, III, IV). 
Therefore, wild-type transactivation domain of AHR is a prerequisite for TCDD-
induced hindrance of conversion of biliverdin to bilirubin. More detailed molecular 
causes of biliverdin accumulation might be related to BVR-A and they are discussed 
in the next section. (3) Biliverdin monoglucuronide and other biliverdin conjugates 
are most likely secondary products of biliverdin. (4) Since biliverdin accumulation 
was absent in feed-restricted L-E control rats, it mechanistically originates from 
other effects of TCDD than weight loss. (5) After acutely toxic doses of TCDD, 
hepatic biliverdin level is probably prone to increase in all rats expressing wild-type 
AHR. However, only in semi-TCDD-resistant rat strains (such as line B and the F1 
offspring of the crosses line A x L-E and line B x L-E), the syndrome is able to 
develop to such a severe stage before the death of the animal that it becomes noticed 
at necropsies. In these semi-TCDD-resistant rats, the resistance is provided by one 
AHRhw allele or one or two Bhw alleles, whereas the presence of at least one AHRwt 
allele enables biliverdin accumulation.  
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Figure 9. Suggested consequences of TCDD exposure on hepatic heme 
degradation in rats with AHRwt allele, resulting in the accumulation of 
biliverdin, bilirubin and their conjugates. Presence of hepatic bilirubin 
oxidase (BRO) has been shown in rats, mice and humans (Abu-Bakar et 
al. 2011, 2012; Cardenas-Vazguez et al. 1986), however, it does not 
seem to play a major role in TCDD-induced biliverdin accumulation. 
*acutely toxic dose. (Original place of publication Basic  & Clinical 
Pharmacology & Toxicology; Study V)  
6.2 Further mechanistic considerations on biliverdin 
accumulation 
6.2.1 Possible reasons for hampered conversion of biliverdin to 
bilirubin 
The remaining key question is how TCDD would suppress conversion of biliverdin 
to bilirubin at the molecular level. Could it be possible that increased hepatic heme 
content and catabolism would simply exceed the normal capacity of BVR-A? The 
results on L-E rats do not support this as the increase in hepatic bilirubin was only 
1.7-fold and yet biliverdin levels were raised (V). According to general 
understanding, there is remarkable excess capacity in biliverdin reduction in 
mammals (McDonagh et al. 2001). Further, results on feed-restricted L-E control 
rats show that 1.7-fold increase in hepatic bilirubin does not necessarily mean any 
change in hepatic biliverdin level (V). These aspects suggest that the question would 
not be simply an overload of normal enzymatic capacity. 
 
Hepatic BVR-A activity was either normal or increased in TCDD-treated line B rats, 
except 32 days after 300 µg/kg when it was only 51% of control (Table 11). One 
Discussion 
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possible reason for decreased BVR-A activity might be substrate inhibition (Kutty 
and Maines 1981) as in necropsy, these rats exhibited severe hepatic swelling and 
leakage of dark green/black fluid, indicating biliverdin accumulation. At the same 
time-point, line A rats exhibited 1.5-fold increase in hepatic BVR-A activity and 
yellowish liver, suggesting increased hepatic content of bilirubin (IV). Concurrently, 
serum total bilirubin was significantly and similarly increased in both rat lines (mean 
values 45 µM and 36 µM in line A and line B rats, respectively; unpublished results). 
A possible interpretation for these findings is that hepatic heme degradation is 
strongly increased in both rat lines A and B, but only in line B rats part of biliverdin 
is conjugated rather than reduced to bilirubin. Why? A simple explanation would be 
that in line B, BVR-A might not function as efficiently as in line A under increased 
heme degradation caused by TCDD. BVR-A is known to be a versatile enzyme 
having pleiotropic functions, and its catalytic activity is critically regulated by 
phosphorylation state (Kapitulnik and Maines 2009; Maines 2005; Salim et al. 2001; 
see Section 2.5.3 for literature review on BVR-A). BVR-A is also prone to 
inhibition by biliverdin and bilirubin (Kutty and Maines 1981; Rigney and Mantle 
1988). Therefore, although it is not possible to name the exact alteration, it might 
not be surprising if some specific difference would exist in the function or regulation 
of BVR-A between rat lines A and B, which would manifest under increased need 
for BVR-A-catalyzed reduction of biliverdin. This potential difference would have 
to be related to the AHR genotype, and in fact, it might be a difference e.g. in post-
translational modification of BVR-A protein itself, or a difference in some regulator 
or interplayer of BVR-A. In humans, two case reports exist concerning hetero- and 
homozygous mutations in the gene of BVR-A. These individuals were 
phenotypically normal until an emergence of a specific stressor such as alcoholic 
liver failure or obstructive cholestasis due to gallstones, after which biliverdinaemia 
was observed (Gåfvels et al. 2009; Nytofte et al. 2011). The coding sequence of line 
B rat´s BVR-A was found to be equal to one in GenBank (Niittynen et al. 2003), 
however, there might be some post-translational change in rat line B affecting the 
function of BVR-A, which under a specific stressor − such as increased heme 
degradation due to TCDD − would lead to biliverdin accumulation. 
 
When comparing line B and L-E rats in terms of biliverdin accumulation, two 
possibilities exist. A common part to both choices is the above conclusion, that after 
acutely toxic doses of TCDD, hepatic biliverdin level is probably prone to increase 
in all rats expressing wild-type AHR. However, only in semi-TCDD-resistant rat 
strains, such as line B, the syndrome seems to be able to develop to such a severe 
stage before the death of the animal that it becomes noticed at necropsies. In semi-
TCDD-resistant rats, the resistance is provided by one AHRhw allele or one or two 
Bhw alleles, whereas the presence of at least one AHRwt allele enables biliverdin 
accumulation. Having this background in mind, two possible scenarios can be 
constructed: 
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−  According to Choice 1, the role of Bhw in relation to this syndrome is only 
in increasing rats´ TCDD-resistance by a mechanism not related to 
biliverdin accumulation. If L-E rats would stay alive a longer time after 
acutely toxic dose of TCDD, as high biliverdin levels would be detected in 
them as are detected in line B rats.  
− According to Choice 2, although biliverdin levels increase in response to 
TCDD in both line B and L-E rats, the observed difference in the magnitude 
of effect (level of hepatic biliverdin) is significant. This means that even if 
L-E rats would stay alive longer after a high dose of TCDD, biliverdin 
levels would never become as high as in line B rats. What follows from 
Choice 2 is that Bhw allele would be a necessary factor for substantial 
biliverdin accumulation, whereas Bwt would limit biliverdin accumulation to 
relatively low levels. Hence, Bhw allele would make the rat more susceptible 
to biliverdin accumulation than Bwt allele but simultaneously more resistant 
to TCDD-induced acute lethality. Although hypothetical, this is 
mechanistically an intriguing option, as a possible role for BVR-A in 
TCDD toxicity can be suggested. Namely, it has been shown that inhibition 
of BVR-A increases cellular glucose intake (Lerner Marmarosh et al. 2005). 
If the function of BVR-A in line B would be abnormal, it might lead to 
accumulation of biliverdin, and concurrently to increased cellular glucose 
intake and thus better TCDD resistance, assuming that problems in cellular 
glucose intake would be crucial to TCDD’s acute lethality. It is known that 
TCDD has effects on cellular glucose uptake and metabolism (Enan et al. 
1992; Liu and Matsumura 1995, 2006; Olsen et al. 1994; Tonack et al. 2007; 
Viluksela et al. 1999), however, the significance of these effects in TCDD-
induced acute lethality is unresolved.  
6.2.2 Does oxidative stress play a role in biliverdin accumulation? 
According to an early hypothesis, TCDD-induced oxidative stress might be an 
important player in TCDD-induced biliverdin accumulation, as oxidative stress is 
known to induce HO-1 (Section 2.3.3 and references therein) and thereby increase 
heme degradation. On the other hand, it was pondered whether the accumulated 
biliverdin and its conjugates might be formed oxidatively from bilirubin and its 
conjugates in TCDD-exposed rats. Quite surprisingly, TCDD did not induce hepatic 
mRNA expression of HO-1 in any studied rat strain, however, it clearly induced 
protein expression of HO-1, although only after the dose 100 µg/kg or more (Table 
11; IV, V). In spleen, TCDD even dramatically decreased the expression of HO-1 
mRNA (Table 11; IV). Therefore, while TCDD-induced oxidative stress may 
explain part of the observed HO-1 induction, increased hepatic free heme 
concentration may be even more important effector, as discussed in Section 6.1.2. In 
concordance with this, splenic decrease in HO-1 mRNA expression could be 
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explained by a quantitative swift of heme degradation from spleen to liver – for an 
unknown but TCDD-related reason.  
 
What comes to the second hypothesis, that biliverdin and its conjugates might be 
formed oxidatively from bilirubin and its conjugates, the results of correlation 
analysis do not support this option (Figure 8; V). As explained in Section 6.1.3, 
biliverdin conjugates seem to be formed as secondary products of biliverdin. This 
conclusion is supported by literature, as chemical oxidation of bilirubin mostly leads 
to degradation products other than biliverdin (McDonagh 2010c). On the other hand, 
presence of hepatic bilirubin oxidase has been shown in rats, mice and humans 
(Abu-Bakar et al. 2011, 2012; Cardenas-Vazguez et al. 1986), and the reaction 
catalyzed by it apparently leads to formation of biliverdin. It is indeed possible that 
this reaction takes place in the livers of TCDD-exposed rats, however, it does not 
seem to play a major role in TCDD-induced biliverdin accumulation for the 
following two reasons. Firstly, correlation between biliverdin and bilirubin was poor 
(Figure 8; V). Secondly, biliverdin conjugates rather than free compound were the 
main accumulating form of biliverdin (V).  
 
Third possibility of oxidative stress as a cause for biliverdin accumulation is related 
to the observations of Barone et al. (2011b) that in human brain, oxidative or 
nitrosative stress-induced modifications decrease the activity of BVR-A. This is an 
intriguing observation, however, we did not observe decreased hepatic BVR-A 
activity in vitro in rats whose hepatic biliverdin content was largely increased (V). 
As the oxidative stress-induced modifications mostly seem to be covalent (Barone et 
al. 2011b), they hardly are reversible without enzymatic action, for which reason in 
vivo inhibition of enzymatic activity should be observable in in vitro measurements 
in study settings used in IV and V. Therefore, this possibility for oxidative stress as 
the fundamental cause of biliverdin accumulation in TCDD-exposed rats does not 
seem likely either. Only at the late stage of the biliverdin accumulation syndrome, 
when the livers were swollen and leaked black fluid, clear decrease in BVR-A 
activity was observed in vitro (IV), but this does not explain biliverdin accumulation 
at earlier stages of the syndrome, when macroscopic signs of biliverdin 
accumulation were very mild or absent, but the HPLC analysis showed significantly 
elevated levels of biliverdin and its conjugates (V). 
 
In conclusion, the current knowledge on the cellular effects of TCDD-induced 
oxidative stress does not provide ultimate explanations for biliverdin accumulation. 
Problems or insufficiency in the function of BVR-A are anyhow possible, especially 
those reversible in nature, which option was discussed in previous section (6.2.1). 
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6.2.3 Possible linkage of biliverdin accumulation and hepatic peliosis 
In line B rats, a concurrent TCDD-induced finding with biliverdin accumulation was 
dilatation of hepatic sinusoids which eventually reached hepatic peliosis –like state. 
In this condition, liver parenchyma is substituted with blood-filled cavities 
(Tzirogiannis et al. 2004). TCDD-induced sinusoidal distension/hepatic peliosis 
does not require wild-type AHR as it was detected also in line A and H/W rats, 
however, these strains showed milder effects than line B rats. After our findings (I), 
TCDD-induced sinusoidal distension has been described in mice and rhesus 
monkeys during repeated or long-term exposures (Chang et al. 2005; Korenaga et al. 
2007). In rats and mice, TCDD-induced sinusoidal distension has been found to start 
at the centrilobular area of hepatic tissue, which is also the area of AHR localization 
in liver (III; Chang et al. 2005; Lindros et al. 1997). There was no clear potency 
difference between TCDD and HxCDD in the ability to cause sinusoidal distension, 
in fact, HxCDD induced the worst cases (III). Altogether, sinusoidal distension may 
be quite a common effect of dioxins, if the administrated dose is relatively high 
and/or duration of exposure subacute, subchronic or chronic. 
 
In humans, hepatic peliosis has been detected in context of various infections, 
chronic illnesses, malignancies and drugs, for example, human immunodeficiency 
virus (HIV) infection, hepatocellular carcinoma, tuberculosis, anabolic steroids, oral 
contraceptives, corticosteroids and many other (Bashir et al. 2012; Perkocha et al. 
1990). However, it is an uncommon finding and its pathogenesis is uncertain (Bashir 
et al. 2012; Gushiken 2000). Hypothesis for the pathogenesis of hepatic peliosis 
includes breakdown of the sinusoidal borders / sinusoidal epithelial damage, hepatic 
outflow obstruction and dilatation of the central vein of the hepatic lobule (Bashir et 
al. 2012; Gushiken 2000). Interestingly, thrombocytopenia has been shown to 
induce hepatic peliosis (Sullivan et al. 2010) and thrombocytopenia is one of the 
effects of dioxins in rats (Pohjanvirta and Tuomisto et al. 1994; Viluksela et al. 
1998). The essentiality of peliotic findings in regard to biliverdin accumulation 
comes from the increased amount of blood in liver due to this condition, which 
might contribute to the increased hepatic and/or serum levels of biliverdin and 
bilirubin detected in TCDD-treated rats, as it is plausible that increased amount of 
blood in liver would lead to increased hepatic heme degradation and subsequent 
elevation of biliverdin and bilirubin levels. On the other hand, TCDD increases 
serum bilirubin levels with lower doses and/or sooner than what probably is required 
for sinusoidal distension (III, V; Simanainen et al. 2003), suggesting that the 
TCDD-induced heme degradation starts before sinusoidal distension can be detected 
in histological examination. In fact, equimolar amounts of carbon monoxide, an 
established vasorelaxant (Wu and Wang 2005), is formed during heme degradation 
(Figure 7). This prompts to speculate, whether the probable increased production of 
carbon monoxide might contribute to TCDD-induced hepatic peliosis. 
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6.3 HxCDD-specific mechanism of dioxin toxicity 
The results of Study III suggest that two different mechanisms of PCDD lethality 
and toxicity exist. The other is the classical AHR-mediated mechanism, where both 
AHR and gene B affect sensitivity to responses such as mortality, body weight loss 
and biliverdin accumulation. Further, TEFs mainly apply. In contrast, the other 
mechanism seems to be specifically related to HxCDD and possibly to another 
higher chlorinated PCDD, 1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin (Pohjanvirta et 
al. 1995). The typical endpoints of the HxCDD-specific mechanism are mortality, 
rapid body weight loss, fatty degeneration of the liver, and gastrointestinal 
hemorrhage. The lack of differences between rat strains/lines in these responses 
suggests that the AHR and gene B do not play a role here. The HxCDD-specific 
mechanism is not very sensitive, as the effects started to appear only when the dose 
was 600 (fatty liver) − 2000 µg/kg (other effects) or more. Further studies are 
needed to clarify the HxCDD-mechanism at the molecular level. One of its main 
manifestations is liver toxicity: fatty liver and hepatic peliosis. Thus, in addition to 
the AHR-mediated mechanism, HxCDD seems to impair the function of hepatocytes 
via another mechanism not used by TCDD. Another possibility is that TCDD indeed 
uses the HxCDD-specific mechanism, but with such small potency that the 
responses are always masked by the AHR-mediated effects. The responses mediated 
by the HxCDD-mechanism are probably modified and confounded by the AHR-
mediated effects.  
6.4 Implications for dioxin toxicology, risk assessment and 
heme metabolism 
Implications for dioxin toxicology 
The results of this thesis strongly suggest that TCDD increases hepatic heme 
degradation in rats, which is a novel finding. The observed threshold for this effect 
was 10 µg/kg TCDD in line B rats, as elevation of unconjugated serum bilirubin was 
observed with this dose (V). As discussed above, increased heme degradation might 
be a consequence of increased amount of free heme in liver, in addition, oxidative 
stress might play a role. On the other hand, splenic degradation of heme seems to be 
decreased (IV). Clarifying the pathogenesis of decreased splenic and increased 
hepatic heme degradation might be interesting in regard to toxic mechanisms of 
TCDD. On the other hand, all products of heme degradation − carbon monoxide, 
iron and biliverdin/bilirubin − are biologically active and might thus either potentiate 
or alleviate the toxicity of TCDD. 
 
Other important implications of this study are those related to gene B and the 
ultimate cause of biliverdin accumulation. Unfortunately, the identity of gene B 
still remains unknown, however, the results of Study III support previous views 
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(Simanainen et al. 2003; Tuomisto et al. 1999b) that gene B is most likely part of the 
AHR signaling cascade. It remains unclear, whether Bhw allele increases TCDD-
resistance independently of biliverdin metabolism, or whether Bhw allele − in 
addition to increasing TCDD resistance − is a prerequisite for substantial 
accumulation of biliverdin and its conjugates.   
 
The ultimate cause of biliverdin accumulation is related to increased heme 
degradation due to TCDD exposure and, most probably, concurrent insufficient 
action of BVR-A on biliverdin in rats expressing wild-type AHR (V). In addition to 
this connection, both BVR-A and TCDD have complicated connections to protein 
kinase activities (Barone et al. 2014; Carlson and Perdew 2002; Ebner et al. 1993; 
Gibbs et al. 2012) and glucose transport (Lerner-Marmarosh et al. 2005; Olsen et al. 
1994; Tonack et al. 2007), which might be crucial to TCDD-induced mortality and 
other toxicity. Therefore, in order to reveal downstream pathways of dioxin toxicity 
beyond AHR activation, studies concerning the various functions of BVR-A in 
relation to dioxin toxicity might be worthwhile. Even a speculative view could be 
constructed on how possible abnormalities in the function of BVR-A in line B rats 
might explain both increased TCDD-resistance and biliverdin accumulation  
(Section 6.2.1, Choice 2) – it would be very interesting if someone could prove this 
view right or wrong in the future. 
Implications for dioxin risk assessment 
This study does not have direct effects on dioxin risk assessment since all the effects 
were observed after moderately or very high doses of TCDD or HxCDD, to which 
humans do not get exposed in their everyday life. However, results provide indirect 
impacts on risk assessment. Most importantly, TCDD-induced biliverdin 
accumulation was most pronounced in semi-TCDD-resistant rat strains such as line 
B, absent in resistant strains such as line A, and very mild in sensitive L-E rats. 
Therefore, although biliverdin accumulation clearly belongs to Type II dioxin 
endpoints, it is an especially complex response, as most other Type II responses are 
most pronounced in sensitive rat strains such as L-E. Thus, biliverdin accumulation 
serves as a reminder that differences in genes other than AHR may also have 
major influence on the manifestations of dioxin toxicity. This should be kept in 
mind when carrying out dioxin risk assessments. 
 
The present results on acute toxicity of HxCDD (III) suggest caution in regard to 
TEF-concept, as the AHR-mediated effects may not cover all toxic effects of 
PCDDs and unexpected effects are possible due to e.g. genetic variation or after 
high doses. However, the results do not warrant change in the settled TEF value of 
HxCDD (0.1), since the AHR does not seem to be involved in HxCDD-specific 
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toxicity, and the HxCDD-specific toxic effects appeared only after very high doses, 
to which humans are unlikely to be exposed. 
Implications for heme metabolism 
Results of this thesis suggest that efficient hepatic conjugation of biliverdin in 
rats is possible (V). Conjugation of biliverdin has been suggested to occur in 
mammals (Garay et al. 1965), but definite proof is lacking in literature. Possibly 
biliverdin has other potential fates in the body in addition to reduction to bilirubin. 
Technical implications 
TCDD was found to modify the expression level of several housekeeping genes (II). 
Therefore, the housekeeping gene used for normalization of qRT-PCR data in 
toxicological dioxin studies should be carefully validated in advance. Among the 
18 housekeeping genes studied, the expression levels of GAPDH and Pgk 1 were 
most refractory to changes due to TCDD exposure (II), therefore, they are good 
first-line candidates for normalization of gene expression data in dioxin studies. 
Discussion 
 
 
 
THL — Research 133 • 2014 99 
TCDD-Induced Accumulation 
of the Heme Degradation 
Product Biliverdin in Rat Liver 
 
 
 
7 Conclusions 
1. In semi-TCDD-resistant line B rats, TCDD causes a novel type of liver 
toxicity characterized by hepatic accumulation of green pigment. According 
to HPLC-MS/MS analysis, the accumulating pigment consists of the heme 
degradation product biliverdin and its conjugates, mainly biliverdin 
monoglucuronide. Biliverdin conjugates are most likely secondary products 
of biliverdin. An associated finding to TCDD-induced biliverdin 
accumulation was sinusoidal distension eventually progressing to hepatic 
peliosis. In contrast to biliverdin accumulation, also TCDD-resistant rats are 
prone to sinusoidal distension. 
 
2. At least one AHRwt allele is required for biliverdin accumulation. TCDD-
resistant rat strains such as line A and H/W expressing only mutated AHR 
seem to be completely protected from the syndrome, whereas a slight 
increase in hepatic biliverdin was observed in TCDD-sensitive L-E rats due 
to TCDD exposure. Biliverdin accumulation belongs to Type II dioxin 
endpoints, which are sensitive to alterations in the transactivation domain of 
AHR. 
 
3. In line B rats, the lowest observed adverse effect level (LOAEL) for hepatic 
biliverdin accumulation is 100 µg/kg TCDD after subacute exposure (28 
days), which is somewhat more than the observed LOAEL for wasting (30 
µg/kg TCDD) and significantly more than the LOAEL for increased serum 
unconjugated bilirubin (10 µg/kg TCDD). 
 
4. The principal cause for TCDD-induced increase in serum bilirubin, a well-
known effect in many rat strains, is increased hepatic heme degradation, not 
decreased biliary excretion of bilirubin. The probable reason for TCDD-
induced biliverdin accumulation in line B and L-E rats is increased heme 
degradation coupled with non-quantitative conversion of biliverdin to 
bilirubin. The molecular cause for the non-quantitative conversion of 
biliverdin to bilirubin remains obscure, however, it is possible that TCDD 
exposure leads to insufficient catalytic potential of BVR-A in line B rats 
versus, for example, in line A rats, relative to the actual need for BVR-A 
activity during increased heme degradation. 
 
Conclusions 
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5. Results support the role of gene B as part of the AHR signaling cascade. In 
regard to biliverdin accumulation, two possible roles for Bhw allele exist: 
either Bhw is unrelated to biliverdin metabolism but enables detection of the 
syndrome via increased TCDD-resistance of the rat, or Bhw allele 
simultaneously increases rat´s TCDD-resistance and is necessary for 
substantial accumulation of biliverdin. 
 
6. In addition to biliverdin, protein kinase activities and glucose transport are 
aspects connecting BVR-A and TCDD. Therefore, studies in these areas 
might give further insight into mechanisms of TCDD toxicity, including the 
biliverdin accumulation syndrome. 
 
7. HxCDD did not induce biliverdin accumulation but it induced severe 
hepatic peliosis. There seem to be two different mechanisms of PCDD 
toxicity and lethality. One is the classical AHR-mediated mechanism where 
TEFs apply. The other is characteristic to HxCDD, whereas if TCDD 
ignites this mechanism at all, it is a weak inducer. Typical endpoints of 
HxCDD-specific mechanism are liver toxicity, body weight loss, 
gastrointestinal hemorrhage and mortality. HxCDD-specific toxic effects 
appear only after high doses. 
 
8. The expression level of several housekeeping genes is modified by dioxin 
exposure. 
 
 
 
 
THL — Research 133 • 2014 101 
TCDD-Induced Accumulation 
of the Heme Degradation 
Product Biliverdin in Rat Liver 
 
8 Acknowledgements 
This work was carried out in the Department of Environmental Health, National 
Institute for Health and Welfare, Kuopio, during years 2002−2014. I wish to thank 
Professors Jouko Tuomisto, Terttu Vartiainen, Juha Pekkanen and Hannu 
Komulainen, the former and present directors of the Department, for providing the 
facilities for these studies. In addition, my special thanks belong to Jouko Tuomisto 
for originally engaging me to the dioxin research group to work on a novel TCDD-
induced hepatic phenomenon, as well as for his personal interest in this topic. 
 
I wish to express my sincere gratitude to my principal supervisor, Docent Jouni T. 
Tuomisto, for his inventive scientific guidance, encouragement and wide-ranging 
knowledge on environmental health, which has inspired me throughout this work. I 
am also deeply grateful to Professor Raimo Pohjanvirta for his excellent co-
authorship and guidance in methods of molecular biology. His state-of-the-art 
knowledge of dioxins was a firm pillar during the writing of the articles. I also 
would like to thank Professor Matti Viluksela for his advice and support in many 
matters. 
 
I was lucky in getting Dr. Timothy J. Mantle from the Trinity College, Dublin, 
Ireland, to be my second supervisor. I would like to thank Tim for helpful and 
pleasant collaboration around that little complex enzyme, biliverdin reductase, and 
for sharing his wide understanding of heme metabolism. I also wish to thank Dr. 
Edward Franklin from Tim´s research group for practical guidance in certain 
methods of enzymology.  
 
I am grateful to the reviewers of this thesis, Professors Helen Håkansson and 
Christopher J. Portier, for their careful review and useful comments.  
 
It has been a privilege to work in such enthusiastic and lively research environments 
as the former dioxin group and during last years, YMAL (Assessment and Modeling 
Unit). My warmest thanks belong to all their former and present members. 
Especially I want to thank my closest colleagues Merja Korkalainen, Sanna Lensu, 
Hanna Miettinen and Ulla Simanainen from dioxin group for friendship, co-
operation and support, as well as Virpi Kollanus, Olli Leino, Päivi Meriläinen, 
Mikko Pohjola and Sari Ung-Lanki for numerous discussions on scientific and non-
scientific matters and relaxing and cheerful moments. 
 
I wish to express my sincere thanks to my co-authors not yet mentioned, namely, 
Paula Syrjälä, Jere Lindén, Ivy D. Moffat, Paul C. Boutros and Professors Seppo 
Acknowledgements 
 
THL — Research 133 • 2014 102 
TCDD-Induced Accumulation 
of the Heme Degradation 
Product Biliverdin in Rat Liver 
 
Auriola, Satu Sankari and Allan B. Okey, for their expertise and valuable 
contribution to the original publications of this thesis.  
 
I owe my special thanks to Arja Moilanen, Ulla Naukkarinen, Virpi Tiihonen and 
Janne Korkalainen for their excellent technical assistance. In addition, many other 
colleagues in the Department of Environmental Health have helped me in various 
practicalities during this work; my sincere thanks belong to you all. I also wish to 
express my gratitude to Docent Anne Hyvärinen for my current position in the 
Environmental Microbiology Unit, and to the entire YMIK personnel for the 
friendly and inspiring working atmosphere. 
 
I am grateful to my mother Eeva-Liisa for her care and generous help throughout my 
life and especially during the past quite busy years. I am also most indebted to my 
departed father Jorma for all precious support and encouragement during those 29 
years we had time in common; that carries me even today. I extend my warmest 
thanks to my friends and relatives, especially to my sister Päivi and her family, for 
many joyous moments spent together. Finally, my heartfelt gratitude belongs to my 
husband Paavo for his most essential support, love and patience, and our daughter 
Pauliina for being the sunshine of my life. 
 
This study was financially supported by the Academy of Finland, the European 
Commission, the Graduate School in Environmental Health (‘SYTYKE’), the Emil 
Aaltonen Foundation, the Finnish Cultural Foundation and the National Technology 
Fund (‘TEKES’). 
 
 
Kuopio, October 2014 
 
 
Marjo Niittynen 
 
 
 
 
THL — Research 133 • 2014 103 
TCDD-Induced Accumulation 
of the Heme Degradation 
Product Biliverdin in Rat Liver 
 
9 References 
Abraham NG, Kappas A. Pharmacological and 
clinical aspects of heme oxygenase. Pharmacol 
Rev. 2008; 60(1):79-127.  
 
Abu-Bakar A, Arthur DM, Aganovic S, Ng JC, Lang 
MA. Inducible bilirubin oxidase: a novel 
function for the mouse cytochrome P450 2A5. 
Toxicol Appl Pharmacol. 2011; 257(1):14-22.  
 
Abu-Bakar A, Arthur DM, Wikman AS, Rahnasto 
M, Juvonen RO, Vepsäläinen J, Raunio H, Ng 
JC, Lang MA. Metabolism of bilirubin by human 
cytochrome P450 2A6. Toxicol Appl Pharmacol. 
2012; 261(1):50-58.  
 
Ahlfors CE. Competitive interaction of biliverdin 
and bilirubin only at the primary bilirubin 
binding site on human albumin. Anal Biochem. 
1981; 110(2):295-307. 
 
Ahmad Z, Salim M, Maines MD. Human biliverdin 
reductase is a leucine zipper-like DNA-binding 
protein and functions in transcriptional activation 
of heme oxygenase-1 by oxidative stress. J Biol 
Chem. 2002; 277(11):9226-9232. 
 
Akhtar FZ, Garabrant DH, Ketchum NS, Michalek 
JE. Cancer in US Air Force veterans of the 
Vietnam War. J Occup Environ Med. 2004; 
46(2):123-136. 
 
Alaluusua S, Calderara P, Gerthoux PM, Lukinmaa 
P-L, Kovero O, Needham L, Patterson DG, 
Tuomisto J, Mocarelli P. Developmental dental 
aberrations after the dioxin accident in Seveso. 
Environ Health Perspect. 2004; 112(13):1313-
1318.  
 
Alaluusua S, Lukinmaa P-L, Pohjanvirta R, Unkila 
M, Tuomisto J. Exposure to 2,3,7,8-
tetrachlorodibenzo-para-dioxin leads to 
defective dentin formation and pulpal perforation 
in rat incisor tooth. Toxicology. 1993; 81(1):1-
13. 
 
Alaluusua S, Lukinmaa P-L, Torppa J, Tuomisto J, 
Vartiainen T. Developing teeth as biomarker of 
dioxin exposure. Lancet. 1999; 353(9148):206. 
 
Alaluusua S, Lukinmaa P-L, Vartiainen T, Partanen 
M, Torppa J, Tuomisto J. Polychlorinated 
dibenzo-p-dioxins and dibenzofurans via 
mother´s milk may cause developmental defects 
in the child´s teeth. Environ Toxicol Pharmacol. 
1996; 1(3):193-197. 
 
Alam J, Cook JL. Transcriptional regulation of the 
heme oxygenase-1 gene via the stress response 
element pathway. Curr Pharm Des. 2003; 
9(30):2499-2511. 
 
Alam J, Stewart D, Touchard C, Boinapally S, Choi 
AM, Cook JL. Nrf2, a Cap'n'Collar transcription 
factor, regulates induction of the heme 
oxygenase-1 gene. J Biol Chem. 1999; 
274(37):26071-26078. 
 
Alonso-Magdalena P, Quesada I, Nadal A. 
Endocrine disruptors in the etiology of type 2 
diabetes mellitus. Nat Rev Endocrinol. 2011; 
7(6):346-353.  
 
Alsharif NZ, Lawson T, Stohs SJ. Oxidative stress 
induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin 
is mediated by the aryl hydrocarbon (Ah) 
receptor complex. Toxicology. 1994; 92(1-3):39-
51. 
 
An Y, Bekesova S, Edwards N, Goldman R. Peptides 
in low molecular weight fraction of serum 
References 
 
 
THL — Research 133 • 2014 104 
TCDD-Induced Accumulation 
of the Heme Degradation 
Product Biliverdin in Rat Liver 
 
associated with hepatocellular carcinoma. Dis 
Markers. 2010; 29(1):11-20. 
 
Baccarelli A, Giacomini SM, Corbetta C, Landi MT, 
Bonzini M, Consonni D, Grillo P, Patterson DG, 
Pesatori AC, Bertazzi PA. Neonatal thyroid 
function in Seveso 25 years after maternal 
exposure to dioxin.  PLoS Med. 2008; 5(7):e161. 
 
Barañano DE, Rao M, Ferris CD, Snyder SH. 
Biliverdin reductase: a major physiologic 
cytoprotectant. Proc Natl Acad Sci U S A. 2002; 
99(25):16093-16098. 
 
Barone E, Di Domenico F, Cenini G, Sultana R, Cini 
C, Preziosi P, Perluigi M, Mancuso C, 
Butterfield DA. Biliverdin reductase-A protein 
levels and activity in the brains of subjects with 
Alzheimer disease and mild cognitive 
impairment. Biochim Biophys Acta. 2011a; 
1812(4):480-487.  
 
Barone E, Di Domenico F, Cenini G, Sultana R, 
Coccia R, Preziosi P, Perluigi M, Mancuso C, 
Butterfield DA. Oxidative and nitrosative 
modifications of biliverdin reductase-A in the 
brain of subjects with Alzheimer's disease and 
amnestic mild cognitive impairment. J 
Alzheimers Dis 2011b; 25(4):623-633. 
 
Barone E, Di Domenico F, Mancuso C, Butterfield 
DA. The Janus face of the heme 
oxygenase/biliverdin reductase system in 
Alzheimer disease: It's time for reconciliation. 
Neurobiol Dis. 2014; 62:144-159.  
 
Barone E, Mancuso C, Di Domenico F, Sultana R, 
Murphy MP, Head E, Butterfield DA. Biliverdin 
reductase-A: a novel drug target for atorvastatin 
in a dog pre-clinical model of Alzheimer disease. 
J Neurochem. 2012; 120(1):135-146.  
 
Bashir O, Gaillard F et al. Hepatic peliosis. 2012. 
Available: http://radiopaedia.org/articles/hepatic-
peliosis  
 
Basu NK, Ciotti M, Hwang MS, Kole L, Mitra PS, 
Cho JW, Owens IS. Differential and special 
properties of the major human UGT1-encoded 
gastrointestinal UDP-glucuronosyltransferases 
enhance potential to control chemical uptake. J 
Biol Chem. 2004; 279(2):1429-1441.  
 
Beatty PW, Vaughn WK, Neal RA. Effect of 
alteration of rat hepatic mixed-function oxidase 
(MFO) activity on the toxicity of 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD). Toxicol 
Appl Pharmacol. 1978; 45(2):513-519.  
 
Bell DR, Clode S, Fan MQ, Fernandes A, Foster PM, 
Jiang T, Loizou G, MacNicoll A, Miller BG, 
Rose M, Tran L, White S. Interpretation of 
studies on the developmental reproductive 
toxicology of 2,3,7,8-tetrachlorodibenzo-p-
dioxin in male offspring. Food Chem Toxicol. 
2010; 48(6):1439-1447.  
 
Bertazzi PA, Bernucci I, Brambilla G, Consonni D, 
Pesatori AC. The Seveso studies on early and 
long-term effects of dioxin exposure: a review. 
Environ Health Perspect. 1998; 106(Suppl 
2):625-633.  
 
Bertazzi PA, Consonni D, Bachetti S, Rubagotti M, 
Baccarelli A, Zocchetti C, Pesatori AC. Health 
effects of dioxin exposure: a 20-year mortality 
study. Am J Epidemiol. 2001; 153(11):1031-
1044. 
 
Birnbaum LS. Developmental effects of dioxins and 
related endocrine disrupting chemicals. Toxicol 
Lett. 1995; 82-83:743-750. 
 
  
THL — Research 133 • 2014 105 
TCDD-Induced Accumulation 
of the Heme Degradation 
Product Biliverdin in Rat Liver 
 
Birnbaum LS, Cummings AM. Dioxins and 
endometriosis: a plausible hypothesis. Environ 
Health Perspect. 2002; 110(1):15-21. 
 
Birnbaum LS, Fenton SE. Cancer and developmental 
exposure to endocrine disruptors. Environ Health 
Perspect. 2003; 111(4):389-394.  
 
Birnbaum LS, Tuomisto J. Non-carcinogenic effects 
of TCDD in animals. Food Addit Contam. 2000; 
17(4):275-288.  
 
Blauer G, Wagnière G. Conformation of bilirubin 
and biliverdin in their complexes with serum 
albumin. J Am Chem Soc. 1975; 97(7):1949-
1954. 
 
Bock KW. Regulation of bilirubin clearance by 
ligand-activated transcription factors of the endo- 
and xenobiotic metabolism system. Front 
Pharmacol. 2011a; 2:82.  
 
Bock KW. From differential induction of UDP-
glucuronosyltransferases in rat liver to 
characterization of responsible ligand-activated 
transcription factors, and their multilevel 
crosstalk in humans. Biochem Pharmacol. 
2011b; 82(1):9-16.  
 
Bock KW, Köhle C. The mammalian aryl 
hydrocarbon (Ah) receptor: from mediator of 
dioxin toxicity toward physiological functions in 
skin and liver. Biol Chem. 2009; 390(12):1225-
1235. 
 
Bock KW, Köhle C. Contributions of the Ah 
receptor to bilirubin homeostasis and its 
antioxidative and atheroprotective functions. 
Biol Chem. 2010; 391(6):645-653.  
 
Bonkovsky HL, Wood SG, Howell SK, Sinclair PR, 
Lincoln B, Healey JF, Sinclair JF. High-
performance liquid chromatographic separation 
and quantitation of tetrapyrroles from biological 
materials. Anal Biochem. 1986; 155(1):56-64. 
 
Boutros PC, Yan R, Moffat ID, Pohjanvirta R, Okey 
AB. Transcriptomic responses to 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) in liver: 
comparison of rat and mouse. BMC Genomics. 
2008; 9:419.  
 
Boutros PC, Yao CQ, Watson JD, Wu AH, Moffat 
ID, Prokopec SD, Smith AB, Okey AB, 
Pohjanvirta R. Hepatic transcriptomic responses 
to TCDD in dioxin-sensitive and dioxin-resistant 
rats during the onset of toxicity. Toxicol Appl 
Pharmacol. 2011; 251(2):119-129. 
 
Boverhof DR, Burgoon LD, Tashiro C, Chittim B, 
Harkema JR, Jump DB, Zacharewski TR. 
Temporal and dose-dependent hepatic gene 
expression patterns in mice provide new insights 
into TCDD-mediated hepatotoxicity. Toxicol 
Sci. 2005; 85(2):1048-1063.  
 
Boverhof DR, Burgoon LD, Tashiro C, Sharratt B, 
Chittim B, Harkema JR, Mendrick DL, 
Zacharewski TR. Comparative toxicogenomic 
analysis of the hepatotoxic effects of TCDD in 
Sprague Dawley rats and C57BL/6 mice. Toxicol 
Sci. 2006; 94(2):398-416. 
 
Bradford MM. A rapid and sensitive method for the 
quantitation of microgram quantities of protein 
utilizing the principle of protein-dye binding. 
Anal Biochem. 1976; 72:248-254. 
 
Braggins PE, Trakshel GM, Kutty RK, Maines MD. 
Characterization of two heme oxygenase 
isoforms in rat spleen: comparison with the 
hematin-induced and constitutive isoforms of the 
liver. Biochem Biophys Res Commun. 1986; 
141(2):528-533. 
 
References 
  
THL — Research 133 • 2014 106 
TCDD-Induced Accumulation 
of the Heme Degradation 
Product Biliverdin in Rat Liver 
 
Brewster DW, Uraih LC, Birnbaum LS. The acute 
toxicity of 2,3,4,7,8-pentachlorodibenzofuran 
(4PeCDF) in the male Fischer rat. Fundam Appl 
Toxicol. 1988; 11(2):236-249. 
 
Brower JO, Lightner DA, McDonagh AF. Aromatic 
congeners of bilirubin: synthesis, 
stereochemistry, glucuronidation and hepatic 
transport. Tetrahedron. 2001; 57(37):7813-7827. 
 
Bulmer AC, Ried K, Blanchfield JT, Wagner KH. 
The anti-mutagenic properties of bile pigments. 
Mutat Res. 2008; 658(1-2):28-41.  
 
Bulmer AC, Ried K, Coombes JS, Blanchfield JT, 
Toth I, Wagner KH. The anti-mutagenic and 
antioxidant effects of bile pigments in the Ames 
Salmonella test. Mutat Res. 2007; 629(2):122-
132. 
 
Buu-Hoi NP, Chanh PH, Sesque G, Azum-Gelade 
MC, Saint-Ruf G. Enzymatic functions as targets 
of the toxicity of "dioxin" (2,3,7,8-
tetrachlorodibenzo-p-dioxin). 
Naturwissenschaften. 1972; 59(4):173-174. 
 
Cantoni L, Salmona M, Rizzardini M. Porphyrogenic 
effect of chronic treatment with 2,3,7,8-
tetrachlorodibenzo-p-dioxin in female rats. Dose 
− effect relationship following urinary excretion 
of porphyrins. Toxicol Appl Pharmacol. 1981; 
57(2):156-163. 
 
Cardenas-Vazquez R, Yokosuka O, Billing BH. 
Enzymic oxidation of unconjugated bilirubin by 
rat liver. Biochem J. 1986; 236(3):625-633. 
 
Carlson DB, Perdew GH. A dynamic role for the Ah 
receptor in cell signaling? Insights from a diverse 
group of Ah receptor interacting proteins. J 
Biochem Mol Toxicol. 2002; 16(6):317-325. 
 
Chang JW, Ou HY, Chen HL, Guo HR, Liao PC, 
Lee CC. Interrelationship between exposure to 
PCDD/Fs and hypertension in metabolic 
syndrome in Taiwanese living near a highly 
contaminated area. Chemosphere. 2010; 
81(8):1027-1032. 
 
Chang H, Wang YJ, Chang LW, Lin P. A 
histochemical and pathological study on the 
interrelationship between TCDD-induced AhR 
expression, AhR activation, and hepatotoxicity in 
mice. J Toxicol Environ Health A. 2005; 68(17-
18):1567-1579. 
 
Choi AM, Alam J. Heme oxygenase-1: function, 
regulation, and implication of a novel stress-
inducible protein in oxidant-induced lung injury. 
Am J Respir Cell Mol Biol. 1996; 15(1):9-19.  
 
Ciftci O, Ozdemir I. Protective effects of quercetin 
and chrysin against 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD) induced oxidative stress, body 
wasting and altered cytokine productions in rats. 
Immunopharmacol Immunotoxicol. 2011; 
33(3):504-508.  
 
Cohen AN, Kapitulnik J, Ostrow JD, Webster CC. 
Effect of combined treatment with 2,3,7,8-
tetrachlorodibenzo-p-dioxin and phototherapy on 
bilirubin metabolism in the jaundiced Gunn rat. 
Hepatology. 1986; 6(3):490-494. 
 
Converso DP, Taillé C, Carreras MC, Jaitovich A, 
Poderoso JJ, Boczkowski J. HO-1 is located in 
liver mitochondria and modulates mitochondrial 
heme content and metabolism. FASEB J. 2006; 
20(8):1236-1238. 
 
Couture LA, Elwell MR, Birnbaum LS. Dioxin-like 
effects observed in male rats following exposure 
to octachlorodibenzo-p-dioxin (OCDD) during a 
13-week study. Toxicol Appl Pharmacol. 1988; 
93(1):31-46. 
References 
  
THL — Research 133 • 2014 107 
TCDD-Induced Accumulation 
of the Heme Degradation 
Product Biliverdin in Rat Liver 
 
 
Covaci A, Voorspoels S, Schepens P, Jorens P, Blust 
R, Neels H. The Belgian PCB/dioxin crisis-8 
years later An overview. Environ Toxicol 
Pharmacol. 2008; 25(2):164-170.  
 
Cranmer M, Louie S, Kennedy RH, Kern PA, 
Fonseca VA. Exposure to 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) is 
associated with hyperinsulinemia and insulin 
resistance. Toxicol Sci. 2000; 56(2):431-436. 
 
Croutch CR, Lebofsky M, Schramm K-W, Terranova 
PF, Rozman KK. 2,3,7,8-Tetrachlorodibenzo-p-
dioxin (TCDD) and 1,2,3,4,7,8-
hexachlorodibenzo-p-dioxin (HxCDD) alter 
body weight by decreasing insulin-like growth 
factor I (IGF-I) signaling. Toxicol Sci. 2005; 
85(1):560-571.  
 
Davies R, Clothier B, Robinson SW, Edwards RE, 
Greaves P, Luo J, Gant TW, Chernova T, Smith 
AG. Essential role of the AH receptor in the 
dysfunction of heme metabolism induced by 
2,3,7,8-tetrachlorodibenzo-p-dioxin. Chem. Res. 
Toxicol. 2008; 21(2):330-340. 
 
Dennery PA, McDonagh AF, Spitz DR, Rodgers PA, 
Stevenson DK. Hyperbilirubinemia results in 
reduced oxidative injury in neonatal Gunn rats 
exposed to hyperoxia. Free Radic Biol Med. 
1995; 19(4):395-404. 
 
Doré S, Takahashi M, Ferris CD, Hester LD, 
Guastella D, Snyder SH. Bilirubin, formed by 
activation of heme oxygenase-2, protects 
neurons against oxidative stress injury. Proc Natl 
Acad Sci U S A. 1999; 96(5):2445-2450. 
 
Downey DC. Porphyria and chemicals. Med 
Hypotheses. 1999; 53(2):166-171. 
 
Ebner K, Matsumura F, Enan E, Olsen H. 2,3,7,8-
Tetrachlorodibenzo-p-dioxin (TCDD) alters 
pancreatic membrane tyrosine phosphorylation 
following acute treatment. J Biochem Toxicol. 
1993; 8(2):71-81. 
 
Elferink CJ, Whitlock JP. Dioxin-dependent, DNA 
sequence-specific binding of a multiprotein 
complex containing the Ah receptor. Receptor. 
1994; 4(3):157-173. 
 
Enan E, Liu PC, Matsumura F. 2,3,7,8-
Tetrachlorodibenzo-p-dioxin causes reduction of 
glucose transporting activities in the plasma 
membranes of adipose tissue and pancreas from 
the guinea pig. J Biol Chem. 1992; 
267(28):19785-19791. 
 
 Eskenazi B, Mocarelli P, Warner M, Samuels S, 
Vercellini P, Olive D, Needham LL, Patterson 
DG, Brambilla P, Gavoni N, Casalini S, Panazza 
S, Turner W, Gerthoux PM. Serum dioxin 
concentrations and endometriosis: a cohort study 
in Seveso, Italy. Environ Health Perspect. 2002; 
110(7):629-634. 
 
Eskenazi B, Warner M, Marks AR, Samuels S, 
Needham L, Brambilla P, Mocarelli P. Serum 
dioxin concentrations and time to pregnancy. 
Epidemiology. 2010; 21(2):224-231. 
 
Eskew JD, Vanacore RM, Sung L, Morales PJ, 
Smith A. Cellular protection mechanisms against 
extracellular heme. Heme-hemopexin, but not 
free heme, activates the N-terminal c-jun kinase. 
J Biol Chem. 1999; 274(2):638-648. 
 
EU (European Union) Standing Committee on the 
Food Chain and Animal Health, Statement 2011. 
Available: 
http://ec.europa.eu/food/food/chemicalsafety/con
taminants/20110222_statement_final_en.pdf 
 
References 
  
THL — Research 133 • 2014 108 
TCDD-Induced Accumulation 
of the Heme Degradation 
Product Biliverdin in Rat Liver 
 
Ewing JF, Maines MD. Rapid induction of heme 
oxygenase 1 mRNA and protein by hyperthermia 
in rat brain: heme oxygenase 2 is not a heat 
shock protein. Proc Natl Acad Sci U S A. 1991; 
88(12):5364-5368. 
 
Falchuk KH, Contin JM, Dziedzic TS, Feng Z, 
French TC, Heffron GJ, Montorzi M. A role for 
biliverdin IXα in dorsal axis development of 
Xenopus laevis embryos. Proc Natl Acad Sci U S 
A. 2002; 99(1):251-256. 
 
Fang J, Akaike T, Maeda H. Antiapoptotic role of 
heme oxygenase (HO) and the potential of HO as 
a target in anticancer treatment. Apoptosis. 2004; 
9(1):27-35. 
 
Fang LS, Bada JL. The blue-green blood plasma of 
marine fish. Comp Biochem Physiol B. 1990; 
97(1):37-45. 
 
Feeley M, Brouwer A. Health risks to infants from 
exposure to PCBs, PCDDs and PCDFs. Food 
Addit Contam. 2000; 17(4):325-333. 
 
FELASA: Rehbinder C, Baneux P, Forbes D, van 
Herck H, Nicklas W, Rugaya Z, Winkler G. 
FELASA recommendations for the health 
monitoring of mouse, rat, hamster, gerbil, guinea 
pig and rabbit experimental units. Report of the 
Federation of European Laboratory Animal 
Science Associations (FELASA) Working Group 
on Animal Health accepted by the FELASA 
Board of Management, November 1995. Lab 
Anim. 1996 30(3):193-208.  
 
FELASA: Nicklas W, Baneux P, Boot R, Decelle T, 
Deeny AA, Fumanelli M, Illgen-Wilcke B; 
FELASA (Federation of European Laboratory 
Animal Science Associations Working Group on 
Health Monitoring of Rodent and Rabbit 
Colonies). Recommendations for the health 
monitoring of rodent and rabbit colonies in 
breeding and experimental units. Lab Anim. 
2002; 36(1):20-42. 
 
Fenech FF, Bannister WH, Grech JL. Hepatitis with 
biliverdinaemia in association with indomethacin 
therapy. Br Med J. 1967; 3(5558):155-156. 
 
Fletcher N, Wahlström D, Lundberg R, Nilsson CB, 
Nilsson KC, Stockling K, Hellmold H, 
Håkansson H. 2,3,7,8-Tetrachlorodibenzo-p-
dioxin (TCDD) alters the mRNA expression of 
critical genes associated with cholesterol 
metabolism, bile acid biosynthesis, and bile 
transport in rat liver: a microarray study. Toxicol 
Appl Pharmacol. 2005; 207(1):1-24. 
 
Florczyk U, Golda S, Zieba A, Cisowski J, 
Jozkowicz A, Dulak J. Overexpression of 
biliverdin reductase enhances resistance to 
chemotherapeutics. Cancer Lett. 2011; 
300(1):40-47. 
 
Florczyk UM, Jozkowicz A, Dulak J. Biliverdin 
reductase: new features of an old enzyme and its 
potential therapeutic significance. Pharmacol 
Rep. 2008; 60(1):38-48.  
 
Foresti R, Green CJ, Motterlini R. Generation of bile 
pigments by haem oxygenase: a refined cellular 
strategy in response to stressful insults. Biochem 
Soc Symp. 2004; 71:177-192.  
 
Franklin E, Browne S, Hayes J, Boland C, Dunne A, 
Elliot G, Mantle TJ. Activation of biliverdin-IXα 
reductase by inorganic phosphate and related 
anions. Biochem J. 2007; 405(1):61-67. 
 
Furuyama K, Kaneko K, Vargas PD. Heme as a 
magnificent molecule with multiple missions: 
heme determines its own fate and governs 
cellular homeostasis. Tohoku J Exp Med. 2007; 
213(1):1-16. 
 
References 
  
THL — Research 133 • 2014 109 
TCDD-Induced Accumulation 
of the Heme Degradation 
Product Biliverdin in Rat Liver 
 
Gambone CJ, Hutcheson JM, Gabriel JL, Beard RL, 
Chandraratna RA, Soprano KJ, Soprano DR. 
Unique property of some synthetic retinoids: 
activation of the aryl hydrocarbon receptor 
pathway. Mol Pharmacol. 2002; 61(2):334-342. 
 
Garay ER, Noir B, Royer M. Biliverdin pigments in 
green biles. Biochim Biophys Acta. 1965; 
100:411-417.  
 
Geusau A, Abraham K, Geissler K, Sator MO, Stingl 
G, Tschachler E. Severe 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) 
intoxication: clinical and laboratory effects. 
Environ Health Perspect. 2001; 109(8):865-869. 
 
Gibbs PE, Maines MD. Biliverdin inhibits activation 
of NF-κB: reversal of inhibition by human 
biliverdin reductase. Int J Cancer. 2007; 
121(11):2567-2574. 
 
Gibbs PE, Miralem T, Lerner-Marmarosh N, Tudor 
C, Maines MD. Formation of a ternary complex 
of human biliverdin reductase-protein kinase Cδ-
ERK2 protein is essential for ERK2-mediated 
activation of Elk1 protein, NF-κB and inducible 
nitric-oxidase synthase (iNOS). J Biol Chem. 
2012; 287(2):1066-1079.  
 
Gibbs PE, Miralem T, Maines MD. Characterization 
of the human biliverdin reductase gene structure 
and regulatory elements: promoter activity is 
enhanced by hypoxia and suppressed by TNF-α-
activated NF-κB. FASEB J. 2010; 24(9):3239-
3254. 
 
Gibbs PE, Tudor C, Maines MD. Biliverdin 
reductase: more than a namesake - the reductase, 
its peptide fragments, and biliverdin regulate 
activity of the three classes of protein kinase C. 
Front Pharmacol. 2012; 3:31. 
 
Goldstein JA, Hickman P, Bergman H, Vos JG. 
Hepatic porphyria induced by 2,3,7,8-
tetrachlorodibenzo-p-dioxin in the mouse. Res 
Commun Chem Pathol Pharmacol. 1973; 
6(3):919-928.  
 
Goldstein JA, Linko P, Bergman H. Induction of 
porphyria in the rat by chronic versus acute 
exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. 
Biochem Pharmacol. 1982; 31(8):1607-1613. 
 
Goodman DG, Sauer RM. Hepatotoxicity and 
carcinogenicity in female Sprague-Dawley rats 
treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD): a pathology working group 
reevaluation. Regul Toxicol Pharmacol. 1992; 
15, 245-252. 
 
Gorski JR, Weber LW, Rozman K. Tissue-specific 
alterations of de novo fatty acid synthesis in 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-
treated rats. Arch Toxicol. 1988; 62(2-3):146-
151. 
 
Gorski JR, Weber LW, Rozman K. Reduced 
gluconeogenesis in 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD)-treated rats. Arch Toxicol. 1990; 
64(1):66-71. 
 
Goven D, Boutten A, Leçon-Malas V, Marchal-
Sommé J, Soler P, Boczkowski J, Bonay M. 
Induction of heme oxygenase-1, biliverdin 
reductase and H-ferritin in lung macrophage in 
smokers with primary spontaneous 
pneumothorax: role of HIF-1α. PLoS One. 2010; 
5(5):e10886. 
 
Gozzelino R, Jeney V, Soares MP. Mechanisms of 
cell protection by heme oxygenase-1. Annu Rev 
Pharmacol Toxicol. 2010; 50:323-354. 
 
Gray LE, Ostby JS, Kelce WR. A dose-response 
analysis of the reproductive effects of a single 
References 
  
THL — Research 133 • 2014 110 
TCDD-Induced Accumulation 
of the Heme Degradation 
Product Biliverdin in Rat Liver 
 
gestational dose of 2,3,7,8-tetrachlorodibenzo-p-
dioxin in male Long Evans Hooded rat offspring. 
Toxicol Appl Pharmacol. 1997; 146(1):11-20. 
 
Greenberg AJ, Bossenmaier I, Schwartz S. Green 
jaundice. A study of serum biliverdin, 
mesobiliverdin and other green pigments. Am J 
Dig Dis. 1971; 16(10):873-880. 
 
Guberman AS, Scassa ME, Giono LE, Varone CL, 
Cánepa ET. Inhibitory effect of AP-1 complex 
on 5-aminolevulinate synthase gene expression 
through sequestration of cAMP-response 
element protein (CRE)-binding protein (CBP) 
coactivator. J Biol Chem. 2003; 278(4):2317-
2326.  
 
Gushiken FC. Peliosis hepatis after treatment with 2-
chloro-3'-deoxyadenosine. South Med J. 2000; 
93(6):625-626. 
 
Guyton AC. Red blood cells, anemia and 
polycythemia. In: Guyton, AC (ed.), Textbook of 
Medical Physiology, 7th ed., WB Saunders 
Company, Philadelphia, 1986; 42-50. 
 
Gåfvels M, Holmström P, Somell A, Sjövall F, 
Svensson JO, Ståhle L, Broomé U, Stål P. A 
novel mutation in the biliverdin reductase-A 
gene combined with liver cirrhosis results in 
hyperbiliverdinaemia (green jaundice). Liver Int. 
2009; 29(7):1116-1124.  
 
Haarmann-Stemmann T, Abel J. Influence of HIF-1α 
and Nrf2 signaling on AHR-mediated gene 
expression, toxicity, and biological functions. In: 
Pohjanvirta R (ed.) The AH receptor in biology 
and toxicology. John Wiley & Sons, Inc. 
Hoboken, New Jersey, 2012; 109-126. 
 
Hallikainen A, Airaksinen R, Rantakokko P, Koponen 
J, Mannio J, Vuorinen P, et al. Environmental 
pollutants in Baltic fish and other domestic fish: 
PCDD/F, PCB, PBDE, PFC and OT compounds. 
Finnish Food Safety Authority Evira. Report No. 
2/2011. 
 
Hamilton JW, Bement WJ, Sinclair PR, Sinclair JF, 
Alcedo JA, Wetterhahn KE. Heme regulates 
hepatic 5-aminolevulinate synthase mRNA 
expression by decreasing mRNA half-life and 
not by altering its rate of transcription. Arch 
Biochem Biophys. 1991; 289(2):387-392. 
 
Hassan MQ, Stohs SJ, Murray WJ. Inhibition of 
TCDD-induced lipid peroxidation, glutathione 
peroxidase activity and toxicity by BHA and 
glutathione. Bull Environ Contam Toxicol. 1985; 
34(6):787-796.  
 
Hassoun EA, Al-Ghafri M, Abushaban A. The role 
of antioxidant enzymes in TCDD-induced 
oxidative stress in various brain regions of rats 
after subchronic exposure. Free Radic Biol Med. 
2003; 35(9):1028-1036. 
 
Himes JA, Cornelius CE. Biliverdin and bilirubin 
excretion in the turkey. Cornell Vet. 1975; 
65(3):374-379. 
 
Huang TJ, Maines MD. Bromobenzene-mediated 
alteration in activity and electrophoretic pattern 
of biliverdin reductase variants in rat kidney. 
Mol Pharmacol. 1990; 37(1):25-29. 
 
Huang TJ, Trakshel GM, Maines MD. Detection of 
10 variants of biliverdin reductase in rat liver by 
two-dimensional gel electrophoresis. J Biol 
Chem. 1989a; 264(14):7844-7849. 
 
Huang TJ, Trakshel GM, Maines MD. Multiple 
forms of biliverdin reductase: modification of the 
pattern of expression in rat liver by 
bromobenzene. Arch Biochem Biophys. 1989b; 
270(2):513-520. 
 
References 
  
THL — Research 133 • 2014 111 
TCDD-Induced Accumulation 
of the Heme Degradation 
Product Biliverdin in Rat Liver 
 
Huang TJ, Trakshel GM, Maines MD. 
Microheterogeneity of biliverdin reductase in rat 
liver and spleen: selective suppression of enzyme 
variants in liver by bromobenzene. Arch 
Biochem Biophys. 1989c; 274(2):617-625. 
 
Huffman C, Chillag S, Paulman L, McMahon C. It's 
not easy bein' green. Am J Med. 2009; 
122(9):820-822. 
 
Huuskonen H, Unkila M, Pohjanvirta R, Tuomisto J. 
Developmental toxicity of 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) in the most 
TCDD-resistant and -susceptible rat strains. 
Toxicol Appl Pharmacol. 1994; 124(2):174-180. 
 
Hwang SW. Effect of 2,3,7,8-tetrachlorodibenzo-p-
dioxin on the biliary excretion of indocyanine 
green in rat. Environ Health Perspect. 1973; 
5:227-231. 
 
IARC. IARC Monographs on the evaluation of 
carcinogenic risks to humans. Polychlorinated 
dibenzo-para-dioxins and polychlorinated 
dibenzofurans, 1997; 69:1–666. 
 
Idriss NK, Blann AD, Lip GY. Hemoxygenase-1 in 
cardiovascular disease. J Am Coll Cardiol. 2008; 
52(12):971-978. 
 
Inamdar NM, Ahn YI, Alam J. The heme-responsive 
element of the mouse heme oxygenase-1 gene is 
an extended AP-1 binding site that resembles the 
recognition sequences for MAF and NF-E2 
transcription factors. Biochem Biophys Res 
Commun. 1996; 221(3):570-576. 
 
Jandal JM. Studies on biliverdin in Awassi sheep 
milk. Small Ruminant Research. 1995; 
18(3):273-275. 
 
Jansen PL, Bittar EE. Bilirubin metabolism. In: 
Bittar EE (ed). The Liver in Biology and 
Disease. Principles of Medical Biology, Elsevier 
Ltd., 2004; 15:257-289. 
 
Jansen T, Daiber A. Direct antioxidant properties of 
bilirubin and biliverdin. Is there a role for 
biliverdin reductase? Front Pharmacol. 2012; 
3:30. 
 
Kamisako T, Kobayashi Y, Takeuchi K, Ishihara T, 
Higuchi K, Tanaka Y, Gabazza EC, Adachi Y. 
Recent advances in bilirubin metabolism 
research: the molecular mechanism of hepatocyte 
bilirubin transport and its clinical relevance. J 
Gastroenterol. 2000; 35(9):659-664. 
 
Kapitulnik J. Bilirubin: an endogenous product of 
heme degradation with both cytotoxic and 
cytoprotective properties. Mol Pharmacol. 2004; 
66(4):773-779. 
 
Kapitulnik J, Gonzalez FJ. Marked endogenous 
activation of the CYP1A1 and CYP1A2 genes in 
the congenitally jaundiced Gunn rat. Mol 
Pharmacol. 1993; 43(5):722-725. 
 
Kapitulnik J, Maines MD. Pleiotropic functions of 
biliverdin reductase: cellular signaling and 
generation of cytoprotective and cytotoxic 
bilirubin. Trends Pharmacol Sci. 2009; 
30(3):129-137.   
 
Kattainen H, Tuukkanen J, Simanainen U, Tuomisto 
JT, Kovero O, Lukinmaa P-L, Alaluusua S, 
Tuomisto J, Viluksela M. In utero/lactational 
2,3,7,8-tetrachlorodibenzo-p-dioxin exposure 
impairs molar tooth development in rats. Toxicol 
Appl Pharmacol. 2001; 174(3):216-224.     
 
Kawano Y, Nishiumi S, Tanaka S, Nobutani K, Miki 
A, Yano Y, Seo Y, Kutsumi H, Ashida H, 
Azuma T, Yoshida M. Activation of the aryl 
hydrocarbon receptor induces hepatic steatosis 
References 
  
THL — Research 133 • 2014 112 
TCDD-Induced Accumulation 
of the Heme Degradation 
Product Biliverdin in Rat Liver 
 
via the upregulation of fatty acid transport. Arch 
Biochem Biophys. 2010; 504(2):221-227.  
 
Kelling CK, Christian BJ, Inhorn SL, Peterson RE. 
Hypophagia-induced weight loss in mice, rats, 
and guinea pigs treated with 2,3,7,8-
tetrachlorodibenzo-p-dioxin. Fundam Appl 
Toxicol. 1985; 5(4):700-712. 
 
Kikuchi A, Yamaya M, Suzuki S, Yasuda H, Kubo 
H, Nakayama K, Handa M, Sasaki T, Shibahara 
S, Sekizawa K, Sasaki H. Association of 
susceptibility to the development of lung 
adenocarcinoma with the heme oxygenase-1 
gene promoter polymorphism. Hum Genet. 2005; 
116(5):354-360. 
 
Kim HP, Wang X, Galbiati F, Ryter SW, Choi AM. 
Caveolae compartmentalization of heme 
oxygenase-1 in endothelial cells. FASEB J. 
2004; 18(10):1080-1089. 
 
Kiviranta H, Ovaskainen M-L, Vartiainen T. Market 
basket study on dietary intake of PCDD/Fs, 
PCBs, and PBDEs in Finland. Environ Int. 2004; 
30(7):923-932. 
 
Knerr S, Schrenk D. Carcinogenicity of 2,3,7,8-
tetrachlorodibenzo-p-dioxin in experimental 
models. Mol Nutr Food Res. 2006; 50(10):897-
907.  
 
Kociba RJ, Keeler PA, Park CN, Gehring PJ. 2,3,7,8-
Tetrachlorodibenzo-p-dioxin (TCDD): results of 
a 13-week oral toxicity study in rats. Toxicol 
Appl Pharmacol. 1976; 35(3):553-574. 
 
Kociba RJ, Keyes DG, Beyer JE, Carreon RM, Wade 
CE, Dittenber DA, Kalnins RP, Frauson LE, 
Park CN, Barnard SD, Hummel RA, Humiston 
CG. Results of a two-year chronic toxicity and 
oncogenicity study of 2,3,7,8-
tetrachlorodibenzo-p-dioxin in rats. Toxicol Appl 
Pharmacol. 1978; 46(2):279-303.  
 
Korenaga T, Fukusato T, Ohta M, Asaoka K, Murata 
N, Arima A, Kubota S. Long-term effects of 
subcutaneously injected 2,3,7,8-
tetrachlorodibenzo-p-dioxin on the liver of 
rhesus monkeys. Chemosphere. 2007; 
67(9):S399-404. 
 
Korkalainen M, Lindén J, Tuomisto J, Pohjanvirta R. 
Effect of TCDD on mRNA expression of genes 
encoding bHLH/PAS proteins in rat 
hypothalamus. Toxicology. 2005; 208(1):1-11. 
 
Korkalainen M, Tuomisto J, Pohjanvirta R. 
Identification of novel splice variants of ARNT 
and ARNT2 in the rat. Biochem Biophys Res 
Commun. 2003; 303(4):1095-1100. 
 
Korkalainen M, Tuomisto J, Pohjanvirta R. Primary 
structure and inducibility by 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) of aryl 
hydrocarbon receptor repressor in a TCDD-
sensitive and a TCDD-resistant rat strain. 
Biochem Biophys Res Commun. 2004; 
315(1):123-131. 
 
Krasner J, Juchau MR, Niswander KR, Yaffe SJ. 
Theoretical considerations regarding the 
presence of biliverdin in amniotic fluid. Am J 
Obstet Gynecol. 1971; 109(1):159-165. 
 
Krasner J, Spencer RA, Yaffe SJ. Isolation of 
biliverdin from amniotic fluid. Clin Chim Acta. 
1969; 23(3):437-439. 
 
Kravets A, Hu Z, Miralem T, Torno MD, Maines 
MD. Biliverdin reductase, a novel regulator for 
induction of activating transcription factor-2 and 
heme oxygenase-1. J Biol Chem. 2004; 
279(19):19916-19923. 
 
References 
  
THL — Research 133 • 2014 113 
TCDD-Induced Accumulation 
of the Heme Degradation 
Product Biliverdin in Rat Liver 
 
Kreuzer PE, Csanády GA, Baur C, Kessler W, Päpke 
O, Greim H, Filser JG. 2,3,7,8-
Tetrachlorodibenzo-p-dioxin (TCDD) and 
congeners in infants. A toxicokinetic model of 
human lifetime body burden by TCDD with 
special emphasis on its uptake by nutrition. Arch 
Toxicol. 1997; 71(6):383-400. 
 
Krysiak-Baltyn K, Toppari J, Skakkebaek NE, 
Jensen TS, Virtanen HE, Schramm KW, Shen H, 
Vartiainen T, Kiviranta H, Taboureau O, Brunak 
S, Main KM. Country-specific chemical 
signatures of persistent environmental 
compounds in breast milk. Int J Androl. 2010; 
33(2):270-278. 
 
Kumar MA, Dastur NN, Ganguli NC. Biliverdin 
reductase-like activity in buffalo mammary 
tissues. Experientia. 1983; 39(9):1010-1011. 
 
Kutty RK, Maines MD. Purification and 
characterization of biliverdin reductase from rat 
liver. J Biol Chem. 1981; 256(8):3956-3962. 
 
Kutty RK, Maines MD. Biliverdin reductase: 
characterization in the rat kidney and the 
inhibition of activity by mercuric chloride. 
Biochem Pharmacol. 1983; 32(13):2095-2102. 
 
Köhle C, Bock KW. Activation of coupled Ah 
receptor and Nrf2 gene batteries by dietary 
phytochemicals in relation to chemoprevention. 
Biochem Pharmacol. 2006; 72(7):795-805.  
 
Lafarge-Frayssinet C, Morel-Chany E, Trincal G, 
Frayssinet C. Promoting effect of biliverdin for 
liver cells initiated by aflatoxin B1. Cancer Lett. 
1983; 18(3):277-282. 
 
Larson EA, Evans GT, Watson CJ. A study of the 
serum biliverdin concentration in various types 
of jaundice. J Lab Clin Med. 1947; 32(5):481-
488. 
 
Lascano Alcoser VH, Velthuis AG, Hoogenboom 
LA, van der Fels-Klerx HJ. Financial impact of a 
dioxin incident in the Dutch dairy chain. J Food 
Prot. 2011; 74(6):967-979.  
 
Latchoumycandane C, Chitra KC, Mathur PP. 
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) 
induces oxidative stress in the epididymis and 
epididymal sperm of adult rats. Arch Toxicol. 
2003; 77(5):280-284.  
 
Lee DH, Lee IK, Song K, Steffes M, Toscano W, 
Baker BA, Jacobs DR Jr. A strong dose-response 
relation between serum concentrations of 
persistent organic pollutants and diabetes: results 
from the National Health and Examination 
Survey 1999-2002. Diabetes Care. 2006; 
29(7):1638-1644. 
 
Lee JH, Wada T, Febbraio M, He J, Matsubara T, 
Lee MJ, Gonzalez FJ, Xie W. A novel role for 
the dioxin receptor in fatty acid metabolism and 
hepatic steatosis. Gastroenterology. 2010; 
139(2):653-663. 
  
Lehmann E, El-Tantawy WH, Ocker M, 
Bartenschlager R, Lohmann V, 
Hashemolhosseini S, Tiegs G, Sass G. The heme 
oxygenase 1 product biliverdin interferes with 
hepatitis C virus replication by increasing 
antiviral interferon response. Hepatology. 2010; 
51(2):398-404.  
 
Lengyel G, Veres Z, Szabó P, Vereczkey L, Jemnitz 
K. Canalicular and sinusoidal disposition of 
bilirubin mono- and diglucuronides in sandwich-
cultured human and rat primary hepatocytes. 
Drug Metab Dispos. 2005; 33(9):1355-1360.  
 
Lensu S, Tuomisto JT, Tuomisto J, Viluksela M, 
Niittynen M, Pohjanvirta R. Immediate and 
highly sensitive aversion response to a novel 
References 
  
THL — Research 133 • 2014 114 
TCDD-Induced Accumulation 
of the Heme Degradation 
Product Biliverdin in Rat Liver 
 
food item linked to AH receptor stimulation. 
Toxicol Lett. 2011; 203(3):252-257.  
 
Lerner-Marmarosh N, Shen J, Torno MD, Kravets A, 
Hu Z, Maines MD. Human biliverdin reductase: 
a member of the insulin receptor substrate family 
with serine/threonine/tyrosine kinase activity. 
Proc Natl Acad Sci U S A. 2005; 102(20):7109-
7114.  
 
Liem AK, Fürst P, Rappe C. Exposure of populations 
to dioxins and related compounds. Food Addit 
Contam. 2000; 17(4):241-259. 
 
Lin GL, Himes JA, Cornelius CE. Bilirubin and 
biliverdin excretion by the chicken. Am J 
Physiol. 1974; 226(4):881-885. 
 
Lindén J, Lensu S, Tuomisto J, Pohjanvirta R. 
Dioxins, the aryl hydrocarbon receptor and the 
central regulation of energy balance. Front 
Neuroendocrinol. 2010; 31(4):452-478.  
 
Lindros KO, Oinonen T, Johansson I, Ingelman-
Sundberg M. Selective centrilobular expression 
of the aryl hydrocarbon receptor in rat liver. J 
Pharmacol Exp Ther. 1997; 280(1):506-511. 
 
Liu PC, Matsumura F. Differential effects of 2,3,7,8-
tetrachlorodibenzo-p-dioxin on the "adipose-
type" and "brain-type" glucose transporters in 
mice. Mol Pharmacol. 1995; 47(1):65-73. 
 
Liu PC, Matsumura F. TCDD suppresses insulin-
responsive glucose transporter (GLUT-4) gene 
expression through C/EBP nuclear transcription 
factors in 3T3-L1 adipocytes. J Biochem Mol 
Toxicol. 2006; 20(2):79-87. 
 
Loonen H, van de Guchte C, Parsons JR, de Voogt P, 
Govers HA. Ecological hazard assessment of 
dioxins: hazards to organisms at different levels 
of aquatic food webs (fish-eating birds and 
mammals, fish and invertebrates). Sci Total 
Environ. 1996; 182(1-3):93-103. 
 
Ma Q. Overview of AHR functional domains and the 
classical AHR signaling pathway: induction of 
drug metabolizing enzymes. In: Pohjanvirta R 
(ed.) The AH receptor in biology and toxicology. 
John Wiley & Sons, Inc. Hoboken, New Jersey, 
2012; 35-45. 
 
Mably TA, Bjerke DL, Moore RW, Gendron-
Fitzpatrick A, Peterson RE. In utero and 
lactational exposure of male rats to 2,3,7,8-
tetrachlorodibenzo-p-dioxin. 3. Effects on 
spermatogenesis and reproductive capability. 
Toxicol Appl Pharmacol. 1992a; 114(1):118-
126. 
 
Mably TA, Moore RW, Goy RW, Peterson RE. In 
utero and lactational exposure of male rats to 
2,3,7,8-tetrachlorodibenzo-p-dioxin. 2. Effects 
on sexual behavior and the regulation of 
luteinizing hormone secretion in adulthood. 
Toxicol Appl Pharmacol. 1992b; 114(1):108-
117. 
 
Mably TA, Moore RW, Peterson RE. In utero and 
lactational exposure of male rats to 2,3,7,8-
tetrachlorodibenzo-p-dioxin. 1. Effects on 
androgenic status. Toxicol Appl Pharmacol. 
1992c; 114(1):97-107. 
 
Maghzal GJ, Leck MC, Collinson E, Li C, Stocker 
R. Limited role for the bilirubin-biliverdin redox 
amplification cycle in the cellular antioxidant 
protection by biliverdin reductase. J Biol Chem. 
2009; 284(43):29251-29259.  
 
Maines MD. New insights into biliverdin reductase 
functions: linking heme metabolism to cell 
signaling. Physiology. 2005; 20(6):382-389. 
 
References 
  
THL — Research 133 • 2014 115 
TCDD-Induced Accumulation 
of the Heme Degradation 
Product Biliverdin in Rat Liver 
 
Maines MD, Ewing JF, Huang TJ, Panahian N. 
Nuclear localization of biliverdin reductase in 
the rat kidney: response to nephrotoxins that 
induce heme oxygenase-1. J Pharmacol Exp 
Ther. 2001; 296(3):1091-1097. 
 
Maines MD, Mayer RD, Erturk E, Huang TJ, 
Disantagnese A. The oxidoreductase, biliverdin 
reductase, is induced in human renal carcinoma 
− pH and cofactor-specific increase in activity. J 
Urol. 1999; 162(4):1467-1472. 
 
Mann PC. Selected lesions of dioxin in laboratory 
rodents. Toxicol Pathol. 1997; 25(1):72-79. 
 
Matsui I, Otani S, Morisawa S. Induction of 
ornithine decarboxylase by biliverdin in rat liver. 
Life Sci. 1979; 24(24):2231-2236.  
 
Matsumura F. Nongenomic route of action of 
TCDD: identity, characteristics, and 
toxicological significance. In: Pohjanvirta R (ed.) 
The AH receptor in biology and toxicology. John 
Wiley & Sons, Inc. Hoboken, New Jersey, 2012; 
197-215.  
 
Mayani A, Barel S, Soback S, Almagor M. Dioxin 
concentrations in women with endometriosis. 
Hum Reprod. 1997; 12(2):373-375. 
 
McCoubrey WK, Cooklis MA, Maines MD. The 
structure, organization and differential 
expression of the rat gene encoding biliverdin 
reductase. Gene. 1995; 160(2):235-240. 
 
McDonagh AF. Turning green to gold. Nat Struct 
Biol. 2001; 8(3):198-200. 
 
McDonagh AF. Controversies in bilirubin 
biochemistry and their clinical relevance. Semin 
Fetal Neonatal Med. 2010a; 15(3):141-147.  
 
McDonagh AF. Green jaundice revisited. Am J Med. 
2010b; 123(9):e23. 
 
McDonagh AF. The biliverdin-bilirubin antioxidant 
cycle of cellular protection: Missing a wheel? 
Free Radic Biol Med. 2010c; 49(5):814-820. 
  
McDonagh AF, Palma LA, Schmid R. Reduction of 
biliverdin and placental transfer of bilirubin and 
biliverdin in the pregnant guinea pig. Biochem J. 
1981; 194(1):273-282. 
 
Miettinen H. The effects of TCDD on the 
development of teeth and cortical bone in rats: 
implications for risk assessment. Publications of 
the National Public Health Institute, A10/2006.  
 
Miettinen HM, Alaluusua S, Tuomisto J, Viluksela 
M. Effect of in utero and lactational 2,3,7,8-
tetrachlorodibenzo-p-dioxin exposure on rat 
molar development: the role of exposure time. 
Toxicol Appl Pharmacol. 2002; 184(1):57-66. 
 
Milbrath MO, Wenger Y, Chang CW, Emond C, 
Garabrant D, Gillespie BW, Jolliet O. Apparent 
half-lives of dioxins, furans, and polychlorinated 
biphenyls as a function of age, body fat, smoking 
status, and breast-feeding. Environ Health 
Perspect. 2009; 117(3):417-425.  
 
Miralem T, Hu Z, Torno MD, Lelli KM, Maines 
MD. Small interference RNA-mediated gene 
silencing of human biliverdin reductase, but not 
that of heme oxygenase-1, attenuates arsenite-
mediated induction of the oxygenase and 
increases apoptosis in 293A kidney cells. J Biol 
Chem. 2005; 280(17):17084-17092.  
 
Mocarelli P, Gerthoux PM, Ferrari E, Patterson DG, 
Kieszak SM, Brambilla P, Vincoli N, Signorini 
S, Tramacere P, Carreri V, Sampson EJ, Turner 
WE, Needham LL. Paternal concentrations of 
References 
  
THL — Research 133 • 2014 116 
TCDD-Induced Accumulation 
of the Heme Degradation 
Product Biliverdin in Rat Liver 
 
dioxin and sex ratio of offspring. Lancet. 2000; 
355(9218):1858-1863. 
 
 Mocarelli P, Gerthoux PM, Needham LL, Patterson 
DG, Limonta G, Falbo R, Signorini S, Bertona 
M, Crespi C, Sarto C, Scott PK, Turner WE, 
Brambilla P. Perinatal exposure to low doses of 
dioxin can permanently impair human semen 
quality. Environ Health Perspect. 2011; 
119(5):713-718.  
 
Mocarelli P, Gerthoux PM, Patterson DG, Milani S, 
Limonta G, Bertona M, Signorini S, Tramacere 
P, Colombo L, Crespi C, Brambilla P, Sarto C, 
Carreri V, Sampson EJ, Turner WE, Needham 
LL. Dioxin exposure, from infancy through 
puberty, produces endocrine disruption and 
affects human semen quality. Environ Health 
Perspect. 2008; 116(1):70-77. 
 
Mohammadpour H, Murray WJ, Stohs SJ. 2,3,7,8-
Tetrachlorodibenzo-p-dioxin (TCDD)-induced 
lipid peroxidation in genetically responsive and 
non-responsive mice. Arch Environ Contam 
Toxicol. 1988; 17(5):645-650.  
 
Montorzi M, Dziedzic TS, Falchuk KH. Biliverdin 
during Xenopus laevis oogenesis and early 
embryogenesis. Biochemistry. 2002; 
41(31):10115-10122. 
 
Mori H, Otake T, Morimoto M, Ueba N, Kunita N, 
Nakagami T, Yamasaki N, Taji S. In vitro anti-
human immunodeficiency virus type 1 activity of 
biliverdin, a bile pigment. Jpn J Cancer Res. 
1991; 82(7):755-757. 
 
Mueller C, Zhou W, VanMeter A, Heiby M, Magaki 
S, Ross MM, Espina V, Schrag M, Dickson C, 
Liotta LA, Kirsch WM. The heme degradation 
pathway is a promising serum biomarker source 
for the early detection of Alzheimer's disease. J 
Alzheimer’s Dis. 2010; 19(3):1081-1091.  
 
Muñoz ME, González J, Esteller A. Bile pigment 
formation and excretion in the rabbit. Comp 
Biochem Physiol A Comp Physiol. 1986; 
85(1):67-71. 
 
Murphy BJ, Laderoute KR, Short SM, Sutherland 
RM. The identification of heme oxygenase as a 
major hypoxic stress protein in Chinese hamster 
ovary cells. Br J Cancer. 1991; 64(1):69-73. 
 
Muzi G, Gorski JR, Rozman K. Mode of metabolism 
is altered in 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD)-treated rats. Toxicol Lett. 1989; 
47(1):77-86. 
 
Nakagami T, Taji S, Takahashi M, Yamanishi K. 
Antiviral activity of a bile pigment, biliverdin, 
against human herpesvirus 6 (HHV-6) in vitro. 
Microbiol Immunol. 1992; 36(4):381-390. 
 
Nebert DW, Roe AL, Dieter MZ, Solis WA, Yang Y, 
Dalton TP. Role of the aromatic hydrocarbon 
receptor and [Ah] gene battery in the oxidative 
stress response, cell cycle control, and apoptosis. 
Biochem Pharmacol. 2000; 59(1):65-85. 
 
Nguyen LP, Bradfield CA The search for 
endogenous activators of the aryl hydrocarbon 
receptor. Chem Res Toxicol. 2008; 21(1):102-
116.  
 
Niittynen M, Mantle T, Tuomisto JT, Tuomisto J, 
Pohjanvirta R. Cloning and sequencing of the 
biliverdin IXα reductase gene from a “black 
liver” syndrome rat. Abstracts of the Heme 
oxygenase: Regulation, Functions & Clinical 
Application, Uppsala, Sweden, Sep 28th-Oct 3rd, 
2003. 
 
References 
  
THL — Research 133 • 2014 117 
TCDD-Induced Accumulation 
of the Heme Degradation 
Product Biliverdin in Rat Liver 
 
Nishimura N, Miyabara Y, Suzuki JS, Sato M, Aoki 
Y, Satoh M, Yonemoto J, Tohyama C. Induction 
of metallothionein in the livers of female 
Sprague-Dawley rats treated with 2,3,7,8-
tetrachlorodibenzo-p-dioxin. Life Sci. 2001; 
69(11):1291-1303. 
 
Noir BA, Garay ER, Royer M. Separation and 
properties of conjugated biliverdin. Biochim 
Biophys Acta. 1965; 100:403-410. 
 
Novelli M, Piaggi S, De Tata V. 2,3,7,8-
Tetrachlorodibenzo-p-dioxin-induced 
impairment of glucose-stimulated insulin 
secretion in isolated rat pancreatic islets. Toxicol 
Lett. 2005; 156(2):307-314. 
 
Nuhn P, Künzli BM, Hennig R, Mitkus T, 
Ramanauskas T, Nobiling R, Meuer SC, Friess 
H, Berberat PO. Heme oxygenase-1 and its 
metabolites affect pancreatic tumor growth in 
vivo. Mol Cancer. 2009; 8:37.  
 
Nytofte NS, Serrano MA, Monte MJ, Gonzalez-
Sanchez E, Tumer Z, Ladefoged K, Briz O, 
Marin JJ. A homozygous nonsense mutation 
(c.214C→A) in the biliverdin reductase alpha 
gene (BLVRA) results in accumulation of 
biliverdin during episodes of cholestasis. J Med 
Genet. 2011; 48(4):219-225. 
 
Oakes GH, Bend JR. Early steps in bilirubin-
mediated apoptosis in murine hepatoma (Hepa 
1c1c7) cells are characterized by aryl 
hydrocarbon receptor-independent oxidative 
stress and activation of the mitochondrial 
pathway. J Biochem Mol Toxicol. 2005; 
19(4):244-255. 
 
Okazaki K, Nishimura H, Arizono H, Nishimura N, 
Suzuki Y. Biliverdin initiates the liver 
regeneration in the rat − a hypothesis. Biochem 
Biophys Res Commun. 1978; 81(2):512-520.  
 
Olsen H, Enan E, Matsumura F. Regulation of 
glucose transport in the NIH 3T3 L1 
preadipocyte cell line by TCDD. Environ Health 
Perspect. 1994; 102(5):454-458. 
 
Papiez MA, Dybala M, Sowa-Kucma M, Krzysciak 
W, Taha H, Jozkowicz A, Nowak G. Evaluation 
of oxidative status and depression-like responses 
in Brown Norway rats with acute myeloid 
leukemia. Prog Neuropsychopharmacol Biol 
Psychiatry. 2009; 33(4):596-604.  
 
Pelclová D, Urban P, Preiss J, Lukás E, Fenclová Z, 
Navrátil T, Dubská Z, Senholdová Z. Adverse 
health effects in humans exposed to 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD). Rev 
Environ Health. 2006; 21(2):119-138. 
 
Pereira PJ, Macedo-Ribeiro S, Párraga A, Pérez-
Luque R, Cunningham O, Darcy K, Mantle TJ, 
Coll M. Structure of human biliverdin IXβ 
reductase, an early fetal bilirubin IXβ producing 
enzyme. Nat Struct Biol. 2001; 8(3):215-220. 
 
Perkocha LA, Geaghan SM, Yen TS, Nishimura SL, 
Chan SP, Garcia-Kennedy R, Honda G, Stoloff 
AC, Klein HZ, Goldman RL, Van Meter S, 
Ferrell LD, LeBoit PE. Clinical and pathological 
features of bacillary peliosis hepatis in 
association with human immunodeficiency virus 
infection. N Engl J Med. 1990; 323(23):1581-
1586. 
 
Pesatori AC, Consonni D, Bachetti S, Zocchetti C, 
Bonzini M, Baccarelli A, Bertazzi PA. Short- 
and long-term morbidity and mortality in the 
population exposed to dioxin after the "Seveso 
accident". Ind Health. 2003; 41(3):127-138. 
 
Pesatori AC, Consonni D, Rubagotti M, Grillo P, 
Bertazzi PA. Cancer incidence in the population 
exposed to dioxin after the "Seveso accident": 
References 
  
THL — Research 133 • 2014 118 
TCDD-Induced Accumulation 
of the Heme Degradation 
Product Biliverdin in Rat Liver 
 
twenty years of follow-up. Environ Health. 2009; 
8:39. 
 
Phelan D, Winter GM, Rogers WJ, Lam JC, Denison 
MS. Activation of the Ah receptor signal 
transduction pathway by bilirubin and biliverdin. 
Arch Biochem Biophys. 1998; 357(1):155-163. 
 
 Pohjanvirta R (ed.) The AH receptor in biology and
toxicology. John Wiley & Sons, Inc. Hoboken, 
New Jersey, 2012. 
 
Pohjanvirta R. TCDD resistance is inherited as an 
autosomal dominant trait in the rat. Toxicol Lett. 
1990; 50(1):49-56. 
 
Pohjanvirta R, Korkalainen M, McGuire J, 
Simanainen U, Juvonen R, Tuomisto JT, Unkila 
M, Viluksela M, Bergman J, Poellinger L, 
Tuomisto J. Comparison of acute toxicities of 
indolo[3,2-b]carbazole (ICZ) and 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) in TCDD-
sensitive rats. Food Chem Toxicol. 2002; 
40(7):1023-1032. 
 
Pohjanvirta R, Korkalainen M, Moffat ID, Boutros 
PC, Okey AB. Role of the AHR and its structure 
in TCDD toxicity. In: Pohjanvirta R (ed.) The 
AH receptor in biology and toxicology. John 
Wiley & Sons, Inc. Hoboken, New Jersey, 2012; 
181-196. 
 
Pohjanvirta R, Kulju T, Morselt AF, Tuominen R, 
Juvonen R, Rozman K, Männistö P, Collan Y, 
Sainio E-L, Tuomisto J. Target tissue 
morphology and serum biochemistry following 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) 
exposure in a TCDD-susceptible and a TCDD-
resistant rat strain. Fundam Appl Toxicol. 1989; 
12(4):698-712. 
 
Pohjanvirta R, Sankari S, Kulju T, Naukkarinen A, 
Ylinen M, Tuomisto J. Studies on the role of 
lipid peroxidation in the acute toxicity of TCDD 
in rats. Pharmacol Toxicol. 1990; 66(5):399-408. 
 
Pohjanvirta R, Tuomisto J. Short-term toxicity of 
2,3,7,8-tetrachlorodibenzo-p-dioxin in laboratory 
animals: effects, mechanisms, and animal 
models. Pharmacol Rev. 1994; 46(4):483-549. 
 
Pohjanvirta R, Unkila M, Lindén J, Tuomisto JT, 
Tuomisto J. Toxic equivalency factors do not 
predict the acute toxicities of dioxins in rats. Eur 
J Pharmacol. 1995; 293(4):341-353. 
 
Pohjanvirta R, Unkila M, Tuomisto J. Comparative 
acute lethality of 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD), 1,2,3,7,8-pentachlorodibenzo-p-
dioxin and 1,2,3,4,7,8-hexachlorodibenzo-p-
dioxin in the most TCDD-susceptible and the 
most TCDD-resistant rat strain. Pharmacol 
Toxicol. 1993; 73(1):52-56. 
 
Pohjanvirta R, Viluksela M, Tuomisto JT, Unkila M, 
Karasinska J, Franc M-A, Holowenko M, 
Giannone JV, Harper PA, Tuomisto J, Okey AB. 
Physicochemical differences in the AH receptors 
of the most TCDD-susceptible and the most 
TCDD-resistant rat strains. Toxicol Appl 
Pharmacol. 1999; 155(1):82-95. 
 
Pohjanvirta R, Wong JM, Li W, Harper PA, 
Tuomisto J, Okey AB. Point mutation in intron 
sequence causes altered carboxyl-terminal 
structure in the aryl hydrocarbon receptor of the 
most 2,3,7,8-tetrachlorodibenzo-p-dioxin-
resistant rat strain. Mol Pharmacol. 1998; 54(1): 
86-93. 
 
Poland A, Glover E. 2,3,7,8-Tetrachlorodibenzo-p-
dioxin: a potent inducer of δ-aminolevulinic acid 
synthetase. Science. 1973; 179(4072):476-477. 
 
Poland A, Knutson JC. 2,3,7,8-Tetrachlorodibenzo-
p-dioxin and related halogenated aromatic 
References 
  
THL — Research 133 • 2014 119 
TCDD-Induced Accumulation 
of the Heme Degradation 
Product Biliverdin in Rat Liver 
 
hydrocarbons: examination of the mechanism of 
toxicity. Annu Rev Pharmacol Toxicol. 1982; 
22:517-554.  
 
Ponka P. Tissue-specific regulation of iron 
metabolism and heme synthesis: distinct control 
mechanisms in erythroid cells. Blood. 1997; 
89(1):1-25. 
 
Ponka P. Overview of cellular iron metabolism: the 
crucial role of heme oxygenase in recycling 
heme iron. Abstracts of the Heme oxygenase: 
Regulation, Functions & Clinical Application, 
Uppsala, Sweden, Sep 28th- Oct 3rd, 2003. 
 
Poss KD, Tonegawa S. Reduced stress defense in 
heme oxygenase 1-deficient cells. Proc Natl 
Acad Sci U S A. 1997; 94(20):10925-10930. 
 
Prichard JS. Biliverdin appearing in a case of 
malnutrition. Br J Clin Pract. 1972; 26(10):481-
482. 
 
Puga A, Ma C, Marlowe JL. The aryl hydrocarbon 
receptor cross-talks with multiple signal 
transduction pathways. Biochem Pharmacol. 
2009; 77(4):713-722. 
 
Puga A, Maier A, Medvedovic M. The 
transcriptional signature of dioxin in human 
hepatoma HepG2 cells. Biochem Pharmacol. 
2000; 60(8):1129-1142. 
 
Päpke O. PCDD/PCDF: human background data for 
Germany, a 10-year experience. Environ Health 
Perspect. 1998; 106 (Suppl 2):723-731.  
 
Radhakrishnan N, Yadav SP, Sachdeva A, Pruthi 
PK, Sawhney S, Piplani T, Wada T, Yachie A. 
Human heme oxygenase-1 deficiency presenting 
with hemolysis, nephritis, and asplenia. J Pediatr 
Hematol Oncol. 2011; 33(1):74-78.  
 
Reichard JF, Dalton TP, Shertzer HG, Puga A. 
Induction of oxidative stress responses by dioxin 
and other ligands of the aryl hydrocarbon 
receptor. Dose Response. 2005; 3(3):306-331.  
 
Remillard RB, Bunce NJ. Linking dioxins to 
diabetes: epidemiology and biologic plausibility. 
Environ Health Perspect. 2002; 110(9):853-858.  
 
Rennert A, Wittsiepe J, Kasper-Sonnenberg M, 
Binder G, Fürst P, Cramer C, Krämer U, 
Wilhelm M. Prenatal and early life exposure to 
polychlorinated dibenzo-p-dioxins, dibenzo-
furans and biphenyls may influence 
dehydroepiandrosterone sulfate levels at 
prepubertal age: results from the Duisburg birth 
cohort study. J Toxicol Environ Health A. 2012; 
75(19-20):1232-1240. 
 
Rigney E, Mantle TJ. The reaction mechanism of 
bovine kidney biliverdin reductase. Biochim 
Biophys Acta. 1988; 957(2):237-242. 
 
Rigney E, Mantle TJ, Dickinson FM. The kinetics of 
ox kidney biliverdin reductase in the pre-steady 
state. Evidence that the dissociation of bilirubin 
is the rate-determining step. Biochem J. 1989; 
259(3):709-713. 
 
Rizzardini M, Carelli M, Cabello Porras MR, 
Cantoni L. Mechanisms of endotoxin-induced 
haem oxygenase mRNA accumulation in mouse 
liver: synergism by glutathione depletion and 
protection by N-acetylcysteine. Biochem J. 1994; 
304(Pt 2):477-483. 
 
Rose JQ, Ramsey JC, Wentzler TH, Hummel RA, 
Gehring PJ. The fate of 2,3,7,8-
tetrachlorodibenzo-p-dioxin following single and 
repeated oral doses to the rat. Toxicol Appl 
Pharmacol. 1976; 36(2):209-226. 
 
References 
  
THL — Research 133 • 2014 120 
TCDD-Induced Accumulation 
of the Heme Degradation 
Product Biliverdin in Rat Liver 
 
Ryter SW. Bile pigments in pulmonary and vascular 
disease. Front Pharmacol. 2012; 3:39. 
 
Safe SH. Comparative toxicology and mechanism of 
action of polychlorinated dibenzo-p-dioxins and 
dibenzofurans. Annu Rev Pharmacol Toxicol. 
1986; 26:371-399.  
 
Safe S. Limitations of the toxic equivalency factor 
approach for risk assessment of TCDD and 
related compounds. Teratog Carcinog Mutagen. 
1997-1998; 17(4-5):285-304. 
 
Salim M, Brown-Kipphut BA, Maines MD. Human 
biliverdin reductase is autophosphorylated, and 
phosphorylation is required for bilirubin 
formation. J Biol Chem. 2001; 276(14):10929-
10934. 
 
Sassa S. Why heme needs to be degraded to iron, 
biliverdin IXα, and carbon monoxide? Antioxid 
Redox Signal. 2004; 6(5):819-824. 
 
Sassa S, Granick S. Induction of δ-aminolevulinic 
acid synthetase in chick embryo liver cells in 
culture. Proc Natl Acad Sci U S A. 1970; 
67(2):517-522. 
 
Saurat J-H, Kaya G, Saxer-Sekulic N, Pardo B, 
Becker M, Fontao L, Mottu F, Carraux P, Pham 
X-C, Barde C, Fontao F, Zennegg M, Schmid P, 
Schaad O, Descombes P, Sorg O. The cutaneous 
lesions of dioxin exposure: lessons from the 
poisoning of Victor Yushchenko. Toxicol Sci. 
2012; 125(1):310-317.  
 
Savouret J-F, Antenos M, Quesne M, Xu J, Milgrom 
E, Casper RF. 7-ketocholesterol is an 
endogenous modulator for the arylhydrocarbon 
receptor. J Biol Chem. 2001; 276(5):3054-3059.  
 
Sedlak TW, Snyder SH. Cycling the wagons for 
biliverdin reductase. J Biol Chem. 2009; 
284(46):le11.  
 
Seidel SD, Winters GM, Rogers WJ, Ziccardi MH, 
Li V, Keser B, Denison MS. Activation of the 
Ah receptor signaling pathway by 
prostaglandins. J Biochem Mol Toxicol. 2001; 
15(4):187-196.  
 
Senft AP, Dalton TP, Nebert DW, Genter MB, 
Hutchinson RJ, Shertzer HG. Dioxin increases 
reactive oxygen production in mouse liver 
mitochondria. Toxicol Appl Pharmacol. 2002; 
178(1):15-21. 
 
Shertzer HG, Nebert DW, Puga A, Ary M, Sonntag 
D, Dixon K, Robinson LJ, Cianciolo E, Dalton 
TP. Dioxin causes a sustained oxidative stress 
response in the mouse. Biochem Biophys Res 
Commun. 1998; 253(1):44-48. 
 
Shibahara S. The heme oxygenase dilemma in 
cellular homeostasis: new insights for the 
feedback regulation of heme catabolism. Tohoku 
J Exp Med. 2003; 200(4):167-186. 
 
Shibahara S, Kitamuro T, Takahashi K. Heme 
degradation and human disease: diversity is the 
soul of life. Antioxid Redox Signal. 2002; 
4(4):593-602. 
 
Shibahara S, Nakayama M, Kitamuro T, Udono-
Fujimori R, Takahashi K. Repression of heme 
oxygenase-1 expression as a defense strategy in 
humans. Exp Biol Med. 2003; 228(5):472-473. 
 
Shishido N, Nakayama K, Nakamura M. Porphyrin-
induced photooxidation of conjugated bilirubin. 
Free Radic Res. 2003; 37(10):1061-1067. 
 
Simanainen U. Dioxin resistance alleles and 
developmental stage at exposure as determinants 
References 
  
THL — Research 133 • 2014 121 
TCDD-Induced Accumulation 
of the Heme Degradation 
Product Biliverdin in Rat Liver 
 
of sensitivity to dioxin-induced short-term 
toxicity and male reproductive effects. 
Publications of the National Public Health 
Institute, A8/2004.  
 
Simanainen U, Tuomisto JT, Pohjanvirta R, Syrjälä 
P, Tuomisto J, Viluksela M. Postnatal 
development of resistance to short-term high-
dose toxic effects of 2,3,7,8-tetrachlorodibenzo-
p-dioxin in TCDD-resistant and -semiresistant 
rats. Toxicol Appl Pharmacol. 2004; 196(1):11-
19. 
 
Simanainen U, Tuomisto JT, Tuomisto J, Viluksela 
M. Structure-activity relationships and dose 
responses of polychlorinated dibenzo-p-dioxins 
for short-term effects in 2,3,7,8-
tetrachlorodibenzo-p-dioxin-resistant and -
sensitive rat strains. Toxicol Appl Pharmacol. 
2002; 181(1):38-47. 
 
Simanainen U, Tuomisto JT, Tuomisto J, Viluksela 
M. Dose-response analysis of short-term effects 
of 2,3,7,8-tetrachlorodibenzo-p-dioxin in three 
differentially susceptible rat lines. Toxicol Appl 
Pharmacol. 2003; 187(2):128-136. 
 
Sinal CJ, Bend JR. Aryl hydrocarbon receptor-
dependent induction of Cyp1a1 by bilirubin in 
mouse hepatoma Hepa 1c1c7 cells. Mol 
Pharmacol. 1997; 52(4):590-599. 
 
Singleton JW, Laster L. Biliverdin reductase of 
guinea pig liver. J Biol Chem. 1965; 
240(12):4780-4789. 
 
Siow RC, Ishii T, Sato H, Taketani S, Leake DS, 
Sweiry JH, Pearson JD, Bannai S, Mann GE. 
Induction of the antioxidant stress proteins heme 
oxygenase-1 and MSP23 by stress agents and 
oxidised LDL in cultured vascular smooth 
muscle cells. FEBS Lett. 1995; 368(2):239-242. 
 
Smith AG, Clothier B, Carthew P, Childs NL, 
Sinclair PR, Nebert DW, Dalton TP. Protection 
of the Cyp1a2(-/-) null mouse against 
uroporphyria and hepatic injury following 
exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. 
Toxicol Appl Pharmacol. 2001; 173(2):89-98. 
 
Smith AG, Elder GH. Complex gene-chemical 
interactions: hepatic uroporphyria as a paradigm. 
Chem Res Toxicol. 2010; 23(4):712-723.  
 
Steenland K, Bertazzi P, Baccarelli A, Kogevinas M. 
Dioxin revisited: developments since the 1997 
IARC classification of dioxin as a human 
carcinogen. Environ Health Perspect. 2004; 
112(13):1265-1268. 
 
Stocker R. Antioxidant activities of bile pigments. 
Antioxid Redox Signal. 2004; 6(5):841-849. 
 
Stocker R, Maghzal G. Reply to Sedlak and Snyder: 
The little bighorn of the biliverdin reductase 
amplification cycle. J Biol Chem. 2009; 
284(46):le12. 
 
Stocker R, Yamamoto Y, McDonagh AF, Glazer 
AN, Ames BN. Bilirubin is an antioxidant of 
possible physiological importance. Science. 
1987; 235(4792):1043-1046. 
 
Stohs SJ. Oxidative stress induced by 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD). Free Radic 
Biol Med. 1990; 9(1):79-90.  
 
Stohs SJ, Shara MA, Alsharif NZ, Wahba ZZ, Al-
Bayati ZA. 2,3,7,8-Tetrachlorodibenzo-p-dioxin-
induced oxidative stress in female rats. Toxicol 
Appl Pharmacol. 1990; 106(1):126-135. 
 
Sullivan BP, Wang R, Tawfik O, Luyendyk JP. 
Protective and damaging effects of platelets in 
acute cholestatic liver injury revealed by 
References 
  
THL — Research 133 • 2014 122 
TCDD-Induced Accumulation 
of the Heme Degradation 
Product Biliverdin in Rat Liver 
 
depletion and inhibition strategies. Toxicol Sci. 
2010; 115(1):286-294.  
 
Swanson H. Dioxin response elements and regulation 
of gene transcription. In: Pohjanvirta R (ed.) The 
AH receptor in biology and toxicology. John 
Wiley & Sons, Inc. Hoboken, New Jersey, 2012; 
81-91. 
 
Sweeney MH, Mocarelli P. Human health effects 
after exposure to 2,3,7,8-TCDD. Food Addit 
Contam. 2000; 17(4):303-316.  
 
Takeda A, Onodera H, Sugimoto A, Itoyama Y, 
Kogure K, Shibahara S. Increased expression of 
heme oxygenase mRNA in rat brain following 
transient forebrain ischemia. Brain Res. 1994; 
666(1):120-124. 
 
Tenhunen R, Marver HS, Schmid R. The enzymatic 
conversion of heme to bilirubin by microsomal 
heme oxygenase. Proc Natl Acad Sci U S A. 
1968; 61(2):748-755. 
 
Thigpen JE, Faith RE, McConnell EE, Moore 
JA.Increased susceptibility to bacterial infection 
as a sequela of exposure to 2,3,7,8-
tetrachlorodibenzo-p-dioxin. Infect Immun. 
1975; 12(6):1319-1324. 
 
Tickner TR, Gutteridge JM. A simple colorimetric 
method for the estimation of plasma biliverdin. 
Clin Chim Acta. 1978; 85(2):125-129. 
 
Tofilon PJ, Piper WN. 2,3,7,8-Tetrachlorodibenzo-p-
dioxin-mediated depression of rat testicular heme 
synthesis and microsomal cytochrome P-450. 
Biochem Pharmacol. 1982; 31(22):3663-3666. 
 
Togawa H, Shinkai S, Mizutani T. Induction of 
human UGT1A1 by bilirubin through AhR 
dependent pathway. Drug Metab Lett. 2008; 
2(4):231-237. 
 
Tonack S, Kind K, Thompson JG, Wobus AM, 
Fischer B, Santos AN. Dioxin affects glucose 
transport via the arylhydrocarbon receptor signal 
cascade in pluripotent embryonic carcinoma 
cells. Endocrinology. 2007; 148(12):5902-5912.  
 
Tudor C, Lerner-Marmarosh N, Engelborghs Y, 
Gibbs PE, Maines MD. Biliverdin reductase is a 
transporter of haem into the nucleus and is 
essential for regulation of HO-1 gene expression 
by haematin. Biochem J. 2008; 413(3):405-416. 
 
Tuomisto JT, Pohjanvirta R, Unkila M, Tuomisto J. 
TCDD-induced anorexia and wasting syndrome 
in rats: effects of diet-induced obesity and 
nutrition. Pharmacol Biochem Behav. 1999a; 
62(4):735-742. 
 
Tuomisto J, Tuomisto JT. Is the fear of dioxin cancer 
more harmful than dioxin? Toxicol Lett. 2012; 
210(3):338-344. 
 
Tuomisto JT, Viluksela M, Pohjanvirta R, Tuomisto 
J. The AH receptor and a novel gene determine 
acute toxic responses to TCDD: segregation of 
the resistant alleles to different rat lines. Toxicol 
Appl Pharmacol. 1999b; 155(1):71-81. 
 
Tuomisto J, Vartiainen T, Tuomisto J. Synopsis on 
dioxins and PCBs. National Institute for Health 
and Welfare. Report No. 14/2011. 
 
Turunen AW, Verkasalo PK, Kiviranta H, Pukkala 
E, Jula A, Männistö S, Räsänen R, Marniemi J, 
Vartiainen T. Mortality in a cohort with high fish 
consumption. Int J Epidemiol. 2008; 37(5):1008-
1017. 
 
Tzirogiannis KN, Panoutsopoulos GI, Demonakou 
MD, Hereti RI, Alexandropoulou KN, 
Mykoniatis MG.  Effect of hepatic stimulator 
substance (HSS) on cadmium-induced acute 
References 
  
THL — Research 133 • 2014 123 
TCDD-Induced Accumulation 
of the Heme Degradation 
Product Biliverdin in Rat Liver 
 
hepatotoxicity in the rat liver. Dig Dis Sci. 2004; 
49(6):1019-1028. 
 
Unkila M, Pohjanvirta R, Honkakoski P, Törrönen R, 
Tuomisto J. 2,3,7,8-Tetrachlorodibenzo-p-dioxin 
(TCDD) induced ethoxyresorufin-O-deethylase 
(EROD) and aldehyde dehydrogenase (ALDH3) 
activities in the brain and liver. A comparison 
between the most TCDD-susceptible and the 
most TCDD-resistant rat strain. Biochem 
Pharmacol. 1993; 46(4):651-659. 
 
Unkila M, Pohjanvirta R, MacDonald E, Tuomisto 
JT, Tuomisto J. Dose response and time course 
of alterations in tryptophan metabolism by 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in 
the most TCDD-susceptible and the most 
TCDD-resistant rat strain: relationship with 
TCDD lethality. Toxicol Appl Pharmacol. 1994; 
128(2):280-292. 
 
Uno S, Dalton TP, Sinclair PR, Gorman N, Wang B, 
Smith AG, Miller ML, Shertzer HG, Nebert DW. 
Cyp1a1(-/-) male mice: protection against high-
dose TCDD-induced lethality and wasting 
syndrome, and resistance to intrahepatocyte lipid 
accumulation and uroporphyria. Toxicol Appl 
Pharmacol. 2004; 196(3):410-421. 
 
Urban P, Pelclová D, Lukás E, Kupka K, Preiss J, 
Fenclová Z, Smerhovský Z. Neurological and 
neurophysiological examinations on workers 
with chronic poisoning by 2,3,7,8-TCDD: 
follow-up 35 years after exposure. Eur J Neurol. 
2007; 14(2):213-218. 
 
U.S. EPA. An inventory of sources and 
environmental releases of dioxin-like compounds 
in the U.S. for the years 1987, 1995, and 2000 
(final, Nov 2006). U.S. Environmental Protection 
Agency, Washington, DC, EPA/600/P-03/002F. 
Available: 
http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?
deid=159286 
 
U.S.  EPA (U.S. Environmental Protection Agency). 
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) 
IRIS assessment summary (2012). Available: 
http://www.epa.gov/iris/subst/1024.htm 
 
Van den Berg M, Birnbaum L, Bosveld AT, 
Brunström B, Cook P, Feeley M, Giesy JP, 
Hanberg A, Hasegawa R, Kennedy SW, Kubiak 
T, Larsen JC, van Leeuwen FX, Liem AK, Nolt 
C, Peterson RE, Poellinger L, Safe S, Schrenk D, 
Tillitt D, Tysklind M, Younes M, Waern F, 
Zacharewski T. (1998) Toxic equivalency factors 
(TEFs) for PCBs, PCDDs, PCDFs for humans 
and wildlife. Environ Health Perspect. 1998; 
106(12):775-792. 
 
Van den Berg M, Birnbaum LS, Denison M, De Vito 
M, Farland W, Feeley M, Fiedler H, Håkansson 
H, Hanberg A, Haws L, Rose M, Safe S, Schrenk 
D, Tohyama C, Tritscher A, Tuomisto J, 
Tysklind M, Walker N, Peterson RE. The 2005 
World Health Organization re-evaluation of 
human and mammalian toxic equivalency factors 
for dioxins and dioxin-like compounds. Toxicol 
Sci. 2006; 93(2):223-241. 
 
Van den Berg M, Peterson RE, Schrenk D. Human 
risk assessment and TEFs. Food Addit Contam. 
2000; 17(4):347-358. 
 
Viluksela M, Bager Y, Tuomisto JT, Scheu G, 
Unkila M, Pohjanvirta R, Flodström S, Kosma 
VM, Mäki-Paakkanen J, Vartiainen T, Klimm C, 
Schramm KW, Wärngård L, Tuomisto J. Liver 
tumor-promoting activity of 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) in TCDD-
sensitive and TCDD-resistant rat strains. Cancer 
Res. 2000; 60(24):6911-6920. 
 
References 
  
THL — Research 133 • 2014 124 
TCDD-Induced Accumulation 
of the Heme Degradation 
Product Biliverdin in Rat Liver 
 
Viluksela M, Stahl BU, Birnbaum LS, Schramm 
KW, Kettrup A, Rozman KK. 
Subchronic/chronic toxicity of a mixture of four 
chlorinated dibenzo-p-dioxins in rats. I. Design, 
general observations, hematology, and liver 
concentrations. Toxicol Appl Pharmacol. 1998; 
151(1):57-69. 
 
Viluksela M, Unkila M, Pohjanvirta R, Tuomisto JT, 
Stahl BU, Rozman KK, Tuomisto J. Effects of 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on 
liver phosphoenolpyruvate carboxykinase 
(PEPCK) activity, glucose homeostasis and 
plasma amino acid concentrations in the most 
TCDD-susceptible and the most TCDD-resistant 
rat strains. Arch Toxicol. 1999; 73(6):323-336. 
 
Wardle EN, Williams R. Raised serum biliverdin in 
hepatic necrosis. Biochem Med. 1981; 26(1):8-
11. 
 
Warner M, Mocarelli P, Brambilla P, Wesselink A, 
Samuels S, Signorini S, Eskenazi B. Diabetes, 
metabolic syndrome, and obesity in relation to 
serum dioxin concentrations: the Seveso 
women's health study. Environ Health Perspect. 
2013; 121(8):906-911. 
 
Warner M, Mocarelli P, Samuels S, Needham L, 
Brambilla P, Eskenazi B. Dioxin exposure and 
cancer risk in the Seveso Women's Health Study. 
Environ Health Perspect. 2011; 119(12):1700-
1705. 
 
Weber LW, Lebofsky M, Greim H, Rozman K. Key 
enzymes of gluconeogenesis are dose-
dependently reduced in 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD)-treated 
rats. Arch Toxicol. 1991a; 65(2):119-123. 
 
Weber LW, Lebofsky M, Stahl BU, Gorski JR, Muzi 
G, Rozman K. Reduced activities of key 
enzymes of gluconeogenesis as possible cause of 
acute toxicity of 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD) in rats. Toxicology. 1991b; 
66(2):133-144. 
 
Wegiel B, Baty CJ, Gallo D, Csizmadia E, Scott JR, 
Akhavan A, Chin BY, Kaczmarek E, Alam J, 
Bach FH, Zuckerbraun BS, Otterbein LE. Cell 
surface biliverdin reductase mediates biliverdin-
induced anti-inflammatory effects via 
phosphatidylinositol 3-kinase and Akt. J Biol 
Chem. 2009; 284(32):21369-21378. 
 
Wegiel B, Gallo D, Csizmadia E, Roger T, 
Kaczmarek E, Harris C, Zuckerbraun BS, 
Otterbein LE. Biliverdin inhibits Toll-like 
receptor-4 (TLR4) expression through nitric 
oxide-dependent nuclear translocation of 
biliverdin reductase. Proc Natl Acad Sci U S A. 
2011; 108(46):18849-18854.  
 
WHO (World Health Organization), 2000. 
Consultation on assessment of the health risk of 
dioxins; re-evaluation of the tolerable daily 
intake (TDI): executive summary. Food Addit 
Contam. 2000; 17(4):223-240. 
 
WHO/IPCS, 2002. Global assessment of the state-of-
the-science of endocrine disruptors. 
WHO/PCS/EDC/02.2, World Health 
Organisation, Geneva, pp.180. Available: 
http://www.who.int/ipcs/publications/new_issues
/endocrine_disruptors/en/ 
 
WHO (World Health Organization), 2009. Persistent 
organic pollutants in human milk. European 
Environment and Health Information System 
ENHIS, Fact sheet 4.3. Available: 
http://www.euro.who.int/__data/assets/pdf_file/0
003/97032/4.3.-Persistant-Organic-Pollutantsm-
EDITED_layouted_V2.pdf 
 
WHO (World Health Organization), 2010. Dioxins 
and their effects on human health. Fact sheet No 
References 
  
THL — Research 133 • 2014 125 
TCDD-Induced Accumulation 
of the Heme Degradation 
Product Biliverdin in Rat Liver 
 
225. Available: 
http://www.who.int/mediacentre/factsheets/fs225
/en/ 
 
Wong EW, Cheng CY. Impacts of environmental 
toxicants on male reproductive dysfunction. 
Trends Pharmacol Sci. 2011; 32(5):290-299.  
 
Woods JS. Studies of the effects of 2,3,7,8-
tetrachlorodibenzo-p-dioxin on mammalian 
hepatic δ-aminolevulinic acid synthetase. 
Environ Health Perspect. 1973; 5:221-225. 
 
 Wu TW. Delta bilirubin: the fourth fraction of bile 
pigments in human serum. Israel J Chem. 1983; 
23(2):241-247. 
 
Wu L, Wang R. Carbon monoxide: endogenous 
production, physiological functions, and 
pharmacological applications. Pharmacol Rev. 
2005; 57(4):585-630.  
 
Yachie A, Niida Y, Wada T, Igarashi N, Kaneda H, 
Toma T, Ohta K, Kasahara Y, Koizumi S. 
Oxidative stress causes enhanced endothelial cell 
injury in human heme oxygenase-1 deficiency. J 
Clin Invest. 1999; 103(1):129-135. 
 
Yamada N, Yamaya M, Okinaga S, Nakayama K, 
Sekizawa K, Shibahara S, Sasaki H. 
Microsatellite polymorphism in the heme 
oxygenase-1 gene promoter is associated with 
susceptibility to emphysema. Am J Hum Genet. 
2000; 66(1):187-195.  
 
Yamamoto M, Hayashi N, Kikuchi G. Evidence for 
the transcriptional inhibition by heme of the 
synthesis of δ-aminolevulinate synthase in rat 
liver. Biochem Biophys Res Commun. 1982; 
105(3):985-990. 
 
Yamamoto M, Hayashi N, Kikuchi G. Translational 
inhibition by heme of the synthesis of hepatic δ-
aminolevulinate synthase in a cell-free system. 
Biochem Biophys Res Commun. 1983; 
115(1):225-231.  
 
Yamamoto M, Kure S, Engel JD, Hiraga K. 
Structure, turnover, and heme-mediated 
suppression of the level of mRNA encoding rat 
liver δ-aminolevulinate synthase. J Biol Chem. 
1988; 263(31):15973-15979. 
 
Yamashita K, McDaid J, Öllinger R, Tsui TY, 
Berberat PO, Usheva A, Csizmadia E, Smith RN, 
Soares MP, Bach FH. Biliverdin, a natural 
product of heme catabolism, induces tolerance to 
cardiac allografts. FASEB J. 2004; 18(6):765-
767.  
 
Yamauchi K, Hayashi N, Kikuchi G. Translocation 
of δ-aminolevulinate synthase from the cytosol 
to the mitochondria and its regulation by hemin 
in the rat liver. J Biol Chem. 1980; 255(4):1746-
1751. 
 
Yang KH, Croft WA, Peterson RE. Effects of 
2,3,7,8-tetrachlorodibenzo-p-dioxin on plasma 
disappearance and biliary excretion of foreign 
compounds in rats. Toxicol Appl Pharmacol. 
1977; 40(3):485-496. 
 
Yang KH, Yoo BS, Choe SY. Effects of halogenated 
dibenzo-p-dioxins on plasma disappearance and 
biliary excretion of ouabain in rats. Toxicol Lett. 
1983; 15(2-3):259-264. 
 
Yasuda H, Okinaga S, Yamaya M, Ohrui T, Higuchi 
M, Shinkawa M, Itabashi S, Nakayama K, Asada 
M, Kikuchi A, Shibahara S, Sasaki H. 
Association of susceptibility to the development 
of pneumonia in the older Japanese population 
with haem oxygenase-1 gene promoter 
polymorphism. J Med Genet. 2006; 43(4):e17. 
 
??ferences 
  
THL — Research 133 • 2014 126 
TCDD-Induced Accumulation 
of the Heme Degradation 
Product Biliverdin in Rat Liver 
 
Yasuda K, Yatomi Y, Matsushima T, Yoneyama A, 
Higashihara M, Kurokawa K, Nakahara K. A 
case of POEMS syndrome with 
thrombocytopenia and biliverdinaemia. Br J 
Haematol. 1994; 86(2):389-390.  
 
Yeager RL, Reisman SA, Aleksunes LM, Klaassen 
CD. Introducing the "TCDD-inducible AhR-
Nrf2 gene battery". Toxicol Sci. 2009; 
111(2):238-246.  
 
Yueh MF, Huang YH, Hiller A, Chen S, Nguyen N, 
Tukey RH. Involvement of the xenobiotic 
response element (XRE) in Ah receptor-
mediated induction of human UDP-
glucuronosyltransferase 1A1. J Biol Chem. 2003; 
278(17):15001-15006.  
 
Zelenka J, Muchova L, Zelenkova M, Vanova K, 
Vreman HJ, Wong RJ, Vitek L. Intracellular 
accumulation of bilirubin as a defense 
mechanism against increased oxidative stress. 
Biochimie. 2012; 94(8):1821-1827. 
 
Zhu Z, Wilson AT, Luxon BA, Brown KE, Mathahs 
MM, Bandyopadhyay S, McCaffrey AP, 
Schmidt WN. Biliverdin inhibits hepatitis C 
virus nonstructural 3/4A protease activity: 
mechanism for the antiviral effects of heme 
oxygenase? Hepatology. 2010; 52(6):1897-1905. 
 
Zinkl JG, Vos JG, Moore JA, Gupta BN. 
Hematologic and clinical chemistry effects of 
2,3,7,8-tetrachlorodibenzo-p-dioxin in laboratory 
animals. Environ Health Perspect. 1973; 5:111-
118. 
 
Öllinger R, Pratschke J. Role of heme oxygenase-1 
in transplantation. Transpl Int. 2010; 
23(11):1071-1081. 
 
References 
